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ABSTRACT
The mechanism of action of some conventional (sodium nitropnisside, NP and S-nitroso- 5
N-acetyl penicillamine, SNAP) and novel (iron-sulphur cluster nitrosyls) nitric oxide (NO) 
‘donor* drugs has been studied.
Experiments were performed on segments of internally-perfused, rat isolated tail artery.
Bolus injections (10/<1) of SNAP and NP produce fully reversible (transient or T-type) 
vasodilator responses. Injections of Roussin’s black salt (RBS), an iron-sulphur cluster 
containing 7 ligated nitrosyl groups, and a related cubane-like iron-sulphur cluster with 4 
ligated nitrosyls (CUB), produce conventional T-type responses at doses below a critical 
threshold concentration (Dt). However, both compounds generate extraordinarily long- 
lasting (sustained or S-type) responses when the injected dose >Dt; these comprise an 
initial, rapid vasodilation, followed by partial recovery only. The resulting ‘plateau* of 
reduced tone persists for several hours. Histochemical and X-ray microprobe analyses 
demonstrate that the plateau is due to slow release of NO from RBS or CUB taken up into 
the endothelium. RBS and CUB are also shown to be photosensitive: vasodilator responses 
to both compounds are potentiated by light.
A study has also been made of the mechanism of vascular smooth muscle (VSM)
photorelaxation. The phenomenon is shown to be due to release of NO from a %1
photodegradable molecular store, which probably exists in the form of nitrosothiol(s), 4
located in VSM cells. The store can be depleted by exposure to laser light, and then I
regenerated in the dark. The repriming process is dependent on basal release of NO: it is 
prevented by known inhibitors of NO synthase and by haemoglobin. Prior treatment of 
vessels with ethacrynic acid, a thiol alkylating agent, also prevents repriming.
The therapeutic implications of these findings are discussed.
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CHAPTER 1 
INTRODUCTION
INTRODUCTION
The functional significance o f the endothelium has only been fully appreciated in the last 20 
years. This monolayer of cells, continuous throughout the vascular system, has emerged as 
a crucial element involved in the local control of blood pressure, as well as platelet adhesion 
and aggregation.
The original breakthrough came with the discovery that endothelial cells release prostacyclin, 
a prostaglandin synthesised from arachidonic acid with vasodilator and anti-aggregating 
properties (Moncada, Giyglewski, Bunting & Vane, 1976). It soon became clear that this 
was one of a number of vasoactive substances released by the endothelium. Of particular 
interest is so-called ‘endothelium-derived relaxing factor’ (EDRF). The free radical nitric 
oxide (NO) is now recognised as being responsible for the vasodilator actions of EDRF, as 
well as fulfilling a wide variety of biological roles outwith the vascular system.
The importance of a fully functional endothelium is highlighted by results that show that in 
some diseased states, notably hypertension (Winquist, Bunting, Baskin, & Wallace, 1984; 
Luscher & Vanhoutte, 1986) and atherosclerosis (Beetens, Coene, Verheyen, Zonnekeyn & 
Herman, 1986; Harrison, Armstrong, Frieman & Heistad, 1987; Forstermann, Mugge, 
Alheid, Haverich & Frolich, 1988), endothelium-dependent relaxations are attenuated. 
Damage to the endothelium is thought to be responsible for this attenuation. In the case of 
atherosclerosis, recent results have suggested that a defect in endothelial NO function 
precedes intimai thickening in a new model for the disease (Dusting, Arthur & Zembetis- 
Bellesis, 1992).
This study focuses on the discovery, actions and pharmacological uses of NO, currently the 
subject of widespread interest in a variety of biological fields.
1.1 DISCOVERY OF ENDOTHELIUM-DERIVED RELAXING FACTOR
In 1980, Furchgott & Zawadzki showed that vasodilation caused by acetylcholine was 
endothelium-dependent and that endothelial cells were responsible for the release of a labile 
relaxing factor. Their experiments showed that precontracted aortic rings which relax on 
exposure to acetylcholine when intact, fail to relax (or even contract) on exposure to the drug 
once the endothelium is removed by gentle rubbing of the intimai surface.
Acetylcholine emerged as one of many compounds capable of releasing EDRF. Others 
include adenine nucleotides, thrombin, substance P, the calcium ionophore A23187, 
bradykinin and histamine. In addition, local physical changes such as hypoxia, increased 
luminal flow and electrical stimulation are all capable of eliciting endothelium-dependent 
relaxations (Furchgott, 1984; Moncada, Palmer & Higgs, 1986).
1.2 CHEMICAL IDENTITY OF EDRF
Furchgott (1984) showed that an intact strip of aorta was capable of relaxing an 
endothelium-denuded strip of aorta when placed intimai surface to intimai surface and 
stimulated with acetylcholine. Other workers at about the same time (Rubanyi, Lorenz & 
Vanhoutte, 1985 Griffith, Edwards, Lewis, Newby & Henderson, 1984) used alternative 
‘donor-detector’ models, where the effluent from an internally perfused length of aorta 
(donor) was made to superfuse endothelium-denuded aortic rings (detector). Stimulation of 
the donor vessel with ACh led to relaxation in the detector tissue. It was later shown that 
endothelial cells cultured on microcarriers packed in chromatography columns were capable 
of bradykinin-stimulated relaxation of detector tissues when superfused with the column 
effluent (Cocks, Campbell & Campbell, 1985; Gryglewski, Moncada & Palmer, 1986). 
Such bioassay techniques offered unique opportunities to study the chemical, physical and 
pharmacological properties of EDRF.
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The first property to be investigated was the biological half-life of EDRF. This was 
estimated by monitoring the effect on relaxation of increasing the delay between the site of 
release and the detector tissue. Results published by Griffith et al ( 1984) & Cocks et al 
(1985) suggest a half-life of a few seconds in oxygenated physiological solution. It was also 
found that EDRF was released under basal conditions as well as when stimulated by 
acetylcholine (Griffith et al, 1984; Rubanyi et al, 1984; Martin, Villani, Jothianandan & 
Furchgott, 1985) and that it was inhibited by haemoglobin and methylene blue (Martin et al, 
1985). By this time, Rapoport & Murad (1983) had already shown that the effect of EDRF 
is mediated by cyclic guanosine 3 ’,5’-monophosphate (cGMP) within the target (vascular 
smooth muscle) cells.
Gryglewski, Palmer & Moncada (1986b), Moncada, Palmer & Gryglewski, (1986) and 
Rubanyi & Vanhoutte (1986) showed that the instability of EDRF was largely due to the 
presence of superoxide free radicals in solution (Og ). Addition of superoxide dismutase 
(SOD; the endogenous enzyme which catalyses the conversion of 0 2 " to H2 O2 ) or 
cytochrome c (which causes oxidation of 0 %" to O2 ) to the superfusate prolonged the 
existence of EDRF in solution whilst Fe^+ or pyrogallol (O2 ' generators) reduced it. 
Haemoglobin and methylene blue (renowned inhibitors of EDRF) are now thought to act at 
least in part through generating 0%" (Steele, Stockbridge, Maljkovic & Weir, 1990; Marczin, 
Ryan & Catravas, 1992) although the major component of the inhibitory effect of 
haemoglobin is still attributed to its ability to bind EDRF.
Armed with these observations regarding the chemical and pharmacological behaviour of 
EDRF, Furchgott (1988) and Ignarro (1988) simultaneously suggested that the free radical 
NO had properties so similar to those of EDRF that either the radical itself, or a closely 
related compound, was EDRF.
However, during the preceding year crucial evidence was obtained finally identifying EDRF 
as NO. Palmer et al (1987), using the reaction of NO with ozone to yield a
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chemiluminescent product, showed that bradykinin was capable of generating enough NO 
from cultured endothelial cells to account for the physiological effects of EDRF, 
Comparative experiments using EDRF and NO in cascade systems showed them to have 
similar if not identical physical and chemical properties. NO was also shown to be 
susceptible to the same inhibitors as EDRF (Fe^+, methylene blue, other redox reagents and 
haemoglobin) and its actions were enhanced by agents such as SOD and cytochrome c 
(Palmer et al, 1987). The actions of both EDRF and NO had by this time been shown to be 
mediated by the stimulation of soluble guanylate cyclase and the subsequent elevation of 
intracellular cGMP (Rapoport & Murad, 1983).
The evidence for EDRF being NO is compelling but not watertight. Controversy still reigns 
over the wide variation in estimated half-lives for EDRF (between 3 and 50 seconds, 
Griffith et al, 1984; Rubanyi et al, 1985; Gryglewski et al, 1986). It is thought that the 
discrepancy lies largely in differing experimental conditions, especially with regard to the 
relative O2  and 0 2 " concentrations, now known to be crucial in determining the half-life of 
EDRF. The reactions of NO with O2  and 0 2 " are considered in section 1.5.
Other controversial issues include the differential binding of EDRF and NO to anion 
exchange columns. EDRF has been reported to bind to anion exchange columns (Long, 
Shikano & Berkowitz, 1987) whereas NO (which is not anionic) does not. Other workers 
have shown that NO in physiological concentrations binds to a lesser extent than EDRF to 
anion exchange columns (Khan & Furchgott, 1987). It has been postulated that EDRF and 
NO undergo a chemical reaction with amines when passing down the column but it is also 
possible that the results indicate that EDRF is an NO-containing compound rather than the 
free radical itself.
Evidence from electron paramagnetic resonance (EPR) studies also raises a question mark 
concerning the exact identity of EDRF, since NO, but not EDRF, can form paramagnetic 
nitrosyl haem (Rubanyi, Greenberg & Wilcox, 1990). Despite these irregularities in the 
evidence that EDRF is NO, it is generally agreed that the actions of EDRF are mediated by 
NO.
1.3 SYNTHESIS OF EDRF
Palmer, Ashton & Moncada (1988a) were the first to identify L-arginine as the precursor to 
EDRF. Their experiment involved the removal of L-arginine from the medium of cultured 
endothelial cells. These cells were shown to have a reduced EDRF output when stimulated 
with bradykinin or A23187. The output could be restored to normal levels by introducing 
L- but not D-arginine. The results were confirmed by experiments using mass 
spectrometry, where i^N-labelled L-arginine (at both the G- and U- nitrogen sites) was 
shown to release on stimulation with bradykinin. The release was shown to depend 
upon an enzymatic reaction, since D-arginine was nota suitable substrate for the production 
of NO.
The enzyme involved, formerly known as the citrulline-forming enzyme, and now nitric 
oxide synthase (NOS), has been shown to be inhibited by an L-arginine analogue, N^ 
monomethyl - L- arginine (LNMMA) but not the D- enantiomer (Palmer et at, 1988). 
LNMMA has since been used extensively, both in vitro and in vivo, specifically for this 
purpose. In vivo studies on a wide variety of preparations, including the human brachial 
artery (Vallance, Collier & Moncada, 1989), have shown that LNMMA increases resting 
arterial tone, suggesting a ‘basal release’ of EDRF by the enzyme even when seemingly 
unstimulated. Palmer, Rees, Ashton & Moncada (1988b) refer to this phenomenon as the 
‘dilator tone’ of the resting vessel. These results are supported by the existence of a basal 
cGMP concentration within unstimulated vascular smooth muscle cells. Removal of the 
vasodilator tone, using agents such as LNMMA, has been shown to supersensitise the tissue 
to NO delivered by endothelium-independent means, both in vivo and in vitro (Moncada, 
Rees, Schulz & Palmer, 1991). This might also explain the ‘desensitisation’ reported when 
using NO-donor drugs (Axelsson & Andersson, 1983; Waldman & Murad, 1987).
LNMMA is now known to be one of a family of inhibitory L-arginine analogues (figure 
1.1). Others include N-iminoethyl-L-omithine (LNIO); N^-nitro-L-arginine methyl ester 
(LNAME); (Rees, Palmer, Schultz, Hodson & Moncada, 1990) and N^-amino-L-arginine
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(Fukuto et al, 1990). A variety of iodic compounds(figure 1.1; Stuehr, Fasehun, Kwon, 
Gross, Gonzalez, Levi & Nathan, 1991) have also been shown to inhibit the enzyme but via 
inhibition of the cofactor nicotinamide adenine dinucleotide phosphate (NADPH). The 
inhibition in this case is irreversible and less specific than with the competitive inhibitors 
mentioned above.
H N
L-Arg N
2 H
HN
LNMMA H H
H 
N
L-NIO N‘
NH,
L-NAME
CO^H
NH,
CO^ H
NH,
COLH
NH,
CO^Me
ID
DTI
DPI
J - i+-
/  \N
Figure 1.1. Structural formulae of L-arginine and some inhibitors o f NO synthase. 
LNMMA, LNIO and L-NAME are reversible, competitive inhibitors. lodoniumdiphenyl 
(ID), di-2-thienylidonium (DTI) and diphenyleneiodonium (DPI) act irreversibly through 
inhibition of the cofactor NADPH.
As intimated above, NO synthase is NADPH-dependent (Palmer & Moncada 1989). It 
can also be inhibited by calcium ion chelators indicating a dependence on calcium (Moncada 
& Palmer 1990). NO synthase has recently been shown to be stimulated by the calcium- 
calmodulin complex since it is inhibited by calmodulin-binding peptides (Busse & Mulsch
1990). Sequence analysis of cloned NOS has revealed a structural resemblance to P450
7
cytochrome c P450 reductase, with binding sites for NADPH, flavine adenine dinucleotide 
(FAD), flavine mononucleotide (FMN) (Bredt, Hwang, Glatt, Lowenstein, Reed & Snyder, 
1991), tetrahedrobiopterin (BH4 ) (Kwon, Nathan & Stuehr, 1989) as well as 
phosphorylation sites, (Bredt et al, 1991), highlighting the multi-factor regulation of the 
enzyme. Full classification of different isoforms so far identified is included in section 1.9.
NOS is now thought to synthesise NO from L-arginine via the intermediate N^-hydroxy-L- 
arginine (Stuehr, Kwon, Nathan, Griffith, Feldman & Wiseman, 1991). Molecular oxygen 
is incorporated into both end products, citrulline and NO (Leone, Palmer, Knowles, Francis, 
Ashton & Moncada, 1992). The current hypothetical reaction mechanism for enzymatic 
NO production is shown in figure 1.2:
NOL-arginine N -hydroxy-L-arginine
^  R-C(OOH)H(NI^
OOH OOHFMNH
f A d 'NADPH
+H+
BH
L-citrullineFMNH
FAD
FMN
FAD
NADP" NADPH + ¥ t FMN
FAD1%
NADR
Figure 1.2. Hypothetical reaction mechanism of enzymatic NO formation (after Stuehr, 
Cho, Kwon & Nathan, 1992)
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1.4 STIMULATION OF GUANYLATE CYCLASE BY NO
The target enzyme for NO (whether endothelium-derived or from an exogenous source) has 
been shown to be guanylate cyclase (Waldman & Murad, 1987). More specifically, it 
appears that its main site of action is on the cytoplasmic isoenzyme (soluble guanylate 
cyclase).
There is some controversy over the exact constitution of soluble guanylate cyclase but it is 
now thought to be a heterodimer with Mr 82,000 and 70,000 subunits (Waldman & Murad, 
1987). Soluble guanylate cyclase purified from bovine lung contains a haem and a copper 
moiety. Highly purified enzyme extracts exhibit three absorption maxima at 433, 550 and 
565nm which are shifted on exposure to either carbon monoxide or NO (Gerzer, Bohme, 
Hoffman & Schultz, 1981). This is consistent with the binding of these species to the haem 
moiety of the enzyme. The involvement of the haem group in the stimulation of the enzyme 
was clarified by the inhibitory effect of adding ferro (Fe^+)-metalloproteins (but not the 
ferric Fe^+ forms) such as haemoglobin or myoglobin, to highly purified extracts of the 
enzyme (section 1.6). Application of NO donor drugs to the purified enzyme in the 
presence of Fe^+ metalloproteins was no longer capable of activating cGMP production 
(Mittal, Arnold & Murad, 1978; Murad, Mittal, Arnold, Katsuki & Kimura, 1978). The 
likely explanation for these observations is that the Fe^+ metallo-proteins act as efficient 
scavengers for NO and prevent its binding to the target haem group. The presence or 
absence of ferro-haem compounds in the cellular environment, therefore, is a significant 
factor in determining the susceptibility of the enzyme to NO stimulation.
In light of these and other experiments, it is thought that the activation of soluble guanylate 
cyclase by NO involves at least one oxidation-reduction event (although O2  and protein 
activators are not necessary for its effects; Murad et al, 1978). In fact, O2  and other 
oxidising agents, such as methylene blue, H2 O2 , O2- and ferrocyanide, appear to inhibit the 
activity of the enzyme, whilst reducing agents (ascorbate, cysteine, glutathione and 
dithiothreitol) promote its activation by NO (Braughler, Mittal & Murad, 1979).
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The inhibitory effect of oxidising agents may occur at different levels. NO itself may be 
converted to higher oxides of nitrogen (e.g. NO2 ), whilst the haem group on the enzyme 
may also be oxidised to the Fe^+ form which is not capable of binding NO (sections 1.5 and 
1.6).
NO stimulation results in striking alterations in the enzyme’s properties. The inactivated 
enzyme displays a preference for Mn^+-GTP (Km 5-50 pM) over Mg^+-GTP (Km 20- 
150/<M). However, once activated by NO, the enzyme can use GTP bound to either 
cofactor equally well, resulting in an increase in the Vmax. The Km for Mg^^-GTP drops 
to about AOpM whilst that for Mn^+-GTP remains unchanged. The proposed reason for the 
change is that a secondary binding site develops for Mg^+-GTP on activation (Lewicki, 
Brandwein, Mittal, Arnold & Murad, 1982). Another curiosity concerning the state of the 
activated enzyme is its ability to form cAMP from Mg^+-ATP. This is inhibited by the 
presence of GTP just as formation of cGMP is inhibited by the presence of ATP (Mittal & 
Murad, 1977).
Studies on the activation of particulate guanylate cyclase by NO have been hampered by the 
effects of detergents in purification but it appears likely that this too is stimulated by NO in 
favourable (similar to soluble guanylate cyclase) redox conditions (Braughler, 1982; 
Katsuki, Arnold, Mittal & Murad, 1977).
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1.5 INTRACELLULAR INTERACTIONS OF NO
The intracellular environment is host to a variety of free radical and molecular species which 
have the potential to react with and inactivate NO before it can stimulate guanylate cyclase 
activity.
A. FREE RADICALS
The most common free radicals present in cells are oxygen-derived byproducts of the 
respiratory chain; superoxide (O2  ) and hydroxyl radicals (OH*; Freeman & Crapo, 1982). 
Other sources of these species are haem and other metal-containing proteins and both free 
and complexed metals (particularly Fe^+; Freeman & Crapo, 1982). The relative 
concentrations of these, and of other potentially harmful radicals, greatly increase when cells 
are exposed to irradiation, pollutants, toxic chemicals or become diseased (Freeman & 
Crapo, 1982; McCord & Fridovich, 1972; Bielski & Gebieki, 1977; Mason & Chignell, 
1982).
Normal levels of oxygen radicals are controlled by enzymes with rapid rate constants and 
low Km values, minimising their cytotoxic effects.
superoxide 
dismutase (SOD)
O2  + O2-+ H+ -------------->  H2 O2  + O2  K = 2 X lO^M-’sec-l
Peroxidase/Catalase
2 H2 O2  ^  2 H2 O + O2  K = 4 X 1Q7 M-lsec-l (Peroxidase)
K = 1 X lO^M-^sec'l (Catalase)
OH*, the extremely reactive and potentially most harmful radical, is controlled as a
consequence of the activity of these two enzymes, since it arises as a result of the reaction
between O2  and H2 O2  (Waldman & Murad, 1987).
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Despite the rapid activity of these enzymes, it is well documented that sufficient O2* exists in 
the intracellular environment to reduce NO stimulation of guanylate cyclase, since addition 
of exogenous SOD to the perfusate has been reported to double the half-life of EDRF 
(Rubanyi & Vanhoutte, 1986). The same workers showed that the effect is augmented by 
reducing the O2  concentration from 95% to 10%, resulting in a five-fold increase in the half- 
life. The inference of these experiments is that 0 2 ‘ inactivates EDRF and that hyperoxia 
favours the inactivation. In addition, inactivation has been found to be potentiated by 
incorporating nitrate reductase, a flavoprotein which catalyses the formation of 0 2 " from O2  
(Waldman & Murad, 1987). A more recent study, involving inhibition of endogenous 
SOD in bovine coronary arteries using diethyldithiocarbamate (DETCA), showed 
attenuation of endothelium-dependent and -independent nitrovasodilator relaxation (Omar,
Cherry & Martelli, 1991). Exogenous O2  generators ( Fe^+, pyrogallol, cytochrome c and 
phenidone) severely attenuate bradykinin-induced (i.e. EDRF mediated) vascular relaxation.
I
Under physiological pH conditions, NO reacts with O2 ' to produce peroxynitrite (ONOO~) à
which then decays following first order kinetics to NO2  and ultimately NO2 " (Saran, Michel |
& Bors, 1990).
Evidence is mounting to show that 0 2 " generation is responsible, at least in part, for the f
actions of traditional inhibitors of NO activation of guanylate cyclase, including 
haemoglobin (Hb) and methylene blue (MB). The inhibition is thought to result from direct 
oxidation of the enzyme, as well as its reaction with NO. Hb is known to have a high 
affinity for NO and its inhibitory effect on NO stimulation of guanylate cyclase has been 
attributed solely to this fact. However, it is now thought that generation of free radicals 
during autoxidation of Hb is an important factor in mediating its inhibitory action in 
cerebrovascular smooth muscle cells (Steele, Stockbridge, Malkjovic & Weir, 1991). 
Similarly, it has been postulated that MB exerts its inhibitory effect on guanylate cyclase via 
the production of 0 2 % since its effects are abolished in the presence of exogenous SOD 
(Marczin, Ryan, Catravas, 1992; Wolin, Cherry, Rodenburg, Messina & Caley, 1990).
Results concerning the interactions of H2 O2  with NO have been conflicting. Rubanyi & 
Vanhoutte (1986) found that catalase had no effect on the half-life of EDRF under their 
experimental conditions, whilst work by Marczin et al, (1992) showed that H2 O2  has a 
profound effect on the production, transport or action of basally released EDRF, as reflected 
by smooth muscle cGMP levels. To complicate matters further, activation of guanylate 
cyclase by the addition of SOD has been shown to be inhibited by catalase, despite the fact 
that H2 O2  alone is incapable of elevating intracellular cGMP (Mittal & Murad, 1977). 
These data imply that both O2  and H2 O2  are required to activate guanylate cyclase via the 
formation of the short-lived radical, OH-.
In smooth muscle, therefore, the interaction between NO and oxygen free radicals ultimately 
results in attenuation of NO-induced vascular relaxation. In other tissues, particularly in 
diseased states, the relevance of the interaction lies in the inactivation of 0 2 " by NO, 
resulting in protection against tissue injury (Rubanyi, Ho, Cantor, Lumma & Botelho,
1991). The cytoprotective effect may also be due to NO inhibition of NADPH oxidase, the 
enzyme largely responsible for O2 * production in activated neutrophils (Clancy, 
Leszczynska-Piziak & Abramson, 1992).
B, MOLECULAR ^SCAVENGING* OF NO
NO is capable of reacting with a vast range of intracellular molecules as well as free radicals. 
First, NO reacts with molecular O2  Originally it was thought that the reaction yielded both 
nitrite and nitrate (Feelisch, 1991), but in a recent review (Butler & Williams, 1993) nitrite 
was seen to be the only product in the knowledge that the intermediate steps in nitrite 
production occur at a faster rate than those for nitrate. Hence the reaction sequence is as 
follows:
1. 2NO + O2 --------------> N 0 2
2. NO + NO2 -------------->  N2 O3
3. N2O3 + H2O-------------->  2 NO2- + 2 H+
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The reaction shown in equation 1 is third order and as such is thought to be slow at 
physiological NO concentrations (Butler & Williams, 1993). In vivo, therefore, inactivation 
of NO is probably due more to its interaction with oxygen-derived free radicals than with 
oxygen itself.
It has recently been shown that albumin readily binds NO (Stamler, Jaraki, Osborne, 
Simon, Keaney, Vita Singel, Valeri & Loscalzo, 1992). This research demonstrates that 
NO binds to the single free cysteine (cys 34) of serum albumin to produce S-nitroso-serum 
albumin. The inference to be drawn from this is that NO can bind to any proteins containing 
accessible cysteines in their structure as well as to free thiols (Stamler et al, 1992).
Porphyrins also bind NO avidly (Antonini & Brunori, 1971). The intracellular importance 
of this is limited since Hb is unable to enter cells. Nevertheless, various other intracellular 
ferroporphyrins, including catalase, myoglobin and cytochrome c, bind NO, forming stable 
nitrosylhaem complexes (Kimura, Mittal & Murad, 1975; Murad, Arnold, Mittal & 
Braughler, 1979; Mittal & Murad, 1979; Murad et at, 1978 - Section 1.6).
Guanylate cyclase in vascular smooth muscle is therefore in direct competition with a wide 
range of free radical and molecular species for NO binding. Interactions with free radicals 
serve both to protect the tissue from damage and, in conjunction with binding to proteins 
and molecules other than guanylate cyclase, to attenuate the vasodilator effect of endogenous 
or exogenous NO.
Evidently, the activation of guanylate cyclase by NO is a complex process which can be 
modulated at a variety of levels, primarily by the redox conditions in the immediate 
environment of both the NO and the haem group of the enzyme.
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1.6 ROLE OF PORPHYRINS IN REGULATION OF GUANYLATE CYCLASE
The fact that ferro-haemoglobin and other haemoproteins are capable of inhibiting the §
stimulation of guanylate cyclase by NO, whilst the actions of hydroxylamine are dependent |
on the presence of other haemoproteins (catalase or cytochrome c), suggests a role for 
porphyrins in regulating guanylate cyclase activity. The role of catalase in the 
hydroxylamine scenario has been shown to be due to the catalytic release of NO from s
hydroxylamine in the presence of H2 O2 . There seemed however, to be a necessity for the I
formation of a catalase-NO intermediate to facilitate enzyme activation (Craven, De Rubertis 
& Pratt, 1979). This suggests that the role of the porphyrin is more as an NO acceptor than 
as an enzyme catalysing the release of NO. The nitrosyl-haem complex is now recognised 
as an important regulator of guanylate cyclase activity.
Further evidence supporting this hypothesis arose from early attempts to purify soluble 
guanylate cyclase. The process repeatedly resulted in a haem-free protein which could not 
be stimulated by NO or nitrovasodilators. Partial activation was restored following 
exposure of the enzyme to haematin, haemoglobin, met-haemoglobin or catalase. The effect 
could be potentiated by incorporating a reducing agent, to maintain the haem iron in the 
ferrous (Fe^ +) state. Preformed NO-haemoglobin maximally activated the partially purified 
enzyme (Craven & De Rubertis, 1978, Craven et al, 1979).
As purification techniques improved, dissociation of the haem moiety from the enzyme 
became less problematic. Confirmation of the essential role played by haem in NO 
activation came when haem-containing guanylate cyclase was chromatographically separated 
from haem-free enzyme and it was shown that only haem-containing enzyme could be 
stimulated by NO (Gei-zer, Bohme, Hoffman & Schultz, 1981; Gerzer, Hoffman, Bohme, 
Krassimira, Spies & Schultz, 1981; Gerzer, Hoffman & Schultz, 1981). A clue to the 
mechanism by which the NO-haem complex causes activation arose from experiments 
where haem-free guanylate cyclase was reconstituted using protoporphyrin IX, the 
demetallated precursor of ferroprotoporphyrin (Gerzer, Radney & Garbers, 1982). This 
was shown to cause activation of the enzyme, with changes in Km and Vmax similar to
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—those obtained with nitrosyl-haem activation (Waldman, Rapoport & Murad, 1987). 
Activation of guanylate cyclase, therefore, is thought to be related to the absence of Fe^+ 
from the porphyrin ring (e.g. protoporphyrin IX - induced activation) or to withdrawal of the 
Fe?+ from the plane of the porphyrin ring (NO - induced activation; figure 1.3).
HAEM
GROUP
GUANYLATE
CYCLASE j—
Figure 1.3 Proposed mecha?iism for NO- induced stimulation of guanylate cyclase.
The mechanism is undoubtedly more complex than illustrated in figure 1.3, with a possible 
role for an activating factor, as yet unidentified. It has also been proposed that 
protoporphyrin IX acts through an alternative mechanism (Ohlstein, Wood & Ignarro, 
1982).
Regulation of particulate guanylate cyclase by protoporphyrin IX (6 -10-fold activation) and a 
variety of other porphyrin structures has also been demonstrated by Lacombe & Eberenz- 
L’Homme (1983), Haemin was found to activate the particulate isoenzyme from some 
tissues (rat lung) but not others. These results suggest that porphyrin regulation of activity is 
not identical for the two isoforms of the enzyme. The soluble form is activated by low 
concentrations of haemin whilst high concentrations inhibit its activity. The particulate form, 
however, requires high haemin concentrations for activation (Waldman, Sinacore, Lewicki, 
Chang & Murad, 1984).
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1.7 ROLE OF THIOLS IN REGULATION OF GUANYLATE CYCLASE
It has become clear that porphyrins are not the only regulatory factor involved in the 
stimulation of guanylate cyclase. As already discussed, regulators of guanylate cyclase 
activity generally exert their effect by altering the redox state of the enzyme. Since 
sulphydryl groups can undergo oxidation-reduction reactions, and are known to regulate 
protein structure and function, it is reasonable to suppose that they may also be involved in 
the regulation of guanylate cyclase.
Even in early studies, alkylating agents which covalently modify free thiol groups (e.g. 
ethacrynic acid) were shown to inhibit basal and nitro-activated cGMP production (Katsuki 
et al, 1977). Similarly, disulphide bridge formation, on addition of cystine or cystamine, 
also inhibited both basal and nitro-activated cGMP production (Kimura, Mittal & Murad, 
1975;Waldman, Lewicki, Chang & Murad, 1983). The link was confirmed when 
radiolabelled cystamine was shown to be incorporated into the enzyme in a manner 
consistent with the time course of inhibition of the enzyme. This effect was reversed using 
the reducing agent dithiothreitol, which breaks disulphide bridges (Brandwein, Lewicki & 
Murad, 1981).
Oxidation of the enzyme, induced by preincubation of crude enzyme preparations in an 
oxygen-rich atmosphere, initially causes stimulation of the enzyme but ultimately leads to 
inhibition of its activity (Lewicki et al, 1982). Reduction by dithiothreitol potentiates 
activation of the enzyme (Bohme, Jung & Mechler, 1974). The apparent anomaly in these 
results has been explained in terms of the initial oxidation of sulphydryl groups leading to 
activation, developing into an, as yet unexplained, ‘overoxidation’, which causes irreversible 
loss of both basal and nitro-activated cGMP production. The inhibition of nitro-activated 
cGMP production could be due to direct inhibition of NO by (or the more potent oxygen 
radicals), as well as by oxidation of the recipient haem group of the enzyme (Waldman & 
Murad, 1987).
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Since these findings were published, it has been suggested that different sulphydryl groups 
on the enzyme are responsible for (a) the regulation of basal cGMP production; and (b) for 
regulation of nitro-activated cGMP production (Braughler, 1983). At least one of these 
sulphydryl groups is located at or near the catalytic site of the enzyme, since preincubation of 
the enzyme with either the activating agent or with Mg^+-GTP protects the enzyme against 
inactivation (Ignarro, Kadowitz & Baricos, 1981). Again, care must be taken when 
interpreting results involving the effects of oxidising and reducing agents on nitro- 
stimulation of the enzyme because such treatments will invariably affect the viability of both 
the NO donor and NO itself en route to the active site of the enzyme.
Ignarro, Lipton, Edwards, Baricos, Hyman, Kadowitz & Greutter (1981) showed that 
partially purified soluble guanylate cyclase requires added free thiol groups to undergo 
activation by a variety of NO-donor compounds. In addition, nitrosocysteine and other 
nitrosothiols are capable of elevating cGMP levels, as well as causing a brief arterial 
relaxation in anaesthetised cats. Ignarro et al (1988) argue that nitrosothiols more closely 
mimic the actions of NO-donor drugs than NO itself, and have suitable half-lives in 
physiological conditions to account for the actions of EDRF.
In summary, therefore, the endogenous vasodilator, EDRF, is NO generated during the NO 
synthase catalysed conversion of L-arginine to L-citrulline. Binding of EDRF to the haem 
moiety of vascular smooth muscle guanylate cyclase stimulates cGMP production from 
GTP leading to relaxation (see section 1.8).
The free radical 0%", a by product of respiration, is an important inhibitor of NO. However, 
NO may also bind to ferroporphyrin-containing compounds or thiols (both free and protein- 
associated), all of which will prevent its stimulating guanylate cyclase.
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Regulation of guanylate cyclase is strongly dependent on the immediate redox environment 
The oxidation state of the haem-iron as well as the protein-bound thiol groups determine the 
affinity of NO for the enzyme.
The vascular L-arginine: NO pathway is summarised in figure 1.4 below:
LUMEN
NO
Donor
Drugs
Endothelium 
dependent - 
vasodilator 
(egACh)
ENDOTHELIUM
L -A R G  L -C IT
NO
synthase►EDRF
+ C a
calmodulin 
2 +
SMOOTH MUSCLE
NO
GTP C G M P-^W Ca2+
cGMP ■ PK
RELAXATION
calciumpumps
Figure 1,4: Diagram summarising the synthesis and actions of NO in vascular tissue.
1.8 MECHANISMS OF ACTION OF cGMP IN VASCULAR SMOOTH
MUSCLE.
I
It is now widely accepted that cGMP is the intracellular mediator involved in NO-stimulated 
relaxation of vascular smooth muscle. Since the discovery of a specific cGMP-dependent 
protein kinase in lobster tail muscle (Kuo & Greengard, 1970), it has been considered likely 
that this mediates the actions of cGMP, in much the same way that cAMP-dependent 
protein kinases regulate the actions of cAMP (Lohmann & Walter, 1984). However, it has 
since been shown that cGMP is also capable of regulating cyclic nucleotide
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phosphodiesterases (Walter, 1984) and plasmalemmal Ca^+-pump activity in vascular 
smooth muscle (Popescu, Panoui, Hinescu & Nuto, 1985). In order to understand how an 
elevation in intracellular cGMP causes vasodilation, it is necessary to outline the process 
involved in vasoconstriction.
A, Contraction o f  vascular smooth muscle.
Cytosolic Ca2+ is the second messenger for activation of vascular (and other) smooth 
muscle cells (Haslam, 1987; Rasmussen, Takuwa & Park, 1987). Intracellular Ca^+ can be 
elevated either directly by voltage- or receptor -dependent stimulation of calcium channels in 
the membrane (Exton, 1988), or by the release of intracellular stores via receptor-mediated 
stimulation of phospholipase C (e.g. a i  adrenoreceptors). Phospholipase C is the 
constituent enzyme of the inositolphosphate pathway that hydrolyses phosphatidylinositol 
4,5-bisphosphate to inositoltrisphosphate. This is a second messanger that stimulates Ca^ + 
release from intracellular stores. The byproduct of the hydrolysis, 1,2 di acyl glycerol 
(DAG), is a potent activator of phosphokinase C.
The rise in intracellular Ca^+ triggers a cascade of events which ultimately leads to 
contraction of smooth muscle. The first step involves the activation of calmodulin. 
Ca^+/calmodulin-dependent myosin light chain kinase activity is then stimulated to 
phosphorylate myosin light chains, a prerequisite for smooth muscle contraction (Walter, 
1989).
The role of phosphokinase C, activated by DAG, is not so clearly defined as that of Ca^ +. It 
is known that phosphokinase C phosphorylates myosin light chains but it is thought that this 
occurs at different sites from those phosphorylated by myosin light chain kinases (Haslam, 
1987). The site of phosphokinase C phosphorylation is thought to be on the structural and 
regulatory components of filamin-actin-desmin fibrillar domain of myosin light chains. It is 
proposed that phosphorylation at these sites produces sustained smooth muscle tone, whilst 
Ca^+Zcalmodulin-stimulated phosphorylation is responsible for the initial phase of 
contraction (Rasmussen et at, 1987).
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B, Role o f  cGMP in relaxation o f vascular smooth muscle.
Essentially, relaxation of smooth muscle involves the removal of intracellular calcium and 
dephosphorylation of myosin light chains. As yet, there is no evidence to suggest that 
cGMP is capable of myosin light chain dephosphorylation directly (as is the case with 
cAMP; Lamb et al, 1988). The major contribution made by cGMP with regard to vascular 
smooth muscle relaxation has therefore been attributed to its ability to down-regulate free 
intracellular Ca?+.
Most, but not all, of the actions of cGMP are mediated by cGMP-dependent kinases. 
Following the discovery of cGMP-dependent protein kinase in lobster tail muscle (Kuo et 
al, 1970), similar findings have come to light in a wide variety of tissues (Hofmann & Sold, 
1972; Gill, Holdy, Walton & Kanstein, 1976). Protein kinase purified from bovine lung has 
now been characterised and is recognised as a Mr 150,000 enzyme composed of two 
identical subunits. All rat cell lines so far tested using radio immunoassay techniques have 
been found to have cGMP-dependent kinases, although highest concentrations exist in the 
cerebellum, heart, lung and aorta (Walter, 1981). The enzyme was primarily thought to be 
soluble but recent evidence, from studies of vascular smooth muscle and platelets 
(Waldman, Bauer, Gobel, Hofmann, Jacobs & Walter, 1986), suggests that in some cases 
particulate protein kinase may be as prevalent.
The principle function of protein kinases is to phosphorylate specific proteins. The pattern 
of phosphorylation, and the resulting response of the tissue, is dependent on whether the 
protein kinase is cGMP- or cAMP-dependent and on the tissue concerned. Attention will 
now focus on the situation in vascular smooth muscle.
cGMP is thought to regulate intracellular Ca^+ in four ways. Firstly, the processes 
responsible for elevating cytosolic Ca^ + are inhibited by both cAMP and cGMP in smooth 
muscle cells (Jones, By land. Forte, 1984; Morgan & Morgan, 1984). It has been 
demonstrated that cGMP-dependent kinases mediate the inhibitory effects of 8 -bromo-
21
cGMP on vasopressin- and depolarisation-induced elevation of cytosolic Ca^ + in vascular 
smooth muscle (Cornwell & Lincoln, 1989). As yet, it is unclear how cGMP-dependent 
protein kinases are able to lower the intracellular calcium concentration but it is likely to 
involve one or more of the following mechanisms:
1. Regulation o f  phospholipid-meiaboUsing enzymes.
Evidence exists to support the view that both cAMP & cGMP-elevating vasodilators inhibit 
agonist-induced activation of the phosphatidylinositol cycle in platelets (Haslam, Salama, 
Fox, Lynam & Davidson, 1980; Waldman & Walter, 1989). c-GMP-elevating vasodilators 
have been shown to have this effect on vascular smooth muscle cells (Rapoport, 1986). The 
resultant reduction in inositoltrisphosphate leads to a decrease in intracellular Ca^ +, whilst the 
reduction in DAG leads to a decrease in stimulation of phosphokinase C. The overall effect 
of both processes is to reduce protein phosphorylation involved in platelet or muscle 
activation (Waldman & Walter, 1989; Rapoport, 1986).
2. Regulation o f  pathways responsible fo r  Ca^+ removal
cGMP is now known to activate plasmalemmal Ca^+-ATPase in intact vascular smooth 
muscle cells (Kobayashi, Kanaide & Nakamura, 1985; Furukawa, Tawada & Shigekawa, 
1987; Lincoln, 1989). Ca^+-ATPase is responsible for removal of Ca^+ from the 
cytoplasm, a process which has been shown to be activated by partially purified cGMP- 
dependent protein kinase (Furukawa & Nakamura, 1987). The precise mechanism is not 
fully understood. It is also unclear whether cGMP-dependent kinases affect Ca^+ uptake 
into smooth muscle sarcoplasmic reticulum (Lincoln, 1989).
Despite uncertainties about the mechanism, the reduction of intracellular Ca?+ concentration 
is clearly the main role of cGMP and cGMP-dependent kinases in vascular smooth muscle 
cells. However, other processes are also thought to play a part.
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3. Regulation o f  cGMP - dependent cAMP phosphodiestererases
It has been known for some time that cGMP stimulates the hydrolysis of cAMP in some 
tissues (Beavo, Hardman, Sutherland, 1971). The picture, however, is now known to be far 
more complex. Evidently, cAMP phosphodiesterases fall into numerous sub-classes, only 
some of which are stimulated by cGMP (Beavo, 1988). Whether a particular cell contains 
cGMP-inhibited or -stimulated cAMP phosphodiesterase seems to be determined by the cell 
type. As a result, elevation of cGMP levels in certain tissues leads to a subsequent decrease 
in cAMP, whilst the reverse is true in other tissues.
In the cardiovascular system, this differentiation is clearly illustrated. Acetylcholine is 
known to exert its negative inotropic effects by stimulating cGMP production (Goldberg & 
Haddox, 1977). It is now believed that the associated drop in cAMP levels (potentiating the 
negative inotropic effect) in cardiac tissue is due to stimulation of cGMP-dependent cAMP 
phosphodiesterases (Flitney & Singh, 1981; Hartzell & Fischmeister, 1986). In vascular 
smooth muscle, there is circumstantial evidence that elevation of intracellular cGMP leads to 
inhibition of cGMP-dependent cAMP phosphodiesterase, elevating intracellular cAMP and 
potentiating vasodilation. The evidence is that cAMP- and cGMP-eievating vasodilators act 
synergistically, both in vascular smooth muscle and platelets (Walter, Niederding & 
Waldman, 1988) and also from experiments that show such inhibition in platelets 
(Macphee, Harrison & Beavo, 1986).
4. Regulation o f  voltage-dependent channels
Recently, NO derived from a variety of sources has been shown to hyperpolarise arterial 
smooth muscle (Tare, Parkington, Coleman, Neild & Dusting, 1991). Whether this is 
cGMP dependent or not is as yet unknown, but hyperpolarisation would be likely to induce 
a reduction in voltage-dependent Ca^+-channel opening, leading to a reduction in intracellular 
Ca2 +.
In vascular smooth muscle, therefore, cGMP is capable of causing vasodilation by a variety 
of mechanisms summarised in figure 1.5:
23
CONTRACTILE
AGONISTS NO DONORS EDRF
PCI
P -  AGONISTS
2+Ca Ca
PLC ACROC
Ca^+
Stores
cGMP cAMP
IP3 cGMP-
PK1,2-DG
Calmodulin cAMP-
PKMLCK
MLC
CONTRACTION
Figure 1,5 Mechanisms o f action ofcGMP. Abbreviations: PLC~phospholipase C; ROC- 
receptor operated channel; GCIAC- Guanylate / adenylate cyclase: cGMP/AMP-PK - 
cGMP/AMP-dependent protein kinase; IPS - inositol trispkosphate; 1,2-DG - 1,2 diacyl 
glycerol; MLC- myosin light chain; MLCK - myosin light chain kinase.
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1.9 OTHER PHYSIOLOGICAL FUNCTIONS OF NITRIC OXIDE
A. Inhibition o f  platelet aggregation.
The discovery of a role for NO in platelet function occured in 1981, when it was found that 
NO and other nitrovasodilators inhibited ADP-induced platelet aggregation by a cGMP- 
dependent mechanism (Mellion, Ignarro, Ohlestein, Pontecorvo, Hyman & Kadowitz,
1981). It was not until 1986 that a link was identified between the actions of NO on platelet 
aggregation and those of EDRF on vascular smooth muscle (Azuma, Ishikawa & Sekikazi,
1986). It was shown by these and other workers that EDRF itself was capable of inhibiting 
platelet aggregation in vitro (Furlong, Henderson, Lewis & Smith , 1987; Radomski, 
Palmer & Moncada, 1987) and in vivo (Hogan, Lewis & Henderson, 1988). Radomski et 
al showed that NO and prostacyclin were both capable of enhancing the disaggregating 
effects of the other on platelets (Radomski, Palmer, Moncada, 1987b), although the effects 
of prostacyclin are mediated by cAMP rather than cGMP (Radomski, Palmer, Moncada, 
1987c), and that both have cytoprotective properties (Radomski, Palmer & Moncada, 1988). 
The cytoprotective effects of NO are now thought to be due to its reacting with the 
potentially harmful oxygen free radicals (O2 " in particular) (Rubanyi, Ho, Cantor, Lumma, 
& Botelho, 1991). At the same time, it was reported that NO inhibited platelet adhesion to 
collagen, endothelial cell matrix and cultured endothelial cell monolayers by a cGMP- 
dependent mechanism (Radomski, Palmer & Moncada, 1987c,d). This, however, is in 
contrast to prostacyclin, which only has a weak, cAMP-mediated inhibitory effect on platelet 
adhesion (Higgs, Moncada, Vane, Caen, Michel & Tobelom, 1978; Radomski et al, 1987c) 
and does not synergise with NO in this case.
It has been shown that nitrovasodilators which release NO spontaneously (sodium 
nitroprusside, organic nitrates and 3,morpholino-sydnonomine) are capable of inhibiting 
platelet aggregation by a cGMP-dependent mechanism. However, some organic nitrates 
(e.g. GTN) which can elicit vasodilation in vascular smooth muscle are not able to inhibit 
platelet aggregation (Gerzer, Karrenbrock, Siess, & Heim, 1988). The inference is that
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platelets lack the necessary mechanism for uptake of organic nitrates and/or their 
biodégradation, leading to release of NO.
It is now known that NO is generated in platelets and that it acts as a negative feedback 
system to modulate aggregation (Radomski, Palmer & Moncada, 1990 a,b). Generation of 
platelet-derived NO is NADPH-dependent, inhibited by LNMMA and dependent on free 
intracellular Ca^+. Addition of L-arginine to the medium does not alter basal NO 
production, but enhances the increase in NO production when aggregation is initiated using 
either collagen, ADP or arachidonic acid. The inference from this is that nitric oxide 
synthase exists in platelets and is stimulated to enhance NO synthesis from L-arginine once 
aggregation is initiated (due to an increase in intracellular Ca^ + : Ware, Johnson, Smith & 
Salzman, 1986). The increase in intracellular NO has been shown to be accompanied by an 
increase in cGMP but not cAMP. The mechanism by which cGMP inhibits aggregation is 
not fully understood, but it may involve sequestration of free intraplatelet Ca^+ (Busse, 
Luckhoff & Bassenge, 1987).
EDRF, therefore, may play an important antithrombotic role in vivo by inhibiting both 
platelet aggregation and adhesion to vessel walls, particularly as its actions are enhanced by 
the synergistic effect of prostacyclin.
B. In the central and peripheral nervous systems
In 1987, the central nervous system (CNS) transmitter, glutamate, was shown to elevate 
cGMP levels in the post synaptic neurone and give rise to an unstable intracellular factor 
(Garthwaite & Garthwaite, 1987). This factor was rapidly identified as having properties 
identical to EDRF or NO (Garthwaite, Charles & Chess-Williams, 1988) and was found to 
require Ca^ + for its production (Knowles, Palacios, Palmer & Moncada, 1988). Earlier 
work had established that NO is capable of stimulating guanylate cyclase (Miki, Kawebe & 
Kuriyama, 1977) and that a small molecule whose actions were inhibited by Hb is produced 
in rat forebrain (Deguchi, 1977). Furthermore, in 1982, the endogenous activator of soluble
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guanylate cyclase in neuroblastoma cells was identified as L-arginine (Deguchi & Yoshioka,
1982). This led to an extensive study of both CNS and peripheral NS in the search for NO 
synthase and further evidence for NO as a neurotransmitter.
Stimulation of N-methyl-D-aspartate (NMDA) receptors has been shown to activate 
synthesis of NO postsynaptically. It seems that NO does not act on the generator cell 
(perhaps because high intracellular Ca^ + inhibits guanylate cyclase activity) but diffuses out 
and acts on one or more neighbouring structures, including presynaptic terminals and 
astrocytes. NO synthesis is blocked by LNMMA and enhanced by L-arginine.
NO is also formed presynaptically, in climbing fibres of the cerebellum. The synthesis is 
stimulated by the influx of Ca^+ into the fibres following action potentials (Shibuki & 
Okada, 1991 ; Southam & Garthwaite, 1991). The apparent effect of NO generated in these 
fibres is the long-term depression of responses in Purkinje fibres, since LNMMA blocks the 
depression.
NO synthase in the brain has since been characterised and shown to be similar to both the 
endothelial and platelet enzyme in that it is inhibited by LNMMA, LNIO and LNA, requires 
NADPH as a cofactor (Schmidt, Wilke, Evers, & Bohme, 1989) and is dependent on 
calcium-calmodulin activation (Bredt & Snyder, 1990). It has been shown to be most 
prevalent in rat cerebellum, although it is also found in the hypothalamus, midbrain, 
striatum, hippocampus and medulla oblongata (Forstermann, Gorsky, Pollock, Schmidt, 
Heller & Murad, 1990).
NO has also been implicated in the pathophysiology of seizures and brain damage in rats 
(Beckman, Chen & Conger, 1992; Bagetta, Mollace, lannone & Nistico, 1992).
In the CNS, therefore, NO performs a variety of functions (although not as a classic 
neurotransmitter or neuromodulator), some of which are positively harmful to the brain 
tissue.
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In the peripheral nervous system, NOS has been discovered in a wide variety of tissues 
fulfilling many different functions. NO is now commonly termed a ‘ non-adrenergic, non- 
cholinergic’ (NANC) neurotransmitter found, for example, in the vagal nerves supplying 
gastrointestinal smooth muscle. In the presence of both adrenergic and cholinergic 
inhibitors, vagal stimulation results in relaxation, which can be inhibited by LNMMA, 
LNAME or LNA. NO has also been shown to be the NANC neurotransmitter involved in 
nocioception (Durte, Faccioli & Ferreira, 1992), relaxation of the lower oesophageal 
sphincter, gastrointestinal smooth muscles (Toda, Baba & Okamura, 1990; Thornbury, 
Ward, Dalziel, Carl, Westfall & Sanders, 1992), bovine retractor penis (Liu, Gillespie, 
Gibson & Martin, 1991; Martin, Gibson & Gillespie, 1992), the smooth muscle sphincter of 
the urinary bladder (Thornbury, Hollywood & McHale, 1992), urethral smooth muscle 
(Persson, Garcia-Pascaul, Foiman, Tottrup & Andersson, 1992) and corpus cavernosum 
(Goessl, Knispel & Beckmamn, 1992). In each case, competitive inhibitors of NO synthase 
block nerve-induced relaxations.
C. In activated macrophages.
In 1987, it was demonstrated that activated macrophages required L- (but not D-) arginine to 
exert their cytotoxic effects on tumour target cells (Hibbs, Taintor, & Vavrin, 1987). It was 
also shown that L-citrulline and NOg" were formed in the process. LNMMA competitively 
inhibits the synthesis of both of these compounds and also the expression of cytotoxicity 
(Hibbs et al, 1987). With the recent identification of the L-arginine:NO synthetic pathway in 
endothelial cells, platelets and in the nervous system, NO was swiftly recognised as the 
most likely active intermediate in activated macrophages (Marietta, Yoon, lyenger. Leaf & 
Wishnok, 1988 ; Hibbs, Taintor, Vavrin & Rachlin, 1988 ; Stuehr & Nathan, 1989), 
especially since the cytotoxicity of activated macrophages is inhibited following endocytosis 
of haemoglobin or erythrocytes (Weinberg & Hibbs, 1977).
Activated macrophages are thought to exert their cytotoxic effects in a variety of ways;
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1. Inhibition of deoxyribonucleic acid (DNA) replication. This is reflected in a reduction 
in the uptake of tritiated (pH]) thymidine in target cells (Krahenbuhl, 1980; Hibbs, Taintor, 
Vavrin, Granger, Drapier, Amber & Lancaster, 1991). It is thought likely that 
deoxyribonucleotide reductase, the rate limiting enzyme in DNA synthesis, is the target for 
macrophage-derived NO. The catalytic site on this enzyme contains non-haem iron which is 
potentially vulnerable to NO attack (Reichard & Ehrennberg, 1983).
2. Inhibition of the mitochondrial respiratory chain. The site of NO-induced inhibition 
of the electron transfer system has now been identified as the two proximal oxidoreductases, 
NADH: ubiquinone oxidoreductase and succinate: ubiquinone oxidoreductase (Granger & 
Lehninger, 1982). Both complexes contain Fe-S groups, known to be susceptible to NO 
binding. Adenosine triphosphate (ATP) synthesis, via the glycolytic pathway, is apparently 
unaffected when target cells are co-cultivated with activated macrophages (Granger, Taintor,
Cook & Hibbs. 1980).
3. Inhibition of aconitase (a citric acid cycle enzyme). As with the electron transport 
chain enzymes inhibited by activated macrophages, aconitase contains a 4(Fe-S) prosthetic w 
group at its catalytically active site (Kilboume, Klostergaard & Lopez-Berestein, 1984). The 
inhibition of this, and the afore-mentioned enzymes, may be associated with the reported 
loss of a significant proportion of intracellular iron from target cells (Hibbs, Taintor & 
Vavrin, 1984), since the effects of NO can be reversed by incubation with ferrous ions 
(Drapier & Hibbs, 1986).
It is interesting to note that activated macrophages themselves are prone to the same 
cytotoxic effects of NO as found in target cells (Drapier & Hibbs, 1988). Activation of 
macrophages to release NO in large quantities is evidently an important immune response 
involved in the control of microorganisms and tumour cells. The non-specific cytotoxicity 
of NO is largely due to its inhibitory effects on enzymes involved in DNA synthesis, 
metabolism and respiration.
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Attempts to characterise the enzyme responsible for NO synthesis in activated macrophages 
proved more difficult than in other systems. It became apparent that the enzyme was only 
expressed in macrophages once they had been activated with Escherichia colt 
-lipopolysaccharide (LPS) alone, or in combination with interferon-g (IFN-y) (Hibbs et at,
1987), and that the process involved protein synthesis (Marietta et al, 1988). Evidently, 
activation of macrophages induces NOS synthesis within the cells. The enzyme was found 
to be inhibited by L-canavanine (lyenger, Stuehr & Marietta, 1987) as well as LNMMA (the 
isoforms found in endothelial cells, platelets and the nervous system are not inhibited by L- 
canvanine). Hereafter, the isoform of NOS found in activated macrophages will be termed 
‘inducible’ whilst that found elsewhere is ‘constitutive’. Recently, a more intensive study of 
the various NO synthase isoforms has revealed further subdivisions of these two classes, 
some of which have been purified and characterised (Forstermann, Schmidt, Poliak, Sheng, 
Mitchell, Warner, Nakane & Murad, 1991). Table 1.1. shows the major differences 
between the six isoforms so far characterised:
ISOFORM
Characteristic l a I b Ic I I I l l IV
Sol. / partie. soluble soluble soluble soluble particulate particulate
Cosubstrates/
Cofactors
N A D P H ,
B H 4 ,
F A D /F M N
N A D P H N A D P H ,
B H 4 ,
F A D
N A D P H , 
B H 4 , R -S H , 
F A D /F M N
N A D P H ,
B H 4
N A D P H
Regulated by: Ca^+/caIm od Ca^+/calm od C a 2 + ? Ca^^/calm od 7
Mr (denatured) 155 kD a ? 150 kD a 125-135 kD a  
or 150 kD a  ?
135 kD a ?
Present in: cerebellum endothelium neutrophils macrophagses 
hepatocyte?  
Kupffer cells?
V S M  ? 
endothelium ? 
lung?liver?
endothelium macrophages
Table 1.1. Isoforms of NO synthase (after Forstermann et al., 1991 ). All isoforms use L- 
arginine as a substrate and are inhibited by LNMMA and LNIO.
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1.10 NO DONOR DRUGS
Considerable reference has already been made to so-called 'nitrovasodilators'. Hereafter, the 
term 'NO donor drug' will be used when referring to any compound capable of releasing 
NO under physiological conditions, either by enzymatic degradation or spontaneous 
decomposition. Figure 1.6 shows the structural formulae of some common nitric oxide 
donor drugs as well as those of two novel compounds.
AMYL NITRITE
(CnpgCH-CI^-CHg-ONO
GLYCERYL TRINITRATE
CHg-O-NOg
NITROPRUSSIDE
(NP)
CH-O-NO.
CHg-O-NOg
S-NITROSO-N-ACETYL PENICILLAMINE 
(SNAP)
NC^
NC
ON
■ rc
N
-CN
'CN
ROUSSIN'S BLACK SALT 
(RBS)
SNO
a c H p g
CH3CONH-CH-COOH
CUBANE
(CUB)
ON Te'
Fe" NO> Fe
NO
F igure 1.6 . Examples o f NO donor drugs. Full chemical names: NP 
pentacyanonitrosylferrate. RBS - heptanitrosyltri-ps-thioxotetraferrate. CUB. 
tetranitrosyltetra-pj-suphido-tetrahedro-tetrairon.
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A. ORGANIC NITRATES
Both amyl nitrite and glyceryl trinitrate have been used for over a century in the treatment of 
angina (Brunton, 1867). The mechanism of action of these compounds remained a mystery 
until 1973 when it was discovered that relaxation of precontracted aortic strips was dependent 
on the presence of -SH groups within the tissue (Needleman et al, 1973; Ignarro et al, 
1981). Ignarro et al, (1981) went on to show that S-nitrosocysteine and S-nitroso-N- 
acetylpenicillamine have similar vasorelaxant properties to GTN, amyl nitrite and NP when 
-SH groups are present (also Kowaluk, Poliszczuk & Fung, 1987). As yet, the mechanism 
by which organic nitrates break down to release NO has not been satisfactorilly explained. 
Current hypotheses include breakdown of GTN to produce NO2  (possibly enzymatic), 
followed by acidification to produce HONG and ultimately NO. The shortfall of this 
hypothesis lies in the requirement for acid conditions; intracellular pH in smooth muscle 
cells has been estimated as between 5.9 and 7.0 (Adler, 1972; Stephens, Mitchell, Kroegger,
1977).
B. NITROPRUSSIDE
The sensitivity of vascular smooth muscle to sodium nitroprusside (NP) has been 
recognised for over a century (Leeuwenkamp, Van Bennekom, Van der Mark & Bult, 
1986). Clinically, NP was used extensively in acute hypertensive crises and malignant 
hypertension (Kreye, 1980). The recent decline in its use is linked to sporadic reports of 
cyanide poisonings (Smith, Kruzyna, 1974; Butler, Glidewell, 1987). It is now widely 
accepted that cyanide is generated from NP on exposure to light in acid conditions (Arnold, 
Longnecker & Epstein, 1984) or in the presence of Hb (Smith & Kruzyna, 1974).
It has been long suspected that the nitrosyl group of NP is the vasodilatory component of the 
molecule. However, the apparent stability of NP when protected from light prompted 
investigation of the intracellular mechanism by which the iron-nitrosyl bond is cleaved in 
vivo. Early work using homogenates from various tissues suggested that the decomposition 
was non-enzymatic (Casinelli, 1956; Hill, 1942; Smith & Kruszyna, 1974). Degradation, 
however, was shown to be accelerated in the presence of cysteine and methionine (Page,
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Corcoran, Dustan & Koppanyi, 1955). Leeuwenkamp et al (1986) suggested the process 
involved reduction of NP by an 'unidentified reductor*. Recent work on subcellular fractions 
of bovine coronary arteries showed that NO was readily generated from NP in subcellular 
fractions and that the dominant site of activity appeared to be in the membrane fractions 
(Kowaluk, Seth & Fung, 1992). The researchers went on to isolate two NO generating 
enzymes of Mr 4 kDa and 112-169 kDa using gel filtration.
Experiments in this laboratory, have shown that half-ventricular preparations of the frog 
heart do not respond to NP in the dark. However, when exposed to laser light, NP was 
shown to have a negative inotropic effect on contractility (Flitney & Kennovin, 1988). The 
inference from these experiments is that no NO generating enzyme exists in this particular 
tissue.
Recently, some doubt has been cast on whether NO production is exclusively responsible 
for the vasodilatory effect of NP. Otsuka, Dipiero, Hirt, Brennamen & Lockette (1988) 
found that endothelium-dependent relaxations are attenuated by agents that inhibit guanylate 
cyclase but that the same was not always true of NP. They found that maximal NP-induced 
relaxations were accompanied by a relatively small increase in intracellular cGMP. Similar 
elevations in cGMP levels by endothelium-dependent vasodilators result in relatively small 
relaxations. Elsewhere, it has been shown that low concentrations of both NP and GTN are 
capable of causing precontracted aortic rings to relax without increasing cGMP levels 
(Diamond & Chu, 1983). The efficacy of the drugs was also shown to be dependent on 
agonist (phenyleplirine) concentration but cGMP levels were unaffected.
In addition, NP does not fit the correlation between guanylate cyclase EC5 0  and NO 
formation that holds true for other NO donor drugs (Feelisch, 1991). Accordingly, it is now 
thought that NP acts through several mechanisms, one or more of which is (are) cGMP- 
mdependent.
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c. S’NITROSO‘N-ACETYL PENICILLAMINE (SNAP)
SNAP is stable in the solid state, but thermally unstable once in solution. The rate of 
decomposition is dependent on pH (most unstable at pH7) and the type of buffer present, as 
well as on the ambient temperature (Butler & Askew, unpublished data). Breakdown 
appears to be non-enzymatic in vivo, since both L- and D-enantiomers give similar dose- 
dependent response curves (Butler, Askew & Flitney, 1993). Degradation of SNAP is 
accelerated on exposure to light (absorption maximum - 339 nm ; Butler & Askew, 
unpublished data).
D. IRON‘SULPHUR NITROSYL CLUSTERS
RBS and CUB (see figure 1.6) belong to a class of compounds which have been known for 
over a century (Roussin, 1858). The chemistry of these compounds is unique, not least in 
respect of their synthesis, which arises by a process known as 'spontaneous self assembly' 
(Sung, Glidewell, Butler & Hoffmann, 1985). That is to say, under appropriate conditions, 
synthesis occurs from mononuclear starting materials without the detectable formation of 
any intermediates. Of all compounds in this class, RBS appears the most stable, as it is the 
end product of numerous reactions involving other iron-sulphur nitrosyl clusters. In the 
solid state, the compounds are relatively stable, particularly if kept under nitrogen and at 
-10°C. The present study (chapter 4) will show that in solution, both compounds have 
vasodilator properties, inhibitable by Hb and MB but not by LNMMA (Flitney, Megson, 
Butler & Clough, 1990; Flitney, Megson, Flitney & Butler, 1992). Evidently, once in 
solution, they decompose to release NO. Ultimately, the products of breakdown of RBS 
have been shown to be iron oxide and elemental sulphur, although it is unclear whether other 
intermediates exist (Butler & Askew, unpublished data). Both compounds are potentially 
potent vasodilators should they decompose to release their full complement of bound 
nitrosyl groups in solution.
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1.11 PHOTORELAXATION
Furchgott, Ehrreich & Greenblatt (1961) first demonstrated that precontracted strips of 
rabbit aorta relax when exposed to light. Using a monochromator, they showed that the 
degree of relaxation was both intensity and wavelength dependent (shorter wavelengths 
eliciting larger photorelaxations). The amplitude of the response was independent of oxygen 
tension, though recovery in the dark was markedly slower under anaerobic conditions. 
Lowering the temperature from 37 to 20^C increased the amplitude of the response and 
prolonged its time course. The nature of the photosensitive material could not be 
established, though the way in which the response varied with wavelength (biological 
‘action’ spectrum) led Furchgott gr al to propose that it could be a ‘complex of a metal, such 
as iron, with a protein’. Since then, research focussed on the mechanism responsible for 
photorelaxation.
It is known that the extent of photorelaxation is attenuated in the presence of GTN 
(Furchgott, 1971). The experimental procedure involved increasing the concentration of 
contractile agonist (phenylephrine) to compensate for the vasodilatory effect of GTN. 
Photorelaxations before and after GTN treatment could then be compared, in the knowledge 
that any differences found were not due to changes in pre-illumination tension. The 
inference from this result was that photorelaxation and GTN-induced relaxation involve a 
common pathway.
However, similar experiments showed that nitrite (NO2  ), potentiated photorelaxation. 
Recently, a comprehensive study of the interaction of ultraviolet light with NO2 ' has shown 
that SOD enhances nitrite-potentiated photorelaxation of aortic rings but not unpotentiated 
responses (Matsunaga & Furchgott, 1988). Photorelaxation was shown to be inhibited by 
Hb (but not met Hb). Photoactivation of N0 2 " before superfusing the preparations also 
resulted in potentiation of the relaxation due to NOy. This effect was augmented by SOD 
and inhibited by Hb. These results suggest that NO2" releases NO on exposure to light, 
resulting in enhanced relaxation.
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Non-vascular smooth muscle does not undergo photorelaxation unless pre-treated with 
N 0 2 “. Experiments by Furchgott (1984) seemingly eliminated the endothelium as a 
possible source of NO in the photorelaxation of vascular smooth muscle since endothelium- 
denuded preparations still relax when exposed to ultraviolet light
However, recent work by Deliconstantinos, Villiotou & Fassitsas (1992) on cultured human 
endothelial cells and isolated NO synthase suggests that ultraviolet light stimulates NO 
synthesis by the enzyme since the effect was inhibited by LNMMA. The authors propose 
that vasodilation of microvessels in the skin due to increased NO synthesis is responsible 
for the redness caused by sunburn.
The involvement of NO in photorelaxation is disputed by work on crude preparations of 
soluble guanylate cyclase from mesenteric arteries (Karlsson, Axelsson & Andersson, 
1984). Ultraviolet irradiation of the enzyme results in an elevation of cGMP, leading to 
claims that photorelaxation is due to direct stimulation of guanylate cyclase.
Controversy as to the involvement and source of NO is evident from these conflicting 
opinions. Previous experiments in this laboratory have shown that photorelaxation in the 
isolated rat tail artery is inhibited by pyrogallol and Hb but not by LNMMA. Detailed 
experiments are reported here, undertaken to determine (a) whether NO is responsible for 
photorelaxation and if so, (b) the possible source of NO released on exposure to light.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 PREPARATION
Experiments were performed on 8  - 12 mm long segments of tail artery taken from 
normotensive adult Wistar rats (270 - 538 g). Animals were killed by cervical dislocation 
and the tail removed. The artery was exposed following removal of the overlying skin and 
connective tissue. Once exposed, the artery was cannulated (Portex cannula), dissected free 
and transferred to a perspex bath. Care was taken to identify and tie-off all side-branches.
2.2 APPARATUS
The apparatus is shown in Figure 2.1. The vessel (V) was perfused internally at a constant 
flow rate of 2ml min'  ^driven by a peristaltic pump (PI: Gilson minipuls 2). The perfusate 
was pre-warmed to 32-33°C by passage through the heat exchanger (HE). Drugs were 
introduced into the lumen of the vessel by bolus injection (lOjdl) through a resealable rubber 
septum (RS). A differential pressure transducer (P: Sensym type SCX 150NC; Parnell 
Electronic Components, Leeds) detected changes in back pressure determined by arterial 
tone.
The outer surface of the vessel was superfused continuously (ca. 8 ml min'^) with solution 
driven by a second peristaltic pump (P2: BDH mini pump). The solution was pre-warmed 
to 32-33°C by passage through a heat exchanger similar to that used in the internal circuit.
•  # RS
95% O. 
5% C Q  -+
H E V
Figure 2.1 Apparatus used for perfusing isolated segments o f rat tail artery. See text for 
full description and explanation of lettering.
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Alterations made to this appparatus for particular experiments will be described in the 
Methods section of the relevent chapters.
2.3 EXPERIMENTAL PROTOCOL
Arteries were perfused internally and externally with oxygenated Krebs solution 
(composition mM: NaCl 118, KCl 4.7, NaHCOs 25, NaH2P04 1.15, CaCb 2.5, MgC^ 
1.1, glucose 5.6, gassed with 95% 0% / 5% CO2  to maintain pH 7.4). Internal perfusion of 
the cannulated vessel was initially slow ( flow rate ca. 0.2 ml min‘ 1). The working flow rate 
of 2 ml min-  ^ was attained by gradually increasing the pump speed over a period of 1 0 - 2 0  
mins. The preparation was then allowed to stabilise for a further 20-30 mins, at which time 
a ’passive’ pressure of 5 - 24 mmHg was recorded. Precontraction was induced by addition 
of phenylephrine hydrochloride (PE) to both internal and external perfusates (figure 2.2).
•ACTIVE'
PRESSURE
20 mm Hg
- 4 mins
'PASSIVE'
PRESSURE
Figure 2,2. Pressure recording showing precontraction with PE. 5pM PE was added to 
both internal and external perfusate reservoirs at the time indicated, reaching the vessel 
through the external perfusate at A and the internal at B. The pressure tnaintained by the 
vessel before PE addition is termed ^passive whilst agonist-induced pressure is ‘active 
E x p t.m  920304.
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The PE concentration was adjusted to maintain a pressure of 90 - 138 mmHg above the 
passive pressure.
At this point in the experimental procedure, the laboratory lights were switched off, leaving a 
red safelight (60W) as the only means of illumination. This precaution served to prevent 
photorelaxation of the vessel and to protect any NO donor drugs in use from photolytic 
decomposition.
2.4 DRUGS
L-phenylephrine hydrochloride (Mr 203.7; Sigma Chemicals). Appropriate volumes of a 
lO'^M stock solution were added to both the internal and external perfusates to produce 
concentrations ranging from 1 - 1 2  pM.
Sodium nitroprusside (Mr 298; Sigma Chemicals). IQ-^ M stock solutions were serially 
diluted to produce the desired range of concentrations immediately prior to use.
Ferrohaemoglobin (Mr 64500; Sigma Chemicals) was prepared by reduction of lOOmls of 
ImM bovine haemoglobin using lOmM sodium dithionite. The dithionite was dialysed out 
of solution against 3x 2 litre volumes of water at 0-5°C. The stock ferrohaemoglobin was 
then split into 3ml samples and frozen (-10°C). Samples were used within 2 weeks.
Methylene blue (Mr 320; Sigma Chemicals). Appropriate volumes of a lO'^M stock 
solution were added to the internal perfusate to produce final concentrations of 10 - 200pcM.
Carbamylcholine chloride (Mr 182; Sigma Chemicals). lO'^M stock solutions were 
serially diluted to produce the desired range of concentrations immediately prior to use. 
Solutions were kept on ice during experiments.
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N^-M onom ethyl-L-arginine (Mr 252; gift of RMJ Palmer & H Hodson, Wellcome 
Research labs., Kent). Appropriate volumes of a 10-3 ^  stock solution were added to the 
internal perfusate to produce a final concentration of 100/<M.
S-nitroso-N-acetylpenicillamine (SNAP; Mr 220; prepared by S. Askew & A.R. Butler, 
Department of Chemistry, University of St. Andrews) was synthesised by reacting N- 
acetylpenicillamine with sodium nitrite (Field, Dilts, Ravichandran, Lenhert & Carnahan,
1978), lO'^M stock solutions were serially diluted to produce the desired concentration 
immediately prior to use. Solutions were kept on ice during experiments.
Roussin's Black Salt (RBS; Mr 553) was prepared in this laboratory and by Dr. S. 
Glidewell (Department of Chemistry, University of St. Andrews) using the protocol detailed 
below. 5x10"3m stock solutions were serially diluted to produce the desired range of 
concentrations immediately prior to use.
Cubane (CUB; Mr 472) was prepared by Dr. S. Glidewell at the Department of Chemistry, 
University of St. Andrews using the protocol detailed below. Unlike RBS, CUB. is not 
soluble in water and as such cannot be dissolved in Krebs solution. The solid was first 
dissolved in dimethyl suphoxide (Sigma Chemicals) to produce a IQ-^M stock solution 
which was then serially diluted with Krebs solution to produce the desired range of 
concentrations.
‘Authentic’ NO. Saturated solutions of NO were prepared by bubbling NO gas, derived 
from the reaction of ascorbic acid with sodium nitrite, through distilled water. Extreme 
precautions were taken to exclude oxygen from the water which was double distilled under 
0 2 "free N2  and kept under argon throughout the entire procedure. A small sample (10ml) 
was transferred into a glass vial, already gassed with argon to drive out oxygen. The 3/4- 
filled vial was then sealed with a rubber septum through which two needles were passed. 
One of the needles was attached to a small, deoxygenated and sealed reaction flask 
containing ascorbic acid and sodium nitrite. NO produced from the reaction passed through 
the distilled water and out via the second needle. The process was allowed to continue for
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—approximately 30 mins, at which point the needles were removed, leaving a saturated 
solution of NO below a NO atmosphere.
Dilutions of the saturated solution were made by injecting a small volume (<10/<1) into 
degassed, sealed vials containing known volumes of ‘0 2 -free’ distilled water.
All procedures were carried out in a fume cupboard
PREPARATION OF ROUSSIN'S BLACK SALT (Sodium heptanitrosyl-tri-;,^- 
sulphido-tetraferrate : Na[Fe4S3 (NO)?])
Figure 2.3 shows the appparatus used to synthesise RBS.
qA A
NaNCh
Figure 2.3. Apparatus used in synthesis o f RBS. Abbreviations: DF - dropping funnel; LP 
- liquid paraffin; HP - hotplate and stirrer.
Sodium nitrite (NaN0 2 ) and sodium sulphide (Na2 S) were stirred and heated under 
nitrogen until boiling. Ferrous sulphate solution (FeS04) was added from a dropping 
funnel (DF) to the accompaniment of black frothing, quelled by the addition of 20% 
ammonia solution. The resulting mixture was hot-filtered through pre-heated Hyflo to 
remove iron oxide and the residue washed with hot / boiling water. The filtrate was cooled 
on ice and crude RBS precipitated out of solution. The precipitate was filtered off, 
recrystallized from hot water and dried in a vacuum dessicator. RBS was stored in the dark.
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under nitrogen and at -10°C. Purity was assesed using infra-red spectroscopy where three 
peaks are seen at 1795,1747 and 1707 cm-i (Figure 2.4).
PREPARATION OF CUBANE (Tetranitrosyî tetra-^3 -sulphido-tetrahedro-tetrairon: 
FC4S4 NO4 ).
RBS and elemental sulphur (Sg) were heated under reflux in dry, redistilled toluene under 
nitrogen for 16 hrs. After cooling, the mixture was filtered through a packed bed of Hyflo 
supercel and the solvent removed (oil-pump vacuum). The residue was dissolved in the 
minimum volume of chloroform and introduced onto a silica chromatography column. The 
black band was eluted with chloroform. The column effluent was then evaporated to yield 
shiny black plates of the product. Purity of the product was assesed by melting point (95- 
97^0) and infra-red spectroscopy, where a single peak is seen at 1790 cm*^  (Figure 2.4).
RBS CUB
*  TRANSMISSION
^105 5
94 -
8606 -
78 -
87 5
62 83 862 -
78 5
38 - 69 538 -
38 65 838 1800
WAVELENGTH (CM ' ) WAVELENGTH (CM * )
Figure 2.4, Infra-red absorption spectra for RBS and CUB (1 mg ml~ )^ dissolved in 
tetrahydrafuran (THF). Note the small, broad peak at ca. 1620 cmr  ^in the CUB spectrum. 
This is due to the presence o f a small amount of water in the sample. Spectra recorded on 
19107191 (RBS) and 1105191 (CUB).
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CHAPTER 3
EFFECTS OF HB ON VASODILATOR RESPONSES 
TO BOLUS INJECTIONS OF NP, SNAP, RBS AND CUB.
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3.1 INTRODUCTION
The vasodilator properties of organic nitrates and nitrites have been used clinically for many 
years, without a clear understanding of the mechanism underlying their actions. Since the 
endogenous vasodilator (EDRF) was recognised as NO (Moncada et al, 1987), it became 
clear that the actions of these and other related compounds were mediated by NO. The term 
'nitrovasodilator' was attributed to any such compound but here they will be referred to as 
NO-donor drugs.
Experiments were performed to determine the relative potency of authentic NO, NP and
SNAP as well as two novel NO donors, RBS and CUB (all molecular structures shown in
figure 1.7). The inhibitory effect of Hb, a recognised NO scavenger, was investigated.
Preliminary experiments in this laboratory (Flitney et al, 1990), have shown that responses
to bolus injections of NP, RBS and CUB are unaffected by the NOS inhibitor, LNMMA.
In contrast responses to carbamylcholine chloride (CCh) were severely attenuated in the
presence of LNMMA (Figure 3.1 (c)). However, responses to CCh, RBS and CUB, but
not NP, were inhibited by both MB and Hb (figure 3.1 (b) and (d)).
LNMMA ---------------------- ---- - ------------------------------ -CONTROL
v1
4mins
L
4mins
CUB RBSr ]rlI1/ ; • 1
4mins
I
4 ^
4mins
Figure 3.1 (a) Vasodilator responses to lOpl test doses o f CCh (IQ-^M), NP (2.5x1 
RBS (SxlQ-'^M) and CUB (lO'^M). Other traces show responses to test doses in the 
presence of internally perfused MB (75pM, (b)), LNMMA (lOOpM, (c)) and Hb (15pM, 
(d)). Experimental details (a,b): 274g male Wistar rat. 5pM  PE produced an active 
pressure of 135mmHg. Basal tone ~ 12mmHg. Expts (c) and (d) 373g male Wistar rat. 
4pM  PE produced an active pressure of 114mmHg. Basal tone = 17mm Hg.
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3.2 MATERIALS AND METHODS
A. ANIMALS
Adult male Wistar rats (250-460 g) were killed by cervical dislocation, their tails removed 
and a length of arteiy (8-15 mm) cannulated and dissected free as described earlier.
B. APPARATUS
The apparatus shown in figure 2.2 was used for all experiments.
C. EXPERIMENTAL PROTOCOL
Vessels were precontracted with PE to produce agonist-induced perfusion pressures of 101 
+/- 3.5 mmHg ([PE] = 6.5 +/- 0.5 pM ; n=21). Responses to 10 pi bolus injections of 
increasing dose (0.1 piM - 10 mM for NP and SNAP; 0.1 pM  - 5 mM for RBS and CUB) 
were compared to responses to the same doses injected into internal perfusate containing 15 
pM  Hb.
D. ANALYSIS OF RESULTS
The amplitude of responses are expressed as a % of the pre-injection pressure and plotted as 
a function of logio dose concentration (M).
From the log-dose response curves, the dose required to elicit half-maximal responses in 
each case was estimated.
46
3.3 RESULTS
A. Responses to SNAP and NP.
Microinjections of either SNAP or NP produced immediate, dose dependent vasodilations. 
Responses consistently recovered to the pre-injection pressure, although the time taken to 
recover displayed a dose-dependence.
Perfusion of the vessel with 15/<M Hb resulted in a reversible increase in pressure of 55.92 
+/- 6.4% (n=15). This compares favourably with the increase in pressure observed when 
vessels are internally perfused with 100/<M LNMMA (57.1 +/- 6.1%, n=10), a 
concentration which exceeds that required to produce total blockade of EDRF-induced 
relaxation in aortic rings (Moncada et al, 1986).
Figure 3.2 shows recordings from experiments using both compounds. The records show 
responses to increasing doses of SNAP or NP before the addition of ISpM Hb followed by 
corresponding responses in the presence of Hb. Vasodilations evoked by both compounds 
are transient, with those to SNAP showing more rapid recovery. In some cases, responses 
to high doses of either compound recover to a level above the pre-injection pressure and then 
return slowly to the expected level (figure 3.2, SNAP).
Addition of Hb to the internal perfusate produces a rapid rise in pressure. Injections of 
either drug in the presence of Hb are still capable of producing substantial vasodilator 
responses. However, responses to both SNAP and NP were found to be significantly 
attenuated in the presence of Hb, when expressed as a % of the pre-injection active pressure.
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SNAP
20%
\5fiM Hb
20% L
4 mins
-6 -5-4.7 -4.3 -4NP
-26-5 4.7 4.3
IS/^ M Hb 20%
20% L _
Figure 3.2, Pressure recordings showing vasodilator responses to bolus injections (lOpl) 
o f increasing doses o f  SNAP or NP, before and during ISpiM Hb perfusion. 
Concentrations indicated for each injection are log [dose](M). Note the change in vertical 
scalebar referring to responses in the presence of Hb (brought about by an increase in 
active pressure). Experimental details: SNAP, expt. No 930115. 304g, male Wistar rat; 
l.S pM P E  produced 120mm Hg active pressure. 15pM Hb caused a further 87% rise in 
active pressure. NP, expt. No 901016. 346g male Wistar rat. 5pM  PE produced 113mm 
Hg active pressure. ISpM Hb caused a further 49% rise in active pressure.
Figure 3.3 shows log dose response curves derived from experiments involving both 
compounds in the absence and presence of l5pM  Hb.
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Figure 3.3. Log dose response curves for SNAP (filled squares; n~5) and NP (filled 
circles; n -5). Corresponding log dose response curves for SNAP (open squares; n -4 )  
and NP (open circles; n=5) in the presence of ISpM Hb are also shown.
From the curves, it is clear that SNAP is the more potent vasodilator and that its effects are 
more severely inhibited by Hb. The inhibition was found to be significant for intermediate 
doses of both compounds (unpaired t-test; P< 0.05 for 10“^  - 10"^M SNAP and 10"^  - 10' 
NP, see appendix I and II for details). It is evident that high doses of either compound 
are still capable of eliciting responses which are not significantly different from control 
responses obtained before introduction of Hb (unpaired t-test; P>0.05 for lO-^M SNAP and 
lO'^M NP - see appendix I and II). ED50 values derived from graph 3.3 are shown in table 
3.1.
SNAP EDso NP EDso
Before Hb 6  iM 52 pM
In Presence of Hb 40 pM 108 pM
Table 3.1. ED50 values for SNAP and NP derived from graph 3.3.
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These values confirm that SNAP is arniore potent vasodilator than NP in the dark and that 
Hb reduces the potency of SNAP by a factor of ca. 7, whilst that of NP is only reduced by a 
factor of ca, 2 .
B. Responses to RBS and CUB.
Figure 3.4 shows recordings of responses to bolus injections of RBS and CUB in the 
absence and presence of \5pM. Hb.
-2.3
RBS
20%
-4.7 ■4.3 -3.7 -3.3 -2.3
20% 1_
4 mins
-2.3
CUB
20%
-7 -6 -W .7 ^.3  ' -3.7 -33 -2.3
15;<M Hb20%
Figure 3,4, Pressure recordings o f experiments showing responses to lOpl injections of
increasing doses of RBS or CUB. Also shown are experiments carried out on different 
preparations, in which IQ-^M and 5 x ICh^M doses o f both compounds were injected in the 
presence o f 15pM  Hb, Concentrations indicated for each injection are log [dose](M). 
Experimental details: RBS, Expt 910121, 404g, male Wistar rat; 5pM PE produced 
97mm Hg active pressure, RBS + Hb, Expt, 910117. 419g male Wistar rat; 8pM  PE 
produced 77mm Hg active pressure, ISpM Hb caused a 90% increase in pressure. CUB, 
Expt, N^901210/l, 247g male Wistar rat,; 4pM  PE produced 82mm Hg active pressure. 
CUB + Hb, Expt, 901210/2. 247g male Wistar rat; 4pM  PE produced 104mm Hg 
active pressure, ISpM Hb caused a 109% rise in pressure.
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Responses to RBS and CUB could nÔt be directly compared with those elicited by SNAP 
and NP since responses to both RBS and CUB displayed an increasing tendency to fail to 
recover fully with increasing dose (Figure 3.4). In the case of the highest dose of RBS 
injected, the vessel consistently showed no recovery at all, even if left for up to 6  hrs. It was 
necessary, therefore, to employ an alternative method of quantifying the results for the 
purposes of plotting log-dose response curves. Figure 3.5 shows log-dose response curves 
for RBS and CUB where each point represents the peak vasodilation acheived by each 
successive dose (X) expressed as a % of the pressure before the first microinjection (Y). 
Experiments to investigate the effect of Hb were carried out on seperate preparations. 
Responses to RBS and particularly CUB were severely attenuated in the presence of Hb, 
with only the highest dose (5mM) in each case, able to cause significant vasodilation. 
Interestingly, the majority of responses obtained in the presence of Hb were fully reversible.
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Figure 3,5. Log-dose respotise curves for RBS (filled circles; n=5) and CUB (filled 
squares; n -6). Also shown are responses to JO-3 and 5 x 10-3M RBS (open circles n=6) 
and CUB (open squares; n~6) in the presence of 15pM Hb.
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From the log-dose response curves shown above, 'ED50' values were obtained for RBS and 
CUB (table 3.2). It was not possible to estimate comparable values for Hb-inhibited 
responses because of the extent of blockade.
RBS EDso CUB EDso
300/<M l l lp M
Table 3.2, ED50 values derived from the log-dose response curves shown in figure 3,5,
These results are surprising in that the compound with the highest NO-capacity (RBS, 7 
nitrosyl groups) is the least potent vasodilator in terms of initial amplitude of response, 
implying that RBS is the most stable of the compounds studied under the conditions o f  
these experiments.
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3.4 DISCUSSION
A. SNAP and NP
The results show that bolus injections of either compound into the internal perfusate elicit 
transient responses which recover rapidly. Hb significantly inhibits, but does not abolish, 
the responses to either drug, with SNAP being more sensitive than NP. This finding 
suggests that NO is responsible for a proportion of vasodilation caused by both compounds. 
However, to explain the results fully, either NO-independent mechanisms are involved in 
SNAP and NP-induced vasodilation, or a proportion of NO released from these compounds 
is protected from Hb attack.
In the case of NP, considerable doubt has already been shed on the assertion that NO is 
solely responsible for its vasodilator properties. Otsuka et al (1988) found that guanylate 
cyclase inhibitors were not always capable of attenuating responses to NP and that maximal 
NP-induced relaxations were accompanied by a relatively small increase in cGMP. Similar 
results were obtained by Diamond & Chu (1983). These findings, coupled with 
irregularities with regards to the kinetics of NP stimulation of guanylate cyclase (Feelisch, 
1991), suggest that NP acts through a number mechanisms, one or more of which is 
cGMP-independent.
In addition, Flitney & Kennovin (1988) showed that NP does not release NO spontaneously 
in the dark. Mounting evidence indicating the existence of a membrane-bound enzyme 
which 'strips' NO off NP (Leeuwenkamp et al, 1986 ; Kowaluk et al, 1992) suggests that 
NP-derived NO may never experience the intra-lumenal environment, thus avoiding Hb 
inactivation at this level.
The involvement of NO in NP-induced relaxation in the dark is further questioned by results 
obtained in this laboratory (Flitney et al, 1990; figure 3.1). The results show that responses 
to bolus injections of NP are not significantly inhibited by Hb or MB, lending further weight
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to the argument that some of its vasodilator properties are mediated by a cGMP-independent 
mechanism.
SNAP is thermally unstable (Butler & Askew, unpublished data) and is likely to release 
some NO spontaneously in the lumen where it would be susceptible to Hb inactivation. 
Recent experiments (Butler et al, 1993) have shown that SNAP undergoes a process known 
as 'cross nitrosation' in the presence of -SH-containing compounds, such as cysteine. It is 
possible, therefore, that NO could be 'stripped' from SNAP in a similar way to NP. NO 
derived in this manner may not be susceptible to Hb inhibition. Potentially, therefore, 
SNAP can release NO by two mechanisms, only one of which is susceptible to Hb 
inhibition.
B. RBS and CUB
Both RBS and CUB, as high-capacity NO-containing compounds, have great potential as 
NO donor drugs. In terms of peak amplitude of response, this is clearly not the case, with 
SNAP and NP proving to be substantially more potent vasodilators. However, responses to 
bolus injections of RBS and CUB showed a tendency to fail to fully recover with increasing 
doses. The loss of pressure does not appear to be due to cytotoxic effects of the drugs 
themselves, since no sustained loss of pressure occured when even the highest dose of either 
compound was injected in the presence of Hb. Cytotoxic effects of NO cannot be ruled out, 
although this too seems unlikely, since similar effects were not seen with SNAP. Instead, it 
appears that the effect is due to genuine, Hb-inhibited vasodilation. Bolus injections of 
moderate to high doses of either iron-sulphur cluster nitrosyl are capable, therefore, of 
producing NO-mediated vasodilator responses which persist long after the bolus passes 
through the vessel.
A more detailed investigation was undertaken to determine the source of NO responsible for 
protracted vasodilator responses produced by bolus injections of RBS and CUB, the results 
of which are reported in chapters 4 and 5.
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CHAPTER 4
IRON-SULPHUR CLUSTER NITROSYLS, A NOVEL CLASS OF
NO GENERATOR.
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4.1 INTRODUCTION
The results from experiments described in the previous chapter establish that both iron- 
sulphur cluster nitrosyls (RBS and CUB) cause vasodilation of the isolated rat tail artery. 
The vasodilation was shown to be NO-mediated on account of its susceptibility to Hb 
inhibition. The NO involved had previously been shown not to be endothelium-derived 
since responses were unaffected after inhibition of NOS using LNMMA. (figure 3.1; 
Flitney er fl/., 1990).
However, as intimated in the previous chapter, both compounds displayed characteristics 
which were qualitatively different from NP and SNAP in that the vasodilation caused by a 
single bolus injection, in contact with the artery for less than 0.5 secs., showed a tendency to 
only partially recover to the pre-injection pressure. This tendency became more pronounced 
at higher concentrations and, in the case of RBS, there was no recovery following 
microinjection of the highest dose used (5xlO'^M).
Here, these characteristics are studied in more detail. Experiments were carried out to 
establish that the smooth muscle cells were still capable of contracting once vessels had been 
injected with high doses of either compound and that the responses obtained were not due to 
a cytotoxic effect of the compounds. Hb and MB were used to show that the responses 
were due to long-term stimulation of guanylate cyclase by NO. A computer model was 
used to determine the underlying components responsible for the unique response profiles.
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4.2 MATERIALS AND METHODS
A. ANIMALS
Adult male Wistar rats (250-460 g) were killed by cervical dislocation, their tails removed 
and a length of arteiy (8-15 mm) cannulated and dissected free as described earlier.
B. APPARATUS
The apparatus shown in figure 2.1 was used for all experiments.
C. EXPERIMENTAL PROTOCOL
Vessels were precontracted with PE to produce agonist-induced perfusion pressures of 101 
+/- 3,5 mmHg ([PE] = 6.5 +/- 0.5 /<M; n=21). Responses to 10 pt\ bolus injections of RBS 
and CUB were compared to those evoked by NP and SNAP. The effects of adding 15 pM  
Hb or >10 ptM MB to the internal perfusate were examined.
D. ANALYSIS OF RESULTS
For the purposes of these experiments it was necessary to record the pressure attained at the 
peak of a response (figure 4.2; X) and at intervals during recovery to establish a response 
profile. The final pressure attained once the vessel had ceased to recover (figure 4.2; Z) was 
also recorded. Modified log-dose response curves for all the compounds (figure 4.3) show 
the extent of both relaxation (X/Y % where Y is the agonist-induced pressure before the first 
injection), and recovery (Z/Y %) for all the drugs tested.
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4.3 RESULTS
Microinjections o fN P  and SNAP produce transient responses.
Pressure recordings made following injections of increasing doses of these compounds 
confirm that they produce transient responses only (figure 4.1).
SNAP
NP
20%
1 0  mins
Figure 4.1. Meaned pressure recordings (+/- s.e., vertical bars) obtained by successsive 
injections ofSNAP(n = 5) and NP (n ~5). 10 p i injections (lO'^M to lO'^Mfor SNAP and 
10~^M to IQ-^M/or NP) were administered as indicated (vertical arrows).
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There is, however, an interesting diff^ence between the response profile obtained for each 
compound: responses to SNAP recover significantly faster (ca. 3 mins for the highest dose) 
than those to NP (ca. 10 mins for the highest dose). This may be indicative of the different 
mechanisms involved in the transport of NO derived from the two compounds from the 
lumen to guanylate cyclase in the smooth muscle.
Microinjections o f  RBS and CUB produce sustained responses
Pressure recordings obtained for RBS and CUB (figure 4.2) show that both compounds 
produce transient (T-type) responses when injected in low concentrations.
RBS
I I i  i I 1 1 I
CUB
I I 1 1 1  I
il!
P‘
20 mins
Figure 4.2, Meaned pressure (+ /- s.e., vertical bars) recordings obtained following 
successsive injections of RBS (n=5) aftd CUB (n=6). Parameters X, Y and Z are defined 
for RBS responses. Note that injection doses above the Dt for both compounds (see text) 
produce progressively more pronounced sustained responses. This is in contrast to the 
responses shown in figure 4.1 which are all transient.
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However, when the injected dose exceeds a critical threshold concentration {Dt\ 1-10 } M  for 
RBS and 20-100 yM  for CUB), both the rate and extent of recovery become progressively 
reduced, resulting in a stepwise and persistent loss of tone.
Figure 4.3 shows perfusion pressure minima (X; filled circles) immediately following 
injection of each drug and the steady-state pressures attained after recovery (Z; open circles) 
both expressed as a % of the initial agonist-induced pressure (Y) and plotted as a function of 
log 1 0  injected dose for each drug used. The ED5 0  values for each drug were listed 
previously in tables 3.1 and 3.2.(a) (b)
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Figure 4 3 . X/Y (filled circles) and Z/Y (open circles) plotted as a junction oflogjo injected 
dose o f SNAP (a), NP (b), RBS (c) and CUB (d).
6 0
The Z/Y curves reflect the tendency df iron-sulphur cluster nitrosyls to generate sustained 
(S-type) responses. The effect is more pronounced for RBS than for CUB as shown by the 
closer proximity of the X/Y and 27Y curves.
Abolition o f the ^plateau' phase o f  S-type responses by Hh or by MB
The S-type responses obtained following 5 mM microinjections of either RBS or CUB were 
remarkable in that prolonged (5 hr.) perfusion (washout) with PE-BCrebs solution failed to 
induce any further vasoconstriction, once the plateau phase was established. However, the 
addition of either 15 pM  Hb or >lOpM  MB to the internal perfusate initiated a prompt and 
complete restoration of all agonist-induced tone; indeed as figure 4.4 clearly shows, the 
perfusion pressure rises well above the pre-injection level (Y). Subsequent removal of Hb 
from the perfusate causes arteries to redilate fully. This is not the case for MB since 
inhibition of guanylate cyclase induced by MB is irreversible.
These observations suggest that extremely brief exposures of arteries to RBS and CUB is 
sufficient to establish a durable source of NO within the tissue.
(a) -Hb
Hb
2 0% I_
4  mins
+ Hb
+Hb
Figure 4.4. Pressure recordings from two preparations showing responses to 15pM  Hb 
added to, and then removed from, the internal perfusate during the plateau phase of 
sustained responses to RBS (a) and CUB (b).
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4.4 DISCUSSION
These results establish iron-sulphur cluster niti'osyls as a novel class of NO donor drug with 
unusual vasodilator properties. The compounds investigated here are able to generate two 
distinct kinds of response, transient and sustained. In this respect they differ from SNAP 
and NP which give transient responses only. The ability of Hb and MB but not NOS 
inhibitors to block both transient and sustained responses shows that they are mediated by 
NO derived from each cluster and not by enhanced EDRF production through stimulation 
of the endothelial L-arginineiNO - pathway.
Composite nature o f  S-type responses
The results shown here suggest that S-type responses represent the sum of two distinct 
vasodilator components: a reversible component (V i), attributable to NO generated by the 
spontaneous decomposition of the clusters in solution and present at the time of injection, 
superimposed on a 'non-recoverable’ component (V2 ), perhaps caused by the delayed release 
of NO from clusters which have penetrated and remained in the tissue. Component V2  
presumably reverses eventually, when the 'store' of cluster becomes depleted, but there is no 
indication of this happening up to 5 hrs after injection.
An estimate of the relative contributions from Vi and V2  can be obtained from the data 
presented in figure 4.3, as follows. The amplitude of V2  for the nth injection is given by:
V2n = (ZA^n-l-Z/Yn) (1)
and Vin when there is no V2  component by:
Vm = (Z/Yn-i-X/Yn) (2 )
Eqn.l gives V2  unambiguously, provided sufficient time is allowed for the plateau phase to 
become fully established. Eqn. 2 gives the correct value for VI for injection doses <Dt, but
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overestimates it when the dose >Dt. R>r simplicity, an exponential recovery is assumed for 
V 1 (P = Pq^P) and also for the time course of the developing component V2  (P = I-Pqc- 
2^ )^, where P is the perfusion pressure, k is the rate constant (min -^ ) and t is time (min). 
Simulated pressure recordings were obtained by summing Vi and V2  using an iterative 
computer programme, varying the amplitude of Vi (but not V2 ) and the rate constants ki 
and K2 . No attempt was made to reproduce the time courses exactly (cf fig 4.2), though this 
could be done, by suitably adjusting ki and k2 . However, the iteration was allowed to run 
until the calculated values for both X/Y and Z/Y were identical to the mean values obtained 
in our experiments.
Computer simulations o f  sustained responses
Figure 4.5 shows computer simulations obtained with ki and k2  set at 0.24.min~l and
0.4.min*l (CUB) and 0.24.min'l and 0.18.min~l (RBS).
RBS CUB
___
20%
4 mins
Figure 4.5, Computer simulations of sustained responses. The simulation allows VI and V2 to be
segregated in an effort to examine the two response profiles responsible for sustained responses. Values 
for K j afid K2 were adjusted until response amplitudes matched those shown in figure 4.2.
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The amplitudes of V i and V2  used in the reconstructions are plotted as a function of the 
injection dose in figure 4.6. The ED5 0  values for component V 1 for CUB and RBS are 
estimated to be 78 /<M and 62 piM respectively. The maximum amplitudes for V 1 are 0.52 
and 0.27 respectively.
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Figure 4.6. Vl (filled symbols) and V2 (open symbols) values plotted as a function of log jo  
injection dose o f RBS (circles) and CUB (triangles).
These results suggest that CUB is less stable in solution than RBS. The Vi log dose 
response curve for RBS can be made to coincide with that for CUB by scaling all CUB 
values by a factor of 1.9x. A statistical comparison of the scaled W\ values for RBS with 
those for CUB (paired students' t-test) shows no significant difference between the two data 
sets at the 95% confidence level (t=0.165 ; 9 degrees of freedom). Since RBS contains 7/4 
the number of nitrosyl groups as CUB, it can be estimated that approximately 3.5 molecules 
of CUB degrade in physiological solution for every molecule of RBS.
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In contrast, the V2  curves in figure 4.6 show this component to be more pronounced in the 
case of RBS than that of CUB, reflected in the Dt values for the two compounds.
A possible explanation for the V2  component of the responses observed is that bolus 
injections in which the concentration exceeds Dt for that compound lead to the uptake of 
small quantities of the drug into the tissue. Once there, NO is released at a rate determined 
by the intracellular environment. The amplitude of V2  would therefore dependent on:
1. The amount of drug taken up by the tissue.
2. The rate of NO release from inside the cell.
With this in mind, a study of the histochemistiy of vessels perfused with RBS or CUB. was 
carried out. The results, detailed in chapter 5, suggest that the hypothesis was correct, a fact 
confirmed by microanalysis on frozen sections of the tissue.
Vanin (1991) has shown that iron-dinitrosyls (FeNO) 2  complexed with low molecular 
weight thiols (e.g. cysteine or glutathione) can vasodilate isolated blood vessels and also 
inhibit platelet aggregation. Interestingly, the vasodilator action exhibits two-phase kinetics 
when tested on intact animals, resembling the sustained responses described here: that is, an 
initial, rapid decrease of arterial pressure, followed by a a persistent (several hours) 
hypotensive action. The rapid and sustained components are attributed to to NO released 
from (i) iron-dinitrosyl low - Mr thiol complexes (rapid phase) and (ii) from iron-dinitrosyl 
protein-thiol complexes (sustained phase) formed within the tissue. The latter are thought to 
result from the transfer of Fe(NO ) 2  groups from low Mr-compounds to protein-borne 
ligands, fonning a long-lasting molecular ’store' of NO in the vascular bed.
Suppression o f endogenous EDRF production did not occur during the plateau phase o f  
S-type responses.
The effects of I-Ib administered during established sustained responses suggest that the 
formation of endogenous NO from L-arginine is not suppressed by either cluster and that its 
continued release from endothelial cells helps to sustain the plateau phase. Thus, perfusing 
vessels with Hb does not merely re-establish the pre-injection perfusion pressure, but
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instead drives it to a level substantially greater than this (figure 4.4). The inference to be 
drawn is that Hb scavenges NO from both exogenous (cluster-derived) and endothelial 
sources.
Physicochemical properties o f  iron sulphur cluster nitrosyls
The physicochemical properties of iron-sulphur cluster nitrosyls (Butler, Glidewell & Min- 
Hsin, 1988) provide some insight into their vasodilator actions. Both compounds are 
potentially able to deliver large quantities of NO (figure 1,7). Extended Huckel orbital 
calculations show that both compounds are electron precise (Sung, Glidewell, Butler and 
Hoffman, 1985), that is to say that addition or removal of an electron is sufficient to cause 
the iron-sulphur framework to disintegrate, releasing all the ligated NO groups as free NO 
(7 per molecule of RBS and 4 per molecule of CUB). The redox status of the immediate 
environment is therefore likely to be a crucial factor in determining the rate of release of NO 
from these compounds.
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CHAPTER 5
HISTOCHEMICAL AND X-RAY MICROPROBE EVIDENCE 
FOR ACCUMULATION OF IRON-SULPHUR CLUSTER 
NITROSYLS IN THE ENDOTHELIUM
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5.1 INTRODUCTION
5.2 MATERIALS AND METHODS
A. PROTOCOL FOR HISTOCHEMICAL STUDIES
Lengths of artery were cannulated and perfused with Krebs solution as described previously 
(sections 2.1, 2.2 and 2.3). Following precontraction, vessels were internally perfused with 
IQ-'^ M RBS or CUB for 5 mins followed by a 15 min washout with PE-Krebs, In both 
cases, pressure dropped to <25% of its original value and showed no signs of recovery 
during the washout period. Vessels were then removed from the perfusion system, frozen 
and transversely sectioned (20 pm). Fixation of the tissue was not possible since the 
process (even vapour fixation) invariably led to destruction of the iron-sulphur cluster 
nitrosyls. Instead, sections were viewed under the microscope unstained, and following 
staining for 7hrs with bathophenanthroline followed by 5 min counterstaining with MB. 
Bathophenanthroline is a recognised stain for iron (II) (Pearse, 1972). Control (untreated) 
vessels did not stain with bathophenanthroline.
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Experiments reported in the previous chapter suggest that the unusual vasodilator responses f
produced by bolus injections of either RBS or CUB are due to a combination of two distinct J
"I
responses:
1. Transient responses, due to the spontaneous release of NO in solution. .
j2. Sustained responses, possibly due to slow release of NO from clusters trapped in the u 
tissue.
Experiments were therefore undertaken to investigate whether RBS and CUB are able to 
accumulate in vessels. To this end, arteries were perfused with both compounds and later 
examined using histochemical techniques. In addition, vessels perfused with RBS were 
subjected to X-ray microprobe analysis in an attempt to pinpoint the locality of clusters |
trapped within the tissue.
.. J
B. PROTOCOL FOR MICROANALYSIS
Vessels were treated with lO'^M RBS for 10 mins followed by a 10 min washout. Once 
removed from the perfusion system, a small length (<lmm) was removed and placed on a 
lead weight which was plunged into liquid N2 . Rapid freezing produced in this way reduces 
the chance of ice-crystal development which can cause distortions within cells. Samples of 
frozen tissue were taken to Glasgow University where Dr H. Elder and J. Pediani analysed 
sections of the tissue using an X-ray microprobe to determine relative amounts of iron and 
sulphur present in endothelial cells and in the adjacent elastic lamina.
5.3 RESULTS
Figure 5.1 shows transverse sections of a freshly-frozen vessel following perfusion with 
RBS. The unstained section (A) shows a brown discolouration, predominantly in the cells 
surrounding the lumen. The discolouration appears to extend into deeper layers of the tissue 
but this may be a result of diffusion after mounting since the sections were unfixed.
Section B shows the effect of bathophenanthroline staining. The red/brown stain is clearly 
confined to the same area of tissue as the brown discolouration in (A).
High magnification of a section counterstained with MB only (C) clearly shows that the 
discolouration is confined to the endothelial layer.
Figure 5.2 shows the chemical composition detected by the X-ray microprobe, in outer 
smooth muscle cells (a), cells in the inner elastic lamina (adjacent to the endothelium; 
(b))and in endothelial cells (c), in an RBS-treated vessel. The results clearly show that in 
RBS-treated vessels, both the Fe and the S levels are significantly higher in endothelial cells 
than in cells located deeper in the tissue, where both exist only as trace elements. The 
detected Fe/S ratio approximates that expected for RBS (4/3).
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Figure 5,1. Transverse sections (20pm) of 
freshly-frozen artery perfused with RBS 
(lOOpM; 2 mis min i for 5 mins followed by 15 
min perfiision (washout) with Krebs solution 
only. A . Unstained, unfixed section. 
Discolouration o f the vessel lining suggests 
entry and retention o f RBS into endothelial 
cells. B. Unfixed section after staining for 7 hrs 
with bathophenanthroline and b r i e f  
counterstaining with methylene blue (4 mins). 
Endothelial cells stain positive for ferrous iron 
(red!brown colouration) derived from the 
cluster. C. Unfixed section stained for 4 mins 
with methylene blue to expose smooth muscle 
cells. Note that brown colouration is confined 
to the endothelial lining of the vessel.
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Figure 5.2. Relative quantities of ions detected by X-ray microprobe analysis in (a) smooth 
muscle cells in the outer region o f the vessel wall, (b) cells immediately adjacent to the 
endothelium and (c) endothelial cells in vessels treated with RBS fo ri Omitis^ollowed
iby a lOmin washout period. Note that Fe and S levels are significantly higher in (c) than in 
(a) or (b). Presumably, this is due to the uptake of RBS into the endothelium. Experimental 
details: Expt 910301. 100 KeV, 30P tilt, x 6,600 magnification, 4 x lO'^A beam current.
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5.4 DISCUSSION
The results shown above strongly support the hypothesis proposed in the previous chapter 
whereby sustained vasodilator responses to iron-sulphur cluster nitrosyls which persist long 
after the drug has cleared the lumen, are due to the entry of a small quantity of drug into the 
tissue. Once there, the compounds decompose slowly, releasing NO and maintaining a 
Vasodilator tone'. Moreover, the results of the histochemical study and especially the results 
obtained from the X-ray microprobe, suggest that the clusters accumulate exclusively in the 
endothelium.
Importantly, the accumulation of either compound does not appear to affect the ability of the 
endothelium to synthesise NO, a point clearly illustrated by the effects of Hb on vessels 
treated with 5 mM RBS or CUB (figure 4.5). Not only did Hb abolish drug-induced 
sustained responses, but also caused an additional vasoconstriction, attributable to inhibition |
of an on-going, EDRF-induced vasodilation.
The apparent ease with which both clusters are able to penetrate the endothelial cell 
membrane is probably related to their high solubility in non-polar solvents (Butler, 
Glidewell & Min Hsin, 1988). RBS is especially interesting in that it is anionic (CUB is |  
neutral) and therefore soluble in polar solvents too.
It should also be noted that preliminaiy experiments using sephadex columns have shown 
that RBS binds non-specifically to both albumin and Hb, a result which may have some 
bearing on the effectiveness of Hb in inhibiting RBS responses. Intracellular proteins, 
therefore, may also be capable of binding these compounds and may contribute to their 
accumulation within endothelial cells, as well as intracellular lipids.
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CHAPTER 6
LASER-INDUCED POTENTIATION OF VASODILATOR 
RESPONSES TO IRON SULPHUR CLUSTER NITROSYLS.
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6.1 INTRODUCTION
The experiments described in this chapter will show that both RBS and CUB are also 
photosensitive. Irradiation either of vessels during the plateau phase of sustained responses, 
or of the internal perfusate containing low concentrations of RBS or CUB, en route to the 
preparation, potentiates their vasodilator actions. The potentiating effects of light are 
attributed to the accelerated release of ligated nitrosyl groups as free NO, since potentiation 
can be prevented by Hb (but not by NOS inhibitors) and enhanced by superoxide dismutase 
(SOD).
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The findings reported in the previous three chapters, show that the iron-sulphur cluster 
nitrosyls, are potent vasodilators with unusual pharmacological properties. Bolus injections 
of either compound into pre-contracted lengths of rat tail artery were found to generate two 
kinds of response. Doses below a critical threshold (<Dt) evoked fully reversible (T-type) 
responses, as seen with conventional NO donor drugs. However, doses >Dt produced 
extraordinarily long-lasting (S-type) responses, comprising an initial, rapid drop in pressure, 
which then either failed to recover or showed partial recovery only. S-type responses were ,| 
characterised by a plateau of reduced tone which could persist for several hours. Both T- 
and S-type responses were shown to be mediated by NO. Histochemical studies showed 
that the plateau component of the S-type response is caused by the protracted release of NO 
from clusters which become trapped within the endothelium. «
6.2 MATERIALS AND METHODS
A. ANIMALS
Adult male Wistar rats (340 - 495g) were killed by cervical dislocation, their tails removed 
and a length of artery (9.6 +/- 0.3mm) cannulated and dissected free as described earlier.
B. APPARATUS
Figure 6 .1 shows the modified apparatus used in these experiments.
h :
nmnn
RS
Route
6 -W
#o# Route A
# o #
Figure 6,1, Apparatus used to irradiate the vessel (V) or the perfusate en route to the 
preparation in the exposure tube (E) through the quartz window (Q). Time delay for outlet 
tubes: 1 - 0.73min. 2 - 1.05min. 3 - L33min. 4 - L69min. 5 - 2.54min. 6 - 3.12min. See 
text for full details and explanation of lettering.
Light from an argon ion laser (L; Spectra Physics, type 160-8) could be directed onto the 
vessel by reflecting the expanded beam off a 45®, front-silvered mirror (M). The perfusate in 
these experiments followed route A. I0p\ injections could be made through the rubber 
septum (RS).
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Alternatively, the perfusate could be diverted through a curved glass tube (E; route B). 
Laser light could be directed in to the tube through a quartz end window (Q) to irradiate 
solutions en route to the preparation. The tube was tapered and its outer surface coated with 
silver to optimise the dispersion of light within. Six PVC outlet tubes (1-6) of different 
lengths were connected to the cannulated artery via a 6 -way tap (6 -WT). Each could be 
selected in order to vary the time delay between formation of photolytic products in tube E 
and arrival at V (0.72 - 3.12 mii|^).
During the perfusion experiments, it became clear that the tubing used to convey the 
perfusate to the preparation rapidly became contaminated with RBS and CUB. It was 
necessary, therefore, to change the tubing frequently to avoid cross-contamination between 
experiments.
C. EXPERIMENTAL PROTOCOLS
Vessels were precontracted with PE to produce agonist-induced perfusion pressures of
102.7 +/- 5mmHg ([PE] = 11.7 +/- 1.3/<M; n=29).
Two experimental protocols were used:
(i) Potentiation o f  photorelaxation during the plateau phase o f  sustained responses.
Following precontraction, vessels perfused via route A were directly exposed to laser light 
by reflecting the laser beam off a front-silvered mirror (M, figure 6 .1 ; beam diameter at 
preparation: 2cm). The illumination conditions (0.2 or 2 mW; = 514.5nm; 1 min 
exposures) were selected to produce small-amplitude (< 1 0 % of active pressure) 
photorelaxant responses (Furchgott et al, 1961). A single bolus injection (10 p\) of RBS or 
CUB was then introduced into the internal perfusate, through the rubber septum (RS, figure
6.1). The concentrations of RBS (250 pM) and CUB (500/^M) were sufficient to induce 
moderate sustained responses. Vessels were again exposed to laser light (as above) at 12 
min intervals, for periods of up to 5 hrs. The photosensitivity of vessels was enhanced by 
this treatment.
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(ii) Perturbation o f  steady-state vasodilator responses to RBS or CUB by laser 
irradiation o f  solutions en route to preparations.
Vessels were perfused with PE Krebs solution via route B (figure 6.1). Pressure recordings 
were made during continuous infusions of RBS or CUB (0.3 pM  or 0.9 ^ M), initially in the 
dark, and then during intermittent laser irradiation of the incoming solution (in tube E, figure
6 .1). Exposure of solutions to light (457.9 nm or 514.5 nm; 5 mins) produced an additional 
vasodilation during the period of illumination. This is termed the light-induced vasodilator 
response (LIVR).
LIVRs were recorded under different illumination conditions (beam output energy and 
wavelength) and in the presence of either Hb (5 pM),  SOD (150 Units, ml'^) or the NO 
synthase inhibitor LNMMA (KX3 pM). The decrease in pressure, measured at the end of the 
illumination period, is expressed as a fraction of that recorded immediately prior to 
illumination.
(Hi) Photodecomposition o f RBS,
Photolysis of RBS was studied under conditions which simulated those used for recording 
LIVRs as closely as possible. Solutions (0.3 or 0.9/<M) were exposed to laser light in the 
photolysis tube (flow rate: 2ml.min ;^ 457.9 nm and 514.5 nm) and collected in a 
spectrophotometer cuvette (10 cm pathlength). It was necessary to make solutions in 
distilled water rather than oxygenated Krebs solution since bubbles and/or precipitate 
produced in Krebs solution distorted the absorption spectra recordings (Cecil double-beam 
UV-VIS spectrophotometer; type CE 594). The decrease in absorbance at 360nm ( 8  = 14,
940 M“^ .cm“i) was measured to determine the quantity of RBS photolysed. The results are 
used to calculate the efficiency of NO production at source.
The rate of inactivation of NO en route to the vessel was estimated by recording the decrease 
in size of LIVRs (produced by standardised illumination conditions) with increasing transit 
times between exposure (in tube E) and the vessel (V). The results are used to relate the * 
amplitude of the LIVR to the [NO] reaching the vessel.
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6,3 RESULTS
V:
Enhanced Photorelaxation Produced By Irradiating Vessels During Sustained  
Responses,
Furchgott et al (1961) showed that exposure to light causes pre-contracted vascular smooth 
muscle to relax (see also sections 1.11 and 7.1). Vessels which had been injected with RBS 
or CUB exhibit enhanced photorelaxant responses (EPR*s) when irradiated during the 
plateau phase of sustained responses.
Typical recordings of EPR’s are shown in figure 6.2 (a) and (b).
(a)
(b)
RBS
L_
(C) RBS
ISOU.ml "^ SOD 150U.ml‘  ^ SOD
Figure 6,2. Pressure recordings showing enhanced photorelaxant responses obtained 
following lOpl injections of (a) and (b) 250pM CUB SOOpMRBS. Irradiations (0.2 niW; 
514.5 nm; 1 min) are indicated by horizontal bars. Trace (c) shows the effect o f 150 U.ml'^ 
SOD perfused before and after a lOpl injection o f RBS. Irradiations of the vessel in the 
presence of SOD following an RBS injection show further enhancement. Scalebar: vertical 
- 20%; horizontal - 5 mins. Expt. N^s (a) 910701, (b) 910704 and (c) 910725.
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Control photorelaxations were elicited before a single bolus injection (lOpl) of either 500;<M 
RBS or ISQpM CUB was administered into the internal perfusate. Typically, vessels 
showed a rapid dilation followed by partial recovery to a level below the pre-injection 
pressure. Once in this sustained phase of the response, vessels were subjected to repeated 
periods of laser irradiation . This treatment produced a marked and long-lasting (up to 5hrs) 
potentiation of the photorelaxant response (figure 6.2 (a), (b)). The addition of SOD (150 
U.m l'l) to the internal perfusate further enhanced the sensitivity of vessels to light (figure 
6 .2 (c)).
Figure 6.3 shows histograms comparing control photorelaxations (open columns) to EPRs.
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Figure 6,3, Histograms showing the effect o f bolus injections o f SOOpM RBS (black 
columns) or 250pM CUB (hatched columns) on photorelaxations (controls, open columns) 
evoked by 0.2 mW or 2mW. Parameters o f photorelaxation investigated; latency o f onset 
(L), amplitude (F), rate o f drop of pressure (dP/dt), and rate o f recovery (r^ /2 ). ** 
indicates a significant difference from the control at P = 0.01 confidence level.
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Four parameters were measured: the time interval between the start of illumination and the 
earliest detectable drop in pressure (latent period, L; secs) ; the maximum rate of drop in 
pressure (dP/dt; mmHg.mim^); the maximum amplitude of the photorelaxant response (P; 
mmHg); and the half-time of recovery in the dark (TV2 ; mins).
The results show, first, that L was decreased and both dP/dt and P were increased following 
injection of either drug. There was no significant effect on the rate of recovery (Tl/2) in the 
dark. Second, enhancement of the photorelaxant response was generally greater for RBS 
(black column) than for CUB (hatched column). This was probably due to the fact that 
500//M RBS was used as opposed to 250pM  CUB. Third, increasing the beam energy 
(from 0.2 to 2.0 mW) increased the potentiating effect of both compounds.
Perturbation o f  Steady-State Vasodilator responses to RBS and CUB by laser irradiation
o f solutions en route to the vessel.
Constant infusion of 0.3pM  RBS caused a sustained drop in pressure of 17.3 +1-23% (n = 
12) whilst the equivalent value for 1.6pM CUB was 9.0 +/-0.2% (n = 11).
A. CHARACTERISTICS OF THE LASER-INDUCED VASODILATOR RESPONSE 
(LIVR).
The main features of the LIVR are illustrated in figure 6.4. The horizontal lines associated 
with each pressure recording indicate the period (5min) of laser irradiation and the beam 
energies (mW) used. It is important to emphasise that vessels were carefully shielded from 
stray light throughout, to avoid evoking photorelaxant responses.
LIVRs produced by irradiating perfusate containing 0.3 pM  RBS under different 
illumination conditions (beam energy; wavelength) are shown in figure 6.4. The LIVR 
typically comprises an initial, rapid drop in pressure, commencing after a short delay (here 
ca. 0.73 min; outlet tube 1).
8 0
This fast component was complete within ca. 1 min. Thereafter, pressure either stayed 
constant throughout the remainder of the illumination period, or it continued to fall but at a 
greatly reduced rate. After illumination ceased, the vessel reconstricted; pressure increased 
rapidly at first and then more slowly, terminating at (or near) the pre-illumination level.
Figure 6.4. LIVRs produced by illuminating solutions o f 0.3pM  RBS en route to the 
preparation. Trace (a) shows responses to 457.9 nm laser light, trace (b) responses to 
514.5 nm laser light. Expt. (a) 920324, (b) 920309.
The results from experiments of this type for both RBS and CUB are summarised in figure 
6.5. The amplitude of the LIVR is plotted as a function of beam energy. The reulting 
curves show that LIVRs increase in size with increasing beam energies, rising asymtotically 
towards a maximum value and that irradiating solutions with light at 457.9 nm is more 
effective at producing LIVRs than at 514.5nm. RBS is more light-sensitive than CUB and 
increasing the concentration of RBS increased the LIVR amplitude produced under standard 
illumination conditions.
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Figure 6,5. Plots o f LIVR amplitudes (% of active pressure) for (a) 0.9 pM  RBS (n = 5), 
(b) 0.3pM  RBS (n ~ 6) and (c) 1.6 pM  CUB (n = 6). Responses to 514.5nm (open 
symbols) and 457.9 pM  (filled symbols) are shown for all three graphs.
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Figure 6 . 6  is a reciprocal plot of the results obtained with RBS. This shows that 1/LIVR 
increases in direct proportion to 1 /beam energy.
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Figure 6,6, Double reciprocal plot of If intensity (l/I) against 1!response (1/R) for 0.3 pM  
and 0.9 pM  RBS solutions. Responses to 457.9nm laser light are represented by filled  
symbols whilst those for 514,5nm light are represented by open symbols.
Linear regression analyses of the data gave the following results:
514.5nm; 0.9/^M 
514.5nm; 0.3/<M 
457.9nm; 0.9pM  
457.9nm; 0.3pM
y  = 2.23X + 1.22 
y = 3.91X + 1.72 
y = 1.19x + 0.99 
y = 0.38x + 1.83
(r2 = 0.995) (1)
(r2 = 0.989) (2)
(r2 = 0.995) (3)
(f2 = 0.993) (4)
where y = 1/LIVR and x = 1/beam energy.
The maximum amplitudes of the LIVR attainable (Pmax) under the different experimental
conditions (for x = 0 in equations 1-4) and the beam energies required to reduce the
perfusion pressure by 50% (l50% values) are listed in table 6 .1.
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X (nm) [RBS] (I^M) Pmax (%) Iso% (mW)
514.5 0.9 82 2.9
514.5 0.3 58 14.1
457.9 0.9 1 0 1 1.17
457.9 0.3 55 2.28
Table 6.1. maximum amplitudes (P max (%) - as calculated from double reciprocal plots 
in figure 6.6) and Iso% values for RBS under the conditions indicated.
The I5 0  values suggest that a considerably higher intensity of light is required to produce 
50% relaxation with 514.5nm laser light than 457.9nm. The situation is particularly clear 
with the lower [RBS] (03//M) where the I5 0  is 7x greater for 514.5nm laser light. Pmax is 
greater for the higher [RBS] with both wavelengths (ca. 100% with 457.9nm; 0.9pM  RBS).
LIVRs are mediated by NO released photochemicaUy.
Figure 6.7 shows that LIVRs are mediated by exogenous NO, generated by 
photodecomposition of the clusters.
Hb
J—LJ—L J—L
10 MCCh
10 MCChlO'-^M CCh
LNMMA
514.5 514.5 457.9514.5 457.9 457.9
Figure 6.7 (a). Pressure recordings showing the fully reversible, inhibitory effect o f 5pM  
Hb on LIVRs induced in RBS-treated vessels (0.3pM ; 3.3mW, 457.9nm and lOniW, 
514.5nm). Trace (b) shows that LIVRs are unaffected by lOOpM LNMMA (3.3mW, 
457.9nm and lOmW, 514.5nm). Periods o f irradiation are indicated by horizontal bars. 
Scale bars: vertical - 20% relaxation; horizontal ; 4 mins.
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First, LIVRs were suppressed by adding 5}4M Hb to the internal perfusate (6.7(a); the effect 
was reversible. In contrast, the addition of 1CX)/<M LNMMA, which inhibited basal release 
of NO, as reflected in a rise in pressure of 57.1% + / - 6  (n = 10), failed to inhibit the LIVR; in 
some cases a small reduction was observed, but more often the response was found to be 
potentiated by LNMMA.
Second, LIVRs were progressively reduced in amplitude when the interval between solution 
leaving the photolysis tube and entering the vessel (delay time) was extended by increasing 
the length of the outlet tube (figure 6 . 8  (a)). SOD was also found to potentiate sub-maximal 
LIVRs (figure 6 .8 (b)).
(a)
Tim e Delay (mins) 0.73 1.05 1.33 1.69 2.54 3.12
(b)
Tim e Delay (mins) 0.73 3.12 0.73 3.12
ISO U .m l SOD
Figure 6,8(a) Effect of increasing delay time between perfusate leaving the exposure tube 
and reaching the vessel on LIVRs (OJpM RBS; 514nm laser light). Delay times for each 
outlet tube are indicated above the corresponding LIVR. (b) Effect o f 150 U.ml~  ^SOD on 
the UVR produced using outlet tube 6 (c.f. (a) above). 0.3pM  RBS; 514nm laser light.
Exposure of 150 Uml“l SOD alone (i.e. in the absence of RBS) en route to the preparation 
on occasion produced small vasodilations. 457.9nm laser light was unlikely to have a direct 
effect on SOD since spectrophotometric measurements showed SOD not to absorb light at
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this wavelength. The results were therefore attributed to RBS contamination of the glass 
exposure tube (E).
Spectrophotoinetric measurements o f  the photodecomposition o f  RBS; photochemical 
efficiency o f  NO production.
Figure 6,9 shows computer-averaged spectra (n = 5 - 7) for unexposed solutions (control, 
upper spectrum) and for solutions illuminated with laser light (514,5 nm) at the beam 
energies indicated (lower 3 spectra).
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Figure 6.9. Computer-averaged absorption spectra for IpM  unexposed RBS (upper trace 
n = 7). The lower traces show the equivalent spectra for RBS exposed to 514.5nm laser 
light as indicated (n = 5). Figure 6.9 (inset) shows the proportion of RBS broken down 
(RBS*/RBS) with increasing intensities of both 514.5nm and 457,9nm laser light.
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Exposure to light resulted in a proportional decrease in absorbance across the range of 
wavelengths 290-600nm. The spectrum was unaltered in all other respects, since the fact 
that the products of RBS breakdown are all insoluble (Fe2 0 3  and Sg; Butler & Askew, 
unpublished data).
Figure 6.9 (inset) shows the breakdown of RBS vs. the beam energy (514.5 nm, open 
circles; 457.9 nm, filled circles). The photodecomposition increased linearly with increasing 
energies, up to ca. lOOmW at 514.5 nm and ca. 30mW at 457.9 nm, ranges which far 
exceed those used for recording LIVRs.
Table 6.2 lists values for the fractional decomposition of RBS per mW of light (f) for the 
different experimental conditions used in the study.
0.9 RBS (n =9) 03uM  RBS (n = 6)
k (nm) f* (mW-l) E (nM.mW'l) f* (mW-1) E (nM.mW-1)
457.9 14.06 X 10-3 (0.43) 8 8 . 6  (2.73) 20.57 X 10-3(0.77) 43.2(1.62)
514.5 3.64 X 10-3(0.23) 22.96 (1.43) 4.10x10-3(1.03) 8.6(2.15)
Table 6.2. Photochemical efficiencies of NO formation. All values are means (S.EM. in 
brackets).
The efficiency of the photolytic process (E), expressed in terms of the steady-state [NO] 
formed at source (nM.mW'l), is given by;
E = fcn (5)
where f = the fractional breakdown of RBS (mW'^) at wavelength 457.9, 514.5 nm 
c = the concentration of RBS (nM) used; 
and n = the number of moles of ligated nitrosyl groups released as free NO per mole of 
RBS photolysed.
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The mean +/- SEM values for E obtained for two concentrations of RBS (c = 0.3 pM  and 
0.9 jwM) at each wavelength appear in table 6.2. A value of n = 7 has been assumed in 
calculating the data (see discussion). These results show (a) that E is considerably greater at 
the shorter wavelength, by a factor of 4-5x; and (b) that increasing the concentration of RBS 
from 0.3 - 0.9 piM results in a 2-3 fold increase in E.
Inactivation o f NO released photochemically.
NO reacts rapidly with oxygen-derived free radicals, such as O2 " (Moncada et at, 1986) and 
the short-lived hydroxyl (OH') radical. In the perfusion system used here, the concentration 
of NO which survives passage through each outlet tube is given by the following equation:
[NO] = EjJprt (6 )
where E)^  = photochemical efficiency of NO production at wavelength X (eqn. 1)
I = beam energy (mW) at wavelength X
Pn = proportion of NO generated at source which reaches the artery for the 
Mth outlet tube.
The time course for the inactivation of NO was determined in the following manner:
First, LIVRs were recorded at increasing delay times, as illustrated in figure 6 .8 (a). 
Solutions (03piM) were irradiated at 457.9 nm and 514.5 nm, using standardised beam 
energies of 3.3mW and lOmW respectively. Figure 6.10 is a semi-logarithmic plot of the 
LIVR amplitude as a function of the delay time.
8 8
Figure 6.10. Effect of increasing delay between exposure of the perfusate containing 0.3pM  
RBS (514.5nm, open circles, n = 5; 457nm, closed circles, w = 5) and the preparation. 
Addition of 150 U.ml-l SOD to the perfusate abolished the effect o f increasing delay on 
LIVR amplitude (filled triangles, n = 3).
The responses decay exponentially, falling to 50% of their maximum values after 58.9 secs 
(514.5 nm; open circles) and 57.9 secs (457.9 nm; filled circles). Note that the addition of 
SOD to the internal perfusate (filled triangles) prevented attenuation of the LIVR (see also 
figure 6 .8 (b)).
Linear regression analyses of the data gave the following results:
X = 514.5nm; y = -0.307x - 0.151 (r^  = 0.985) (7)
X = 457.9nm: y = -0.312x - 0.111 (r^  = 0.968) (8 )
where y = logioLIVR amplitude 
and X = delay time (mins).
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The reationship between LIVR amplitude and [NO] is not iineai' as can be inferred from the 
results of figure 6.5, and so eqns 7 and 8  do not describe the rate of inactivation of NO 
directly. This information was aquired by first evaluating eqns 7 and 8 , for x values ranging 
from 1 - 3.4 mins (0.2 min intervals). The resulting y values (LIVR amplitudes) were then 
inserted into eqns 2 (514.5 nm) and 4 (457.9 nm) to determine the beam energy 
corresponding with each LIVR amplitude. Lastly, the interpolated energy values were 
multiplied by the appropriate E value (table 6.2) to estimate the [NO] reaching the vessel.
The results reveal that the rate of inactivation of NO depends on the illumination conditions. 
Figure 6 .11 shows that the time courses for the inactivation process at the two wavelengths 
are described by the sum of two exponential components ei and C2 .
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Figure 6J1. Exponential components ej and e2 for (a) 514.5nrn and (b) 457,9nm LIVRs. 
[RBSJ = 0.3pM.
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The amplitude (a) and time constant (k) for the rapid component (ei) were greater for 
457.9nm (a = 0.83 and k = 0.39 mins) than for 514.5nm (a = 0.49 and k = 0.63 mins), 
producing a faster rate of inactivation at the shorter wavelength. The time constants for the 
slow component (0 2 ) were the same for both wavelengths (k = 1.15 min). The possible 
reason for this difference is considered in the discussion.
The proportion of NO (P) reaching the vessel for each outlet tube is listed in table 6.3.
Tube N2 Delay Time (mins) P (514.5nm) P (457.9nm)
1 0.73 0.413 0.242
2 1.05 0.289 0.132
3 1.33 0 . 2 1 0 0.076
4 1.69 0.134 0.045
5 2.54 0.059 0.018
6 3.12 0.036 0.017
Table 6.3. The effect o f  increasing delay time on the proportion o f NO (P) reaching the 
vessel for 514.5nm and 457.9nm laser light.
LIVR log-dose response curves.
Figure 6.12 is the log-dose response curve relating the amplitude of LIVRs to the [NO] 
calculated to be reaching the vessel. LIVRs recorded under all experimental conditions used 
(wavelength, concentration and outlet tube delay times) lie on a single curve, with a 
threshold [NO] of ca. InM and an ED5 0  value of 14.1 nM, with a range of 6 . 6  - 27 nM.
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Figure 6J2, Log-dose response curve for NO, calculated by the method described in the 
text. Curves derived from experiments using 514.5nm (open symbols) and 457.9nm (filled 
symbols) laser light at both 0.3 (squares) and 0.9pM RBS (circles) are shown.
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6.4 DISCUSSION
Vasodilator responses produced by nitrosylated iron-sulphur clusters are enhanced by light: 
this applies to sustained responses, resulting from single bolus injections (figures 6.3), and 
to 'steady-state' responses, generated by continuous infusions of RBS or CUB (figures 6.4).
The potentiating effects of light are greater at the shorter wavelength and higher beam energy 
(figure 6.4, table 6 .1 and figure 6.5); they are facilitated by exogenous SOD (figure 6 .8 (b)), 
the enzyme which dismutes 0 2 " (McCord & Fridovich, 1969), a known inactivator of 
endothelium-derived NO (Gryglewski et al, 1986; Moncada et al, 1986); and they are 
blocked by Hb (figure 6.5), a scavenger for NO (Antonini and Brunori, 1971; Martin et al, 
1985).
These observations show that both RBS and CUB are photodegradable and that photolysis 
accelerates the release of ligated nitrosyl groups as free NO, The failure of LNMMA, a 
stereospecific inhibitor of NO synthase (Rees et al, 1990), to suppress LIVRs (figure 6.7
(b)) and enhanced photorelaxations confirms that neither type of potentiation is caused by 
stimulation of endothelium-derived NO synthesis.
Inactivation* o f  NO generated photochemically and the role o f  0 2 '
NO is known to react readily with O2 " to form peroxynitrite and ultimately NO2 " and NO3 " 
(Furchgott et al, 1990). SOD prevents this reaction sequence by catalysing the dismutation 
of O2 " to H2 O2  (McCord & Fridovich, 1969). The ability of SOD to prevent attenuation of 
the LIVR (figure 6.10) clearly implies that inactivation of RBS-derived NO is due to it 
reacting with O2 ".
The time course of the inactivation process (figure 6.10) is more complex than previously 
supposed. The disappearance of NO was more rapid at the shorter wavelength, even though 
the beam energy was only one third of that used at the longer wavelength. McCord & 
Fridovich (1973) showed that photolysis of oxygenated water generates O2 " and hydroxyl
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(OH*) free radicals in equimolar amounts. The observations reported here could be 
explained if we postulate that the shorter wavelength light is more effective at producing 0%" 
by this means. However, for theoretical reasons, it is unlikely that irradiation of oxygenated 
water with either of the two wavelengths used here could have generated significant 
quantities of O2 ". The inactivation is nevertheless related to the wavelength and/or beam 
energies used to generate NO. It is therefore possible that O2 " is formed as a consequence 
of reactions between dissolved molecular O2  and one or more of the products of RBS 
decomposition. A likely candidate is Fe^+, produced by fragmentation of the FeS 
framework, since this is known to catalyse the production of O2 " from 0% (Matsunaga & 
Furchgott, 1989).
Significantly, the time constant for the slow component of the inactivation process was 
found to be independent of the illumination conditions (k = 1.15 mins). This may represent 
the rate of reaction of NO with dissolved molecular oxygen, though recent calculations 
would suggest that this would be slow with the low concentration of NO involved (Butler & 
Williams, 1993).
Sensitivity o f  vessels to NO released photochemically.
The log-dose response curve of figure 6.12 shows that the [NO] required to produce a 
detectable (threshold) LIVR is in the region of InM. The ED5 0  value for LIVRs of 14.1 
nM (ranging from 6.6 - 21 pM) is somewhat less than that quoted for enhanced dilator 
responses by Jacobs et al (1990; rabbit aorta; 63 nM) and by Sakuma et al (1990; 20 - 250 
nM for a variety of arteries) but greater than that cited by Kelm et a/ (1988; 5nM).
There are two possible sources of error in the method of calculation used to interpret the 
results reported here.
First, LIVRs are necessarily superimposed on a 'background' vasodilator response, due to 
the spontaneous release of NO in the dark (Flitney et al, 1992; see also chapters 3 and 4). 
This may reduce the sensitivity of vessels to further NO produced photochemically.
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Second, the estimates of photochemical efficiency (E values) of NO formation under 
different illumination conditions (equation 1; table 6.2) assume that all 7 ligated nitrosyl 
groups are released during photolysis. This assumption is supported by chemical theory 
although there is no direct experimental evidence for it to be so. RBS has an electron precise |
configuration (Sung et al, 1985). The addition or removal of an electron will destabilise the
FeS framework causing it to disintegrate into NO, insoluble iron oxides and elemental 
sulphur (Butler & Askew, unpublished data).
Dual mode o f  action o f  iron-sulphur cluster nitrosyls.
The plateau of sustained responses is due to spontaneous release of NO (in the dark) from 
clusters trapped within the endothelium (Flitney et al, 1992). The ability to enhance 
photorelaxation by irradiating vessels previously injected with either RBS or CUB provides 
further circumstantial evidence for this hypothesis; exposure of treated vessels to light would 
be expected to accelerate the release of NO from clusters trapped within the endothelium and 
cause an additional vasodilation. This interpretation is supported by the finding that EPRs |  
are further potentiated by SOD (figure 6.2(c)).
Relative photosensitivities o f  RBS and CUB
RBS invariably produces larger LIVRs and EPRs than CUB under comparable illumination 
conditions. The concentration of CUB chosen for the LIVR experiments was such that the 
potential NO concentration produced by complete degradation was the same as for RBS (i.e.
[CUB] = 7/4 X [RBS]). The inference from this is that RBS is more photosensitive than 
CUB.
It was not possible to make a photometric study of the photodecomposition of CUB, for 
direct comparison with RBS, because its absorption spectrum showed marked, time 
dependent changes, even when solutions were kept in the dark. Unlike RBS, CUB is 
insoluble in water, which required that it be dissolved first in dimethyl sulphoxide (DMSO) 
prior to use. DMSO is a co-ordinating solvent which has recently been shown to cause
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fragmentation of CUB and subsequent reassembly as RBS, the more stable of the two 
configurations. The reaction proceeds through the formation of mononuclear (dinitrosyl) Isolvo-complexes. The transformation of CUB to RBS by DMSO has been detected by £
1infra-red spectroscopy under conditions which simulated those used here (Glidewell & ?
Giidewell, unpublished data).
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Therapeutic potential o f  iron-sulphur cluster nitrosyls
Haemodynamic studies on experimental animals and human volunteers, using stereospecific 
inhibitors of NO synthase, have established that endothelium-derived NO is a major 
determinant of peripheral resistance in vivo (Vallance et al, 1989; Chu et al, 1991; Aisaka et 
al, 1989; Gardiner et al, 1990; Rees et al, 1989). Significantly, endothelium-dependent 
relaxations are attenuated in hypertension (Luscher & Vanhoutte, 1986; Winquist et al,
1984; Otsuka et al, 1988; Tesmafariam & Halpern, 1988; Sunano et al, 1989) and in 
atherosclerosis (Forstermann et al, 1988; Harrison et al, 1987; Chappel et al, 1987; Henry et 
al, 1987; Guerra et al, 1989). The ability of conventional NO donor drugs to lower blood |  
pressure is due to release of NO into the vascular bed, either spontaneously or after 
metabolic biotransformation (Feelisch & Noack, 1987; Waldman & Murad, 1984). 
However, their hypotensive actions are generally short-lived, so that continuous drug 
infusions are necessary to produced sustained responses (Kreye, 1980). In the previous 
chapter, it was shown that RBS and CUB readily penetrate endothelial cells and accumulate 
therein, releasing NO slowly to produce protracted vasodilator responses. The 
photosensitivity of these compounds adds an important new dimension to their therapeutic 
potential. Their ability to enter endothelial cells and to release NO more rapidly on exposure 
to light presents the possibility of causing local vasodilation with the use of fibre optic light |  
guides and the potential to deliver cytotoxic quantities of NO to specific target sites.
y
CHAPTER 7
EVIDENCE FOR A PHOTOLABILE NO STORE IN 
VASCULAR SMOOTH MUSCLE
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7.1 INTRODUCTION
Pre-contracted vascular smooth muscle relaxes when exposed to visible or ultra-voiolet light 
(Furchgott et al, 1961). The effect is reversible and complete recovery occurs in the dark. 
Photorelaxation was shown to depend on both the intensity and wavelength of light used. 
The amplitude of the response was independent of oxygen tension, though recovery in the 
dark was markedly slower under anaerobic conditions. Lowering the temperature from 37 
to 2CPC increased the amplitude of the response and prolonged its time course. The nature 
of the photosensitive material could not be established, though the manner in which the 
response varied with wavelength (biological ‘action’ spectrum) led Furchgott et al to 
propose that it could be a ‘complex of a metal, such as iron, with a protein’.
Photorelaxation is not seen with non-vascular smooth muscle, save in the presence of N02“ 
(Furchgott & Matsunaga, 1989), and it can be elicited in endothelium-denuded preparations 
(Furchgott et al, 1984). Recently, it has been postulated that ultraviolet light causes 
vasodilation by activating endothelial NO synthase ( Deliconstantinos et al, 1992). In 
addition, irradiation of partially purified guanylate cyclase, the ‘target’ enzyme for 
endothelium-derived NO in vascular smooth muscle cells (Waldman & Murad, 1987), has 
been shown to activate cGMP synthesis both in vitro (Karlsson et al, 1985) and in vivo 
(Karlsson et a l , 1984).
Previous work in this laboratory (Flitney, Watson & Megson, unpublished data) showed 
that exposure of segments of rat tail artery to low level laser irradiation (< 10 mW; 514.5nm 
or <4mW; 457.9nm) produced vasodilator responses similar to those reported by Furchgott 
and his colleagues. Exposure to higher light intensities produced responses whose 
amplitude was not increased but which showed signs of recovery during the period of 
illumination.
In the present study, photorelaxant responses were elicited in both PE- and high potassium 
(80mM) - contracted arteries and their amplitude, expressed as a % of active pressure,
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appeared to be independent of the pre-illumination pressure. Photorelaxations typically 
displayed profiles similar to that shown in figure 7.1 (c).
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Repriming inhibited by LNMMA
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NOT inhibited by Hb or LNMMA
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Figure 7,1. A typical photorelaxant response profile and its theoretical components. The 
illumination period is indicated by the horizontal bar.
The present investigation will show that the photorelaxant response (7.1 (c)) represents the 
sum of two components.
First, a component caused by the release of NO from a photolablile, molecular store within 
the tissue (7.1 (a)). The store can be depleted by exposing arteries to moderately high 
intensity laser light (6.4mW. cm~2) for 4-6mins. Thus, the first photorelaxation in a series 
typically comprises a rapid vasodilation followed by vasoconstriction during the period o f  
illumination. The amplitude of subsequent photorelaxations depends upon the time interval 
between successive exposures. The underlying process involved will hereafter be described 
as 'repriming’.
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Second, a component that is NO-independent, accounting for the small responses seen in 
the presence of Hb and LNMMA (7.1 (b)). This study will focus on the NO-dependent 
component but a possible mechanism for the NO-independent component will be discussed 
later.
100
7.2 MATERIALS AND METHODS
A. ANIMALS
Adult male Wistar rats (270- 327g) were killed by cervical dislocation, their tails removed 
and a length of artery (8-12 mm) cannulated at both ends and dissected free.
B. APPARATUS
Modifications were made to the apparatus shown in figure 2.1 to facilitate laser irradiation 
of vessels. Figure 7.2 shows how light from an argon ion laser (L; Spectra Physics Ltd., 
type 168-09) was passed through an expanding lens and reflected onto the preparation by 
means of a 45° front-silvered mirror (M) to produce a uniform, 2 cm diameter beam at the 
preparation. The vessel (V) was cannulated at both ends for these experiments in order to 
hold it within the beam. Each inadiation was of a standard intensity (6.4mW. cm-^), 
wavelength (514.5nm) and duration (6 mins). Pressure was monitored by a pressure 
transducer (P) as described in section 2.2.
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Figure 7,2, Apparatus used to study the effects of laser light on isolated lengths o f rat tail 
artery. See text for full details and explanation of lettering.
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c . EXPERIMENTAL PROTOCOL
Vessels were precontracted with PE to produce agonist-induced perfusion pressures of
101.7 +/- 4.4 mmHg ([PE] = 6.7+/- 0.5 ptM; n=29). Once pre-contracted, vessels were 
irradiated as described above for 6 mins. The first exposure produces a tmnsient vasodilator 
response which is referrred to as the depletion response (DR). The initial drop in pressure 
is followed by spontaneous recovery during the period of illumination. The peak amplitude 
of the first in a series of photorelaxations is variable (7.3 - 46.6%), and the perfusion 
pressure returns to a level slightly below the pre-illumination pressure within 4-6 min of 
commencing laser treatment. Full recovery is seen when illumination ceases.
An identical period of laser irradiation, delivered shortly after the first, succeeds only in 
producing a photorelaxant response equivalent in amplitude to the component which fails to 
recover during the previous exposure. This component of the response only recovers once 
laser illumination ceases. Importantly, the peak amplitude of subsequent photorelaxations 
depends upon the time interval (TI) between successive periods of laser irradiation. 
However, all photorelaxations elicited under the conditions described were of similar form 
to the initial response (DR).
Figure 7.3 shows pressure recordings made for the depletion exposure and after TIs of 10, 
20, 40, 72 and 150 mins recovery in the dark (control). Also shown are corresponding 
recordings made in the presence of LNMMA or Hb.
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TI = 10 mins
TI = 20 mins
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Figure 7.3. Pressure recordings showing photorelaxations, following the time intervals 
indicated, in the absence of inhibitors (control), in the presence o f 100 pM  LNMMA and in 
the presence of 5 pM Hb. Periods of illumination are indicated by the horizontal bars. All 
responses have been scaled to the vertical scalebar (% amplitude). Experimental details: 
(a) Expt. No 930208: 286g male Wistar rat; 4 pM  PE produced 116 mmHg active 
pressure, (b) Expt. No 930218: 317g male Wistar rat; 5 pM  Hg produced 89 mmHg 
active pressure, (c) Expt. No 930401; 394g male Wistar rat; 4 p M  PE produced 109 
mmHg active pressure. Irradiations; 514.5 nm , 6.4 mW. cm~^ , 6  mins.
I
Experiments were performed to establish the following:
(i) The timecourse of the repriming process. This was acheived by eliciting responses to 
identical irradiations after TIs of 10, 20, 40, 72 and 150 mins. Responses after TIs of 300 
mins were carried out on seperate preparations.
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(ii) The effect of intemaUy perfused LNMMA (100 pM) on the repriming process. 
LNMMA treatment was initiated either immediately, or 20 mins after a depletion exposure. 
Some LNMMA treated vessels were subsequently perfused with lO'^M L-arginine.
(iii) The effect of internally perfused 5 pM  Hb on photorelaxations.
(iv) The effect of pretreatment with internally perfused 1(X) pM  ethacrynic acid (EA) on 
photorelaxations.
(v) The effect of interposed \Qp\ injected doses of SNAP or NPon the amplitude of theTI 
= 20 mins photorelaxations.
D. ANALYSIS OF RESULTS
(i) The peak amplitudes were recorded for responses attained after each TI. In addition, 
response profiles were constructed by taking pressure recordings every 24 seconds 
throughout exposures.
(ii) The peak amplitude of responses attained after each TI in the presence of LNMMA 
were recorded. In order to compensate for differing sensitivities in preparations, the TI = 20 
mins response obtained before LNMMA perfusion was compared to the mean TI = 20 
mins response obtained in (i), and responses in the presence of LNMMA were scaled 
accordingly. In preparations where the introduction of LNMMA was delayed by 20mins, 
the amplitude of the first response obtained in the presence of the inhibitor was compared to 
the equivalent response before LNMMA perfusion, allowing 20 mins for LNMMA to take 
full effect (TI = 40 mins).
(iii) Results for Hb experiments were treated in the same way as for LNMMA described in
(ii).
(iv) The peak amplitude of vasodilator responses to increasing doses of SNAP or NP 
injected immediately after a DR were measured. The amplitude of photorelaxations 
obtained at TI = 20 mins were also measured and compared to the control TI = 20 mins 
response elicited before the first drug injection. Log-dose response curves showing both the 
vasodilator responses and the di'ug-induced enhancement of photorelaxations were plotted.
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7.3 RESULTS
(i) Repriming o f  Photorelaxation.
Figure 7.4 shows the averaged photorelaxations following various TIs, as shown. The peak 
amplitude increases with increasing TI, with exposures after TIs of 300 mins causing the 
perfusion pressure to fall by ca. 35%. Figure 7.4 also illustrates that responses plateau at a 
level 3-8% below the pre-illumination pressure until irradiation ceases.
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Figure 7.4. Meaned response profiles recorded afier the TIs shown (n -  5 for TI = 20, 
40, 72 and 150 mins; n = 3 for TI = 300 mins).
A plot of peak amplitude against TI is shown in figure 7.7 (filled circles), from which, TII/2 
for repriming is estimated as 104 mins.
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(ii) Effect o f  LNMMA on Repriming.
Figure 7.7 (open squaies) shows the effect on the repriming process of perfusing vessels 
with 100 pM  LNMMA immediately following a DR; responses are severely inhibited with 
photorelaxations of <5% being elicited, even after TI=150 mins. Pressure profiles closely 
resemble those of responses elicited immediately after DRs in untreated vessels. The 
amplitude of LNMMA-inhibited responses is also comparable to the element of 
photorelaxant responses that fails to recover during the period of irradiation noted in (i) 
above. This suggests that control response profiles shown in figure 7.4 comprise an 
LNMMA resistant vasodilator element (NO-independent) superimposed on a vasodilator 
element which is dependent on functional NO synthase.
In vessels where the introduction of 100 /<M LNMMA was delayed until 20 mins had 
elapsed following a DR, responses elicited at TI = 40 mins were significantly greater in
amplitude than the equivalent TI = 40 mins control responses (figures 7.5 and 7.6).
40 mins
10 mm
mins
4 mins
Figure 7.5. Pressure recording showing the effect of delayed infusion o f 100 pM  LNMMA 
on the amplitude o f the first and second TI = 40 mins responses in the presence o f the 
inhibitor. Expt. No 930218: 317g male Wistar rat; 5 pM  Hg produced 89 mmHg active 
pressure. Irradiations; 514.5 nm . 6.4mW. cm~^ , 6 mins.
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Figure 7.6. Histogram showing control response for TI = 40 mins (n ~ 6) compared to 
the equivalent response in the presence o f LNMMA (LNMMA; n -  4) and that where 
LNMMA introduction was delayed by 20 mins (LNMMA + 20 mins; n = 3). ** signifies a 
significant difference at the P  = O.OI confidence level and *** a tth eP  -  0.001 confidence 
level.
The result is more surprising since NO synthase was only functioning for 20 of the 40 mins 
following the DR. Responses obtained at TIs after this enhanced response in the presence 
of LNMMA were severely inhibited as detailed above (figures 7.4 and 7.5).
Figure 7.7 (open circles) shows photorelaxations obtained in the presence of 1 mM L- 
arginine following washout of LNMMA. Clearly, the inhibitory effect of LNMMA on the 
repriming process is reversible. Responses obtained in L-arginine are not significantly 
larger than control responses, suggesting that L-arginine levels in the tissue are sufficient to 
sustain normal basal release of NO under the conditions of this experiment.
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(iii) Effect o f  Hb on photorelaxation.
Figure 7.7 (filled triangles) shows the inhibitory effect of 5 pM  Hb, introduced into the 
internal perfusate immediately after a DR, on photorelaxations elicited after increasing TIs. 
The inhibition is comparable to that caused by LNMMA. Again, the results are consistant 
with the existence of a NO-independent vasodilator component, superimposed on a 
transient vasodilator component which is due to NO activation of guanylate cyclase.
0.16
0.12
40 0.081/PR
0.04
0.0030
0.00 0.02 0.04 0.06
1/time
PR(%) 20
Tl/2 = 104 mins
100 200 300 400
Time Interval (mins)
Figure 7.7. Effect o f 100 p M  LNMMA (open squares; n =3 - 5) or 5 pM  Hb (filled
triangles; n = 3 - 4) on repriming o f photorelaxation in the absence of inhibitors (filled 
circles; n = 3 - 5). The effect o f LNMMA can be fully reversed by perfusion with 1 mML- 
arginine (open circles; n -  3). A double reciprocal plot of response amplitude o f control 
responses against time (inset) shows the estimated maximal response at TI = infinity to be 
ca. 45% (1/ y axis intercept).
The results illustrated in figure 7.7 show that in the presence of either LNMMA or Hb, 
response amplitude is severely inhibited. However, a small component (3-6%) of the 
response is resistant to treatment with either inhibitor and is therefore NO-independent.
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(iv) Effect o f EA on photorelaxation
Perfusion of preparations with EA (100//M) had little effect on perfusion pressure. EA is a 
recognised inhibitor of guanylate cyclase and as such would be expected to cause an increase 
in pressure similar to that seen with MB. Some preparations actually showed a slow but 
detectable drop in pressure (< 15%) during EA perfusion, which failed to recover on 
washout.
Figure 7.8 is a histogram illustrating the inhibitory effect of EA treatment on 
photorelaxation after increasing TIs. Photorelaxations are shown to be eliminated in all but 
the longest TI (150 mins), where a 3% response was recorded, as compared to a control 
response of ca. 26%. This level of inhibition is more severe than either that of LNMMA or 
Hb. Significantly, the NO-independent component of the response, which was still present 
in LNMMA or Hb treated vessels, was inhibited by EA treatment.
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Figure 7.8. Histogram illustrating the effect o f EA pretreatment on photorelaxation after 
increasing TIs and on vasodilator responses due to 10p i injections o f ImMNP ( n -  3) or 
l.SmMNO (n = 5). *** indicates a significant difference at the P = 0.001 confidence level. 
* indicates a significant difference at the P = 0.05 confidence level.
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Figure 7.8 also shows that responses to lO-^M NP were severely attenuated by EA, 
reinforcing the hypothesis that tissue thiol groups are a compulsory element in degradation 
of NP in the dark and/or transfer of the resultant NO to guanylate cyclase (chapter 1).
In order to ascertain the viability of guanylate cyclase after EA treatment (in the knowledge 
that thiol groups are involved in regulation of the enzyme), saturated solutions of authentic 
NO were prepared in sealed vials. The precise concentration of NO present remains 
unknown and is the subject of great debate (estimates varying from 1.8 x lO^ M (Feelisch, 
1992) - <10*3 (Martin, personal communication). In this case, a sufficiently high 
concentration of NO was present in microinjections to give maximal responses before EA 
treatment. Evidently, the response is diminished, suggesting that guanylate cyclase may be 
less responsive to NO stimulation following EA treatment. This is especially true since the 
saturated solution of NO used is supermaximal.
(v) Effect o f  bolus injections o f NO, SNAP and NP on repriming.
10/d bolus injections of SNAP and NP (10"^- lO^M) into the internal perfusate produce 
transient vasodilator responses which fully recover (within ca. 5 mins for SNAP and ca. 10 
mins for NP - see chapter 3). Similar injections of authentic NO (10*  ^- 10*3M)were found 
to show comparable response profiles to those of SNAP but with a faster recovery rate (full 
recovery within ca. 3 mins). These results suggest that all three compounds clear the lumen 
rapidly and do not accumulate in the tissue, as was found with RBS and CUB (chapter 4).
Figure 7.9 shows pressure recordings obtained from experiments where \Qp\ bolus 
injections of SNAP (trace A) were interposed betwen TI = 20 mins responses (trace B). 
Responses to all SNAP doses show full recovery before the onset of the TI = 20 mins 
photorelaxations. Clearly, however, photorelaxation is enhanced in a dose-dependent 
manner by prior injection of SNAP. Similar results were obtained following NO injections. 
However, only the highest dose of NP used (10*2 M) caused a significant enhancement of 
the subsequent photorelaxation.
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Figure 7,9. Pressure recordings obtained for vasodilator responses to lOpl injections of 
SNAP (trace A). Photoretaxant responses obtained after TI = 20 mins following injections 
are shown in trace B. Expt. NO. 930226. 297g male Wistar rat; 4pM  PE produced 137 
mmHg active pressure. Exposures 5l4.5nm laser light (6.4mW. cm-^): injections 10 pi.
The effect of \0p \ bolus injections of (a) NO, (b) SNAP or (c) NP, administered 
immediately following a depletion response, on photorelaxations elicited at TI = 20mins is 
shown in figures 7.10. The plot shows vasodilator responses to NO, SNAP and NP plotted 
as a function of log dose and the enhanced  photorelaxation responses ( = potentiated 
responses - control response) produced at TI = 20 mins after each dose.
Figure 7.10 shows the results obtained for (a) authentic NO, (b) SNAP and (c) NP. 
Vasodilator response amplitude (VR (%)) is indicated by filled symbols whilst the 
enhanced photorelaxation following injection is indicated by open symbols.
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Figure 7,10. vasodilator responses (VR (%)) to bolus injections o f (a) NO (filled triangles; 
n = 3), (b) SNAP (filled circles; n = 5) or (c) NP (filled squares; n = 5) and subsequent 
photorelajcant resposes (PR (%)) evoked after TI ~ 20 mins (open triangles after NO, open 
circles after SNAP and open squares after NP).
Figure 7.10 (a) shows the results obtained with autlientic NO. The precise concentrations of 
NO dilutions injected are unknown. Theoretically, the maximum dose administered, a
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saturated solution of NO, should be 1.8 mM at room temperature (Feelisch, 1992). In 
reality, the concentration may be up to a factor of 10 x less than this, depending on the extent 
to which it reacts with O2  in solution (Martin, personal communication). The maximum 
concentration of a saturated solution of NO estimated by Martin et al is ca. 9xlO"'^M. The 
doses plotted in figure 7.10 (a), therefore, are the maximum likely values. In reality, the log 
dose-response curve may fall to the left of that shown.
What is certain, however, is that a bolus injection of NO administered prior to a TI = 20 min 
photorelaxation enhances the latter in a dose-dependent manner. Maximum enhancement 
caused by the saturated NO solution (ca. 72% vasodilation) was ca. 42% (total 
photorelaxation = 49 %). As discussed earlier, the rapid recovery of responses to bolus 
injections of NO suggests that it clears the lumen long before the subsequent 
photorelaxation is evoked. In addition, NO that enters the tissue as the bolus passes through 
the vessel is unlikely to exist as a free entity for more than a few seconds since the 
‘biological half-life’ of NO is estimated to be between 3 and 30 secs (Griffith et a/,1984 & 
Cocks et a/,1985).
As shown in figure 7.9, responses to SNAP also recovered fully before the onset of the TI 
= 20 mins photorelaxations. Figure 7.10 (b) shows a steep log-dose response curve to 
injections of SNAP, reaching a maximum of ca. 85% relaxation at a concentration of lCb% 
M. Subsequent TI = 20 mins responses show significant enhancement after injections of 
<10'^ M. The degree of enhancement is dose dependent, reaching a maximum of ca. 60% 
(total photorelaxation = 67%).
Vasodilator responses to NP likewise recovered fully before irradiation began, although at a 
slower rate than the two drugs described previously. Figure 7.10 (c) shows that responses 
to doses of NP were smaller than those for corresponding doses of SNAP as expected from 
earlier experiments (see chapter 1). In accordance with this, only the highest dose of NP 
( i0 ‘^  M) significantly enhanced subsequent TI = 20 mins photorelaxations (enhanced by 5 
%; total photorelaxation = 12%).
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The results suggest that a threshold concentration of each compound is required to enhance 
the peak amplitude of the following photorelaxant response. Figure 7.11 is a plot of 
vasodilator response amplitude against enhanced photorelaxation amplitude for all three 
compounds.
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This shows that the threshold vasodilator response amplitude for significant photorelaxation 
enhancement is lower for NO microinjections (ca. 45%) than for SNAP or NP (ca. 60%). 
It would appear, therefore, that authentic NO is more efficient at accelerating repriming than 
SNAP or NP where photorelaxations must be preceded by a near-maximal vasodilator 
response to be enhanced.
Control experiments showed that neither perfusion with 10"4M 8-bromo cGMP for Ihr nor 
injection of up to 20p\, lO'^M isoprenaline (a cAMP-mediated agonist) were capable of
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enhancing subsequent photorelaxant responses despite giving substantia! vasodilator 
responses (67.9% for 8-bromo cGMP and 44.2% for isoprenaline). In this knowledge, it is 
apparent that vasodilation per se is not responsible for the phenomenon. Rather, it is 
essential to deliver a high dose of authentic or drug-derived NO to acheive photorelaxation 
enhancement.
Figure 7.12 shows pressure recordings made by a vasodilator responses to a lOjA, lO^M  
bolus injection of SNAP in the presence of 100 pM  LNMMA followed by a TI = 20min 
response. Also shown are the control TI = 20 min response elicited before the introduction 
of LNMMA (note that irradiation continues until after the time when LNMMA first reaches 
the tissue in order to prevent repriming by endothelium-derived NO) and the first TI 
=20min photorelaxation in the presence of LNMMA.
10”* M SNAP
71.4*
20
mm He
4 min#
100 //M LNMMA
Figure 7.12. Pressure recordings showing the ejfect of LNMMA inhibition o f NO synthase
Î
on SNAP-induced enhancement of photorelaxation. Expt. NO- 930305: 249g male Wistar 
rat; 8pM  PE produced 74 mmHg active pressure. All irradiations 514.5mn; 6.4mW.cm‘^ . 
SNAP injection volume - lOpl.
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The photorelaxation evoked following the SNAP injection in the presence of LNMMA was 
6.8% enhanced as compared to the control response evoked before the injection. Although 
this is not as large an effect as in the absence of LNMMA (ca, 19%), the 10"^  M SNAP 
injection produced a surprisingly small vasodilator response of 71.4% (c.f. 80.3 %). 
Typically, responses to NO donor drugs are enhanced in the presence of LNMMA. The 
importance of this experiment is that it shows SNAP-induced accelerated repriming of 
photorelaxation is independent of NO synthase activity.
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7.4 DISCUSSION
Reprinting o f  photorelaxation
The experiments described suggest that photorelaxation is ultimately due to NO stimulation 
of guanylate cyclase, and consequently is abolished by Hb (Figure 7.6 and 7.7). A minor 
component of light-induced responses appears to be NO-independent but may involve direct 
stimulation of guanylate cyclase.
The results suggest that the source of NO involved is a finite molecular 'store' within the 
tissue. The store can be depleted by moderately high intensity light, resulting in responses 
which recover during the period of illumination (figures 7.3 and 7.4). Following depletion, 
the store is slowly reprimed by endothelium-derived NO and the peak amplitude of 
subsequent responses is determined by the duration in the dark over which repriming can 
occur (i.e. the time interval between exposures; figures 7.3,7.4 and 7.7).
Stereospecific inhibition of endothelium-derived NO synthesis by LNMMA deprives the 
store of its source of NO and prevents repriming. If LNMMA treatment commences 
immediately following depletion of the store, responses are severely attenuated and their |
amplitude is independent of the time interval between successive exposures (figures 7.3 and 
7.7). However, when inhibition is delayed by 20 mins following a depletion exposure, 
repriming can occur for the specified time. The first exposure obtained in the presence of 
LNMMA (TI = 40mins) is then significantly larger than the control response for TI = |
40mins (figure 7.5 and 7.6). It seems likely that this reflects the supersensitivity towards 
NO shown by guanylate cyclase when deprived of it for a short length of time (Moncada et 
al , 1991). The first exposure in the presence of LNMMA in vessels treated in this way 
results in the release of the NO which has accumulated in the store during the interval 
between depletion and inhibition of NO synthesis. Subsequent exposures, however, do not 
elicit responses since no repriming can occur following depletion. Normal repriming is 
resumed following washout of LNMMA by 10‘^M L-arginine. Interestingly, 
photorelaxations were not significantly enhanced by L-aiginine, suggesting that L-arginine
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levels within endothelial cells are sufficient to maintain a supply to NO synthase for basal 
synthesis of NO, despite the constant flow of L-arginine-free Krebs past the endothelial 
cells.
Endothelium-denuded preparations have been shown to be capable of photorelaxation 
(Furchgott, 1984). This fact does not contradict the results reported here since the 
illumination conditions used by Furchgott et al were insufficient to deplete the NO store. In 
addition, the store would presumably be at least partly full before the endothelium was 
removed. Therefore, NO was still available for photorelaxation despite the removal of the 
endothelium. The results reported by Furchgott et al show that the store is located in cells 
other than endothelial cells and refute the suggestion that photorelaxation is solely due to 
activation of endothelial NO synthase as proposed by Deliconstantinos et al (1992). Further 
evidence suggesting that the source of NO is not endothelial NO synthase comes from the 
fact that preparations treated with LNMMA were still capable of photorelaxation when NO 
is provided from an exogenous source (e.g. SNAP or NO microinjections; figure 7.12).
The involvement of NO in the photorelaxant process is therefore supported by the 
following:
1. Inhibition by Hb.
2. Inhibition of repriming by LNMMA (fully reversible with L-arginine).
3. Development of supersensitivity to photorelaxation in guanylate cyclase when deprived 
of NO for a short period of time, as described by Moncada et al (1991) for NO donor 
drugs.
Accelerated repriming following microinjections o f NO or SNAP.
Microinjections of NO or SNAP, delivered immediately following a DR, produced 
vasodilator responses which showed rapid recovery to the pre-injection level. This indicates 
that cGMP levels within the tissue have returned to their pre-injection level and suggests that 
none of the injected dose of either NO or SNAP remains within the tissue (chapter 4). 
Photorelaxations elicited at TI = 20 mins were unaffected by prior microinjections of low
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concentrations (< ca. 5 x M of NO; < ca. lO^ M of SNAP). Doses above these 
‘thresholds’ caused enhanced photorelaxations. The amplitude of vasodilator response 
necessary to cause significant enhancement of the subsequent photorelaxation was lower for 
authentic NO than for SNAP (figure 7.11). This suggests that authentic NO is more 
efficient at causing accelerated repriming than NO donor drugs.
Evidently, NO derived from suitably high doses of either SNAP or injected authentic NO 
accelerates the repriming process, leading to enhanced photorelaxant responses. The precise 
concentrations of NO injected were unknown, largely as a result of practical problems 
involved in the exclusion of oxygen from the solution. The true log dose-response curve 
may well lie significantly further to the left than that shown.
Experiments involving microinjections of NP were less conclusive than those using NO 
and SNAP. Only the highest dose used (10‘^ M) was capable of enhancing the subsequent 
photorelaxation. It is possible that NP is unable to enhance photorelaxation in the manner 
seen with SNAP as a result of its unique NO delivery mechanism (chapter 3) but the most 
likely explanation for these results is that lO'^M NP was the only dose used which released 
sufficient quantities of NO to accelerate repriming. NP has already been shown to be a less 
potent vasodilator than SNAP (chapter 3). Figure 7.11 indicates that vasodilation caused by 
SNAP or, it appears, NP, must exceed approximately 60% in order to cause enhancement 
of the subsequent photorelaxation. Ideally, IQ-^ M NP should have been injected to test this 
hypothesis but vasodilator responses to this concentration of NP would have required more 
than 20 mins to recover fully, resulting in the photorelaxation starting on a diminshed 
baseline.
Nature o f  the NO store within vascular tissue
The intracellular environment is host to a wide variety of molecules capable of binding NO 
and releasing it on exposure to light. Experiments were carried out to investigate the 
possibility that tissue thiols (both free and protein-bound) are responsible for binding NO.
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The results suggest that nitrosothiols may constitute at least part of the store since alkylation 
using EA abolishes photorelaxation. The results concerning EA were marred, however, by 
the fact that responses to microinjections of autlientic NO were also inhibited, although to a 
lesser extent than photorelaxation. EA may well, therefore, inhibit guanylate cyclase by 
alkylating thiol groups on the enzyme which are involved in regulating its activity 
(Waldman & Murad, 1987). It may even be the case that these thiol groups constitute part 
of the store when nitrosylated.
Therapeutic implications o f  a pfwtosensitive source o f  NO in blood vessels 
Once the chemical identity of the NO store is established, it may be possible to elicit its 
release in vivo locally using fibre-optic probes to treat conditions such as vasospasm. 
Alternatively, a generalised release may be acheived by infusing compounds known to 
undergo cross-nitrosation and then decompose thermally under intracellular conditions 
(Butler et al, 1993). This would result in a more uniform release of small amounts of NO, 
resulting in a generalised vasodilator response.
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CHAPTER 8 
CONCLUSIONS AND
SCOPE FOR FURTHER STUDY
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8.1. MECHANISMS INVOLVED IN VASODILATOR RESPONSES TO BOLUS 
INJECTIONS OF SNAP AND NP IN THE DARK.
Preliminary experiments performed using bolus injections of test doses of NP, RBS and 
CUB had shown that all were capable of causing vasodilation in isolated segments of rat tail 
artery in the dark(figure 3.1 (a)). Perfusion with the stereospecific NO synthase inhibitor, |
LNMMA did not attenuate responses (figure 3.1 (c)), whilst recognised inhibitors of the ?
NO: guanylate cyclase pathway, MB and Hb (figure 3.1 (b) and (d)) abolished responses to -I
RBS and CUB but did not affect those to NP. These results suggested that vasodilation s
caused by RBS and CUB was NO-mediated but did not involve activation of NO synthase, 
whilst the actions of NP were apparently independent of either NO or guanylate cyclase.
Î'i
The results of chapter 3 suggested that different mechanisms were involved in vasodilation 
evoked by each of these compounds.
A. SNAP
Vasdilations induced by bolus injections of SNAP were rapid, both in onset and recovery.
perfusion pressure returning to its pre-injection level within ca. 3 mins. The ED5 0  value for 
SNAP was estimated as 6pM. Responses to intermediate doses of SNAP were 
significantly inhibited by Hb (reflected in a 7-fold increase in ED5 0  value), though not 
abolished entirely. It is possible, therefore, that only part of SNAP-induced vasodilation is 
due to NO released in solution in the lumen. The Hb-resistant element of vasodilator 
responses to SNAP may either be due to an NO-independent mechanism, or due to ‘cross- 
nitrosation* of SNAP with membrane-bound or intracellular thiols (Butler et al, 1993). In 
the latter case, free NO would not exist as a single entity outside the tissue and would be 
resistant to Hb inactivation, (see figure 8.1 for summary).
I
/:
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Vasodilator responses evoked by bolus injections of NP, though rapid in onset, recovered at 
a much slower rate than SNAP-induced responses. Full recovery of responses produced by 
lO’^ M NP typically took in excess of 10 mins. NP proved to be a less potent vasodilator 
than SNAP, with an ED5 0  of 52pM. Hb inhibition, though statistically significant for 
intermediate doses, was less effective for responses to NP than those to SNAP (2-fold 
increase in ED5 0  value). This result was less surprising in view of the results reported by 
Flitney & Kennovin (1988) which showed that NP does not generate NO in the dark. 
Furtheimore, these authors concluded that mammalian vascular smooth muscle, which 
responds to NP in the dark, has a mechanism for degrading NP which is not present in frog 
ventricle. Recently, a 4 KDa, membrane-bound protein has been isolated which releases 
NO from NP in mammalian tissue (Kowaluk et al, 1992). The apparent resistance of ‘dark 
NP’ could be explained by the fact that the NO generated may never experience the intra­
luminal environment; indeed it may never exist in an unbound form throughout its transition 
from endothelial membrane to smooth muscle guanylate cyclase (see figure 8.1 for 
summary).
Another possible explanation for the actions of NP is that it is capable of causing 
vasodilation through several mechanisms, at least one of which is cGMP independent. This 
possibility is all the more plausible in the knowledge that responses to bolus injections of 
NP are not inhibited by MB, a recognised inhibitor of guanylate cyclase (figure 3.1(b)). 
Reports by Diamond & Chu, 1983, Otsuka et al, 1988 and Feelisch, 1991 show that NP 
behaves differently when compared to other NO donor drugs with respect to cGMP 
elevation. Apparently, NP-induced vasodilation increases disproportionately to increases in 
cGMP levels.
Despite its extensive experimental use as a classic ‘nitrovasodilator’, there is considerable 
evidence to suggest that NP does not act solely through release of NO. Instead, it appears 
that NO stripped from NP by membrane bound proteins is one of perhaps several 
mechanisms by which it exerts its vasodilatory effect.
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8.2 UNUSUALLY PROTRACTED RESPONSES TO BOLUS INJECTIONS OF 
IR O N -SU L P H U R  CLUSTER NITRO SYLS ARE DUE TO THEIR  
ACCUMULATION IN ENDOTHELIAL CELLS AND SLOW RELEASE OF NO 
FROM WITHIN.
Vasodilator responses evoked by bolus injections of low concentrations (< Dt; for
RBS and 20 -100;<M for CUB) of RBS and CUB produced transient (T-type) responses 
similar in profile to those elicited by SNAP and NP. However, doses > Dt produced 
responses which failed to fully recover (figures 3.4, 4.2 and 4.3). Recovery became 
progressively less pronounced with increasing dose, failing altogether following injections 
of 5mM RBS for up to 6 hrs. Perfusion of vessels with Hb or MB during sustained 
responses caused the pressure to rise to a level well above the-pre-injection pressure (figure 
4.4), indicating two points: first, pressure in sustained responses is suppressed by
continuous release of NO; and second, endothelial NO was still functioning in vessels |
i
experiencing sustained responses, since the pressure rose to a level above the pre-injection J
value.
Circumstantial evidence suggesting that both RBS and CUB are likely to be absorbed by the i
itissue, particularly in view of their lipid solubility, was confirmed by histochemical and X- 
ray microprobe analysis of vessels perfused for a short period of time with either compound 
(chapter 5). Both techniques showed that cluster nitrosyls were taken up by the endothelium 
and microprobe analysis revealed that cells immediately adjacent to the endothelium were 
unaffected.
It appears, therefore, that sustained responses evoked by bolus injections of RBS and CUB 
are compound in nature, comprising a transient component, due to spontaneous release of 
NO within the lumen, superimposed on a prolonged response, due to slow release of NO 
from cluster nitrosyls trapped within the endothelium. A computer simulation (figure 4.5) 
permitted an analysis of the kinetics of the two processes to be made (figure 4.6). From 
these results, it was concluded that CUB degraded 3.5 x faster than RBS in physiological
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solution, reflected in a larger transient component to the response. In calculating the relative 
spontaneous breakdown rates, it was assumed that both compounds release their full 
complement of NOs on decomposition, as predicted by their ‘electron precise’ structures 
(Butler et al, 1985). In contrast, RBS uptake into and/or breakdown within the tissue was 
apparently greater for RBS than for CUB, as reflected in a lower Dt for development of S- 
type responses and the greater loss of pressure during the plateau phase.
Evidently, once in the tissue, breakdown of cluster nitrosyls is slow, with responses to 
5mM RBS and CUB showing little or no recovery for up to 6 hrs.
The complex nature of responses to cluster nitrosyls made direct comparisons with SNAP 
and NP impossible. It appeared, however, that neither was as potent a vasodilator as NP, in 
terms of peak amplitude evoked by bolus injections. The severe attenuation of responses to 
RBS and CUB (figure3.5) suggests that both compounds exert their effects almost entirely 
through NO generated by spontaneous decomposition of the compounds within the lumen 
of the vessel.
Therapeutic Potential
The unique properties of RBS in particular, increase its potential as clinically viable NO 
donor drug. If harnessed properly, long-term vasodilation from short-term infusion of RBS 
is theoretically possible. However, studies in this laboratory have shown that RBS is less 
effective in vivo than results reported here would suggest. It appears that the problem lies in 
the avid binding of RBS to albumin, illustrated in pilot experiments using sephadex 
columns. Binding to albumin in vivo would prevent accumulation in the endothelium and 
impair the resulting vasodilation. Preliminary microinjection experiments suggest that RBS 
and CUB will only produce T-type responses in the presence of bovine serum albumin
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8.3 RBS AND CUB ARE PHOTOSENSITIVE
Exposure to ultraviolet and visible light causes pre-contracted vessels to relax (Furchgott et 
al, 1961; Furchgott, 1971; Furchgott, 1984; Matsunaga & Furchgott, 1989 - see section 
1.11). Photorelaxation is though to be due to release of NO from an unknown source.
Exposure of vessels to low intensity, 514.5nm laser light for 1 min evokes small amplitude 
responses which fully recover once irradiation ceases. Similar exposures elicited during 
sustained responses due to bolus injections of moderate doses of RBS or CUB (figure 6.2), 
caused enhancement of photorelaxation (in terms of amplitude and rate of drop in pressure) 
and reduced the latent period between irradiation and onset of response. Vessels continued 
to produce enhanced photorelaxations for up to 5 hrs following a single microinjection of 
RBS or CUB. Further enhancement was shown during SOD perfusion (figure 6.2 (c)), 
suggesting the involvement of NO in the process. It seemed probable that the phenomenon 
was due to light-induced acceleration of release of NO from clusters trapped wihin 
endothelial cells. The phenomenon therefore lends weight to the hypothesis that both cluster 
nitrosyls accumulate in the tissue and remain there long after the bolus injection has cleared 
the lumen.
Separate experiments showed that laser irradiation of low concentrations of RBS or CUB en 
route to the vessel (see figure 6.1) produced intensity- and wavelength-dependent 
vasodilator responses over and above the steady-state response seen in the dark (figures 6.4 
and 6.5). Responses to exposed RBS were found to be inhibited by Hb and potentiated by 
SOD (figure 6.7), suggesting NO involvement. Increasing the delay time between perfusate 
containing RBS leaving the exposure tube and reaching the vessel in the absence of SOD 
had the effect of diminishing the amplitude of light-induced vasodilator responses, 
presumably as a result of NO inactivation between generation in the exposure tube and 
detection in the vessel (figures 6.8 (a)). Inclusion of SOD in the perfusate eliminated NO 
inactivation between generation and detection (figure 6.8(b)). Spectophotometric studies 
revealed that laser light caused intensity- and wavelength-dependent decomposition of RBS
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(figure 6.9). From these results, concentrations of NO reaching the preparation, under 
different illumination conditions, were calculated and an ED5 0  value for NO estimated at ca. 
15nM.
The results of these experiments showed that breakdown of both RBS and CUB is 
accelerated when exposed to light, resulting in an increased liberation of NO, and an increase 
in relaxation in the tissue. The effect occurs when cluster nitrosyls trapped within the tissue 
are exposed to light and when perfusate containing either compound is irradiated en route to 
the preparation.
RBS proved more sensitive to light than CUB and the resultant vasodilator response was 
dependent on the concentration of drug present. The shorter wavelength of light (457.9m W) 
proved more effective at causing accelerated breakdown of either RBS or CUB than 
514.5nm laser light.
Results for CUB were complicated by the fact that DMSO, used as a solvent prior to 
dilution, was found to cause fragmentation of CUB, which subsequently re-assembled as 
RBS, the more stable of the two compounds (Glidewell and Glidewell, unpublished data).
TlterapeiUic potential
The photosensitivity of RBS and CUB adds an important dimension to their possible clinical 
use, especially in view of their ability to penetrate and remain in endothelial cells for 
considerable lengths of time. Local vasodilation could be induced with the use of light 
guides on vessels pretreated with RBS.
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8.4 PHOTORELAXATION IS DUE TO THE RELEASE OF NO FROM A 
PHOTOLABILE STORE WITHIN VASCULAR SMOOTH MUSCLE.
As mentioned in 8.2 above, photorelaxation is a phenomenon which has been known about 
for over 30 years but whose mechanism is still poorly understood. Experimental evidence 
(Furchgott et al, 1961; Furchgott, 1971; Furchgott et al, 1984; Matsunaga et al, 1989) 
strongly suggests the involvement of NO from a source other than the endothelium. Recent 
papers, however, suggest that photorelaxation is due to stimulation of EDRF synthesis by 
endothelial NO synthase (Deliconstantinos et al, 1992). Karlsson et al (1984, 1985), on the 
other hand, believe that photorelaxation is due to direct stimulation of guanylate cyclase in 
the smooth muscle.
Experiments performed here showed that photorelaxation is due to the release of NO from a 
finite molecular store within the tissue (figure 8.1). Once depleted, repriming of the store 
could be acheived by NO derived from the endothelium (blocked by LNMMA; figures 7.3, 
7.6 and 7.7) or by NO from an exogenous source (SNAP, authentic NO or to a lesser 
extent, NP; figure 7.10).
Photorelaxation is abolished by Hb but enhanced in vessels where guanylate cyclase has 
been deprived of basal release of NO for a short period of time, leading to its becoming 
supersensitised as described by Moncada et al, 1991 (figures 7.5 and 7.6). These findings 
together strongly suggest the involvement of NO in photorelaxation.
Photorelaxation is also abolished in vessels pre-treated with ethacrynic acid, an agent which 
irreversibly alkylates thiol groups (figure 7.8). This result suggests that nitrosothiols 
constitute at least part of the store. However, the fact that responses to authentic NO were 
inhibited, although to a lesser extent than photorelaxant responses, suggests that guanylate 
cyclase may be partially inhibited by EA, due to alkylation of essential regulatory thiol 
groups on the enzyme (Waldman & Murad, 1987).
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Nevertheless, the results strongly suggest that release of NO from a photolabile molecular 
store within the tissue is responsible for photorelaxation. It is not considered likely that 
activation of NO synthase is responsible because vessels in which photorelaxation is 
inhibited by LNMMA are still capable of responding to light if an alternative source of NO 
is provided (SNAP; figure 7.12). Rather, it appears that the role of the endothelium is to 
provide NO for repriming of the store.
A detailed study involving comparison of the biological 'action spectrum' with light-induced 
decomposition of known nitrosothiols, nitrosyl-haem and iron-sulphur nitrosyl compounds 
would be necessary to establish the identity of the NO store involved. In addition, the 
possible involvement of glutathione (which accounts for ca. 90% of ‘free’ thiol 
concentration within cells) could be investigated using the glutathione synthesis inhibitor, 
buthionine sulphoximide.
Therapeutic potential
The value of determining the mechanism involved in photorelaxation lies in a better 
understanding of the physiology involved in the L-arginine:NO - guanylate cyclase pathway. 
However, the phenomenon has therapeutic potential, either with the use of light guides to 
cause local vasodilation or by exploiting cross-nitrosation reactions (Butler g/ al, 1993), 
whereby NO could be transferred from the store to a thiol which then degrades under 
physiological conditions, releasing NO in the proximity of guanylate cyclase. The feasibility 
of this as a therapeutic strategy has yet to be investigated.
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8,5 SUMMARY
Figure 8.1 is a diagram summarising the vasodilator mechanism of SNAP, NP, RBS and 
CUB as suggested by the results obtained in this invesigation. In addition, the proposed 
mechanism involved in photorelaxation is illlustrated.
ENDOTHELIUM SMOOTH MUSCLELUMEN
RBS & 
CUB
RBS & 
CUB
NO
storeNO + NO :SNAP
NP
L -A R G  L -C IT PHOTOLYSIS
NO >EDRFsynthase
calmodulin GTP /  / I  calcium
pumps?2 ++ Ca DEPENDENT KINASES.Endothelium 
dependent ■ 
vasodilator 
(eg ACh) RELAXATION
Figure 8,1. Proposed vasodilator mechanisms of RBS, CUB, SNAP and NP as suggested 
by the results obtained in this investigation. The existance of a photolabile NO store within 
the smooth muscle is also illustrated.
RBS and CUB release NO spontaneously either within the lumen or from molecules 
trapped within the endothelium. The process occurs in the dark but is accelerated by light.
SNAP releases some NO spontaneously in the lumen but also appears to be ‘stripped’ of 
NO by the tissue as it passes through the lumen. The mechanism is not yet known but may 
involve cross-nitrosation between SNAP and tissue thiols.
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NP does not release NO spontaneously in the dark, rather it is removed by a small protein ' 
bound to the endothelial membrane.
NO, whether from an exogenous or an endogenous source, passes to the smooth muscle 
and stimulates guanylate cyclase and causes relaxation. However, some NO is utilised to 
replenish a molecular store within smooth muscle. The nature of the store is not yet known 
but nitrosothiols may constitute part of it. NO is released from the store on exposure to 
light, leading to stimulation of guanylate cyclase and photorelaxation.
131
REFERENCES
132
REFERENCES
ADLER, S., 1972. The simultaneous determination of muscle pH using a weak acid and a 
weak base. J. Clin. Invest. 51: 256-265.
AISAKA, K., GROSS, S.S., STEINBERG, GRIFFITH, O.W. & LEVI, R., 1990. Fp- 
monomethyl arginine, an inhibitor of endothelium-derived nitric oxide synthesis is a 
potent pressor agent in the guinea-pig: doesNO regulate blood pressure in vivo? 
Biochem. Biophys. 160: 881-886.
ANTONI NI, E. & BRUNORI, M., 1971 in ‘Haemoglobin & Myoglobin in their reactions 
with ligands. Frontiers in Biology’ vol. 21. NH publishing, Amsterdam & London.
AXELSSON, K.L. & ANDERSSON, R.G.G., 1983. TOLErance towards nitroglycerin, 
induced in vivo, is correlated to a reduced cGMP respose and an alteration in cGMP 
turnover. Eur. J. Pharmacol. 88: 71-93.
AZUMA, K., ISHAKAWA, C. & SEKIKAZI, W., 1986. Endothelium-dependent
inhibition of platelet aggregation. Br. J. Pharmacol. 88: 411-415.
BAGETTA, G., MOLLACE, V., lANNONE, M. & NISTICO, G., 1992. Possible
involvement of nitric oxide in the pathophysiology of seizures and brain damage in 
rats. Biology of nitric oxide (1) (Portland Press) 255-257.
BEAVO, J.A., 1988. Multiple isoenzymes of cyclic nucleotide phosphodiesterase. Adv. 
Second Messenger Phosphoprotein Res. 22: 1-38.
BEAVO, J.A., HARDMAN, J.G. & SUTHERLAND, E.W., 1971. Stimulation of
adenosine 3',5' monophosphate hydrolysis by guanosine 3'.5' monophosphate. J. 
Biol. Chem. 246: 3841-3846.
BEETENS, J.R., COENE, M.-C.,VERHEYEN, A., ZONNEKEYN L., & HERMAN, 
A.G., 1986. Biphasic response of intimai prostacyclin production during the 
development of experimental atherosclerosis. Prostaglandins 32\ 319-334.
BIELSKI, B.H. & GEBIEKI, J.M., 1977. Application of radiation chemistry to biology. 
In Free radicals in biology 3:1 (Ed. Pryor) New York Academic Press.
133
BOHME, E., JUNG, R. & MECHLER, I., 1974. Guanylate cyclase in human platelets. 
Methods Enzymol. 38: 199-202.
BRANDWEIN, H.J., LEWICKI, J.A. & MURAD, P., 1981. Reversible inactivation of 
guanylate cyclase by mixed disulphide formation. J. Biol. Chem. 256: 2958-2962.
BRAUGHLER, J.M., 1982. Involvement of sulphydryl groups in oxidative modulation of 
pai'ticulate lung guanylate cyclase by nitric oxide and N-methyl-N'-nitrosoguanidine. 
Biochem Pharmacol. 31; 1239-1244.
BRAUGHLER, J.M., 1983. Soluble guanylate cyclase activation by nitric oxide and its 
reversal: involvement of sulphydryl group oxidation and reduction. Biochem. 
Pharmacol. 32: 811-818.
BREDT, D.S. & SNYDER, S., 1990. Isolation of nitric oxide synthase, a calmodulin- 
requiring enzyme. Proc. Nat. Acad. Sci. U.S.A., 87:682-685.
BREDT, D.S., HWANG P.M., GLATT G.E., LOWENSTEIN C., REED R.R.,
SNYDER, S.H., 1991. Nature 351: 714-718.
BRUNTON, T.L., 1867. Use of nitrite of amyl in treatment of angina pectoris. Lancet 97- 
98.
BUSSE, R. & MULSCH, A., 1990. Calcium-dependendent nitric oxide synthesis in 
endothelial cytosol is mediated by calmodulin. FEBS Lett. 275: 87-90.
BUSSE, R., LUCKHOFF, A. & BASSENGE, E., 1987. Endothelium-derived relaxing 
factor inhibits platelet activation. Naunyn-Schmiedeberg's Arch, pharmacol. 336: 
566-571.
BUTLER, A.R., ASKEW, S., FLITNEY, F.W. & MEGSON, I.L., 1993. The vasodilator 
action of S-nitrosoglutathione: evidence for NO transfer. In Biology of Nitric Oxide 
(in press).
BUTLER A.R., & GLIDEWELL, C.,1987. Recent chemical studies of sodium
nitropmsside relevent to its hypotensive action. Chem. Soc. Rev. 16: 361-380.
BUTLER, A.R., GLIDEWELL, C. & MIN-HSIN, L., 1988. Nitrosyl complexes of iron- 
sulphur clusters. Adv. Inorg. Chem. 32: 335-392.
134
BUTLER, A.R. & WILLIAMS, L., 1993. The physiological role of NO. Chem. Soc.
Rev. 233-241.
CASINELLI, C.M., 1956. La Accion hypertensoradel nitroprussiato aplicaciones 
terapeuticas. An. Fac. Med., 39:1330-1331.
CHAPPELL, S.P., LEWIS, M.J. & HENDERSON, A.H., 1987. Cardiovasc. Res. 21: 
34-38.
CHU., A., CHAMBERS, D.E., LIN, C. C., KUEHL, W.D., PALMER, R.M.J.,
MONCADA, S. & COBB, P., 1991. Effects of inhibition of NO formation on basal
vasomotion and endothelium- dependent responses of coronaiy arteries in awake 
dogs. J. Clin. Invest. SI: 1964-1968.
CLANCY, LESZCZYNSKA-PIZIAK, ABRAMSON, 1992. Nitric oxide. An endothelial 
cell relaxation factor, inhibits neutrophil superoxide anion production via a direct 
action on NADPH oxidase. J. Clin. Invest. 90(3): 1116-1121.
COCKS, T.M., ANGUS, J.A., CAMPBELL, J.H. & CAMPBELL, G.R., 1985. Release 
and properties of EDRF in culture. J. Cell Physiol. 123: 310-320.
CORNWELL, T.L., & LINCOLN, T.M., 1989. Regulation of intracellular Ca2+ levels in 
cultured smooth muscle cells: Reduction of Ca2+ by atriopeptin and 8, Br-cGMP 
is mediated by cGMP-dependent protein kinase.
CRAVEN, P.A. & DE RUBERTIS, F.R., 1978. Effects of thiol inhibitors on hepatic 
guanylate cyclase activity: evidence for the involvement of vicinal dithiols in the 
expression of basal and agonist-stimulated activity. Biochim. Biophys. Acta. 524: 
231-244.
CRAVEN, P.A., DE RUBERTIS, F.R. & PRATT, D.W., 1979. ESR study of the role of 
NO-catalase in the activation of guanylate cyclase by NaN and NH20H.
Modulation of enzyme responses by haem proteins and their nitrosyl derivatives. J. 
Biol. Chem. 254: 8213-8221.
CUI Y., WITHERS D.E., RAE C.F., NORRIE C.J., TANG Y., SINCLAIR B.D.,
SIBBETT W., & DUNN M., 1993. Optics Letters 18,2: 122 -124.
135
DEGUCHI, T., & YOSHIOKA, M.,1982. L-arginine identified as the endogenous
activator for soluble guanylate cyclase from neuroblastoma cells. J. BioL Cheni,
257: 10147-0152.
DEGUCHI, T., 1977. Endogenous activating factor for guanylate cyclase in synaptosomal- 
soluble fraction of rat brain. J. BioL Chem. 252: 7617-7619.
DELICONSTANTINOS, G., VILLIOTOU, V. & FASSITSAS, C., 1992. Ultraviolet-
irradiated human endothelial cells elaborate nitric oxide that may evoke vasodilatory 
response. J, Cardiovasc. Pharmacol. 20 (S12): S63-65.
DIAMOND, J. & CHU, E.B., 1983. Possible role of cGMP in endothelium-dependent 
relaxation of rabbit aorta by A Ch. Comparison with nitroglycerin. Comms. in 
Chem. Path, and Pharmacol. 41: 369-381.
EXTON, J.H., 1988. Mechanism of action of calcium-mobilizing agonists; some variations 
on a young theme. FASEB J. 2: 2670-2676.
FEELISCH, M., 1991. The biochemical pathways of nitric oxide formation from
nitrovasodilators: appropriate choice of exogenous NO donors and aspects of 
preparation and handling of Aqueous NO solutions. J. Cardiovasc. Pharmacol. 
17(suppl. 3): S25-S33.
FEELISCH, M. & NOACK, E.A., 1987. Correlation between nitric oxide formation
during degradation of organic nitrates and activatioOn of guanylate cyclase. Eur. J. 
Pharmacol. 139: 19-30.
FLITNEY, F.W. & KENNOVIN, G.D., 1986. Laser-induced photolysis of nitroprusside: 
response of isolated frog ventricular traberciilae to photodegradation products. J. 
Physiol. 380: 37P.
FLITNEY, F.W., MEGSON, I.E., CLOUGH,T. & BUTLER A.R., 1990. Nitrosylated 
iron-sulphur clusters, a novel class of vasodilator: studies on the isolated rat tail 
artery. J. Physiol. 430: 42P.
FLITNEY, F.W., MEGSON, I.E., FLITNEY, D.E. & BUTLER A.R., 1992. Iron-suphur 
cluster nitrosyls, a novel class of nitric oxide generator: mechanism of vasodilator 
action on rat isolated tail artery. Br. J. Pharmacol. 107,842-848.
136
FLITNEY, F.W. & SINGH, J., 1980. Adenosine depresses contractility and stimulates 
3’ ,5’ cyclic nucleotide metabolism in the isolated frog ventricle. J. Mol. Cell.
Cardiol. 12: 285-297.
FORSTERMANN, U., GORSKY, L.D., POLLOCK, J.S., SCHMIDT, H.H.H.W.,
HELLER, M. & MURAD, F., 1990. Regional distribution of EDRF/NO synthesising 
enzymes in rat brain. Biochem. Biophys. Res. Commun. 168: 727-732.
FORSTERMANN, U., MUGGE, A., ALHEID, U., HAVERICH, A. & FROLICH, J.C., 
1988. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic 
human coronary arteries. Circ. Res. 62: 185-190.
FORSTERMANN, U., SCHMIDT, H.H.W., POLLOCK, J.S., SHENG, H., MITCHELL,
J.A., WARNER, TD, NAKANE, M. & MURAD, F., 1991. Characterisation and 
classification of constitutive and inducible isoforms of nitric oxide synthase in 
various cell types. Biology of nitric oxide (1) (Portland Press) 21-23.
FREEMAN, B.A., & CRAPO, J.D., 1982 .Biolgy of disease. Free radicals and tissue 
injury. Lab. Invest. 5: 412-426.
FUKUTO, J.M., WOOD, K.S., BYRNS, R.E. & IGNARRO, L.J., 1990. NO-amino-L- 
arginine: a new potent antagonist of L-ai'ginine-mediated endothelium-dependent 
relaxation. Biochem. Biophys Res. Commun. 168: 458-465.
FURCHGOTT, R.F., & ZAWADZKI, J.V., 1980. The obligatory role of endothelial cells 
in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376. 1
FURCHGOTT, R.F., 1988. Studies on relaxation of rabbit aorta by sodium nitrite: the basis 
for the proposal that the acid-activatable factor from retractor penis is inorganic nitrite 
and the endothelium-derived relaxing factor is nitric oxide. In Vasodilation:
Vascular smooth muscle, peptides, autonomic nerves and the endothelium (Ed.
P.M. Vanhoutte) 401-414, Raven Press.
FURCHGOTT, R.F., 1971. Effects of various agents on photorelaxation of rabbit aortic 
strips. In Physiology and pharmacology of vascular neuroeffector systems (Eds. 
Bevan, Furchgott, Maxwell & Somlyo). 247-262.
FURCHGOTT, R.F., 1984. The role of endothelium in responses of vascular smooth 
muscle to drugs. Ann. Rev. Pharmacol. Toxicol. 24:175-197.
137
FURCHGOTT, R.F., EHRREICH, S.J. & GREENBLATT, E., 1961. The photoactvated 
relation of smooth muscle to light. J. Gen. Physiol. 44:499-519.
FURLONG, B., HENDERSON, A.H., LEWIS, M.J & SMITH, J.A., 1987.
Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br. J. 
Physiol. 90: 687-692.
FURUKAWA, K-I. & NAKAMURA, H., 1987. cGMP regulation of (Ca2+-Mg2+) 
ATPase in vascular smooth muscle. J. Biochem. 101: 287-290.
FURUKAWA, K-I., TAWADA, Y. & SHIGEKAWA, M., 1987. Regulation of plasma 
membrane Ca2+ pump by cyclic nucleotides in culture vascular smooth muscle 
cells. J. BioL Chem. 263: 8058-8065.
GARDINER, S.M., COMPTON, A.M., KEMP, P.A. & BENNETT, C., 1990. Regional 
and caidiac haemodynamic effects of NG- nitro-L-arginine methyl ester in concious 
Long Evans rats. Br. J. Pharmacol., 101: 625-631.
GARTHWAITE, J. & GARTHWAITE, G., 1987. Cellular origins of cGMP responsesto 
excitatory amino acid receptor agonists in rat cerebellum in vitro. J. Neurochem. 48: 
29-39.
GARTHWAITE, J., CHARLES, S.L. & CHESS-WILLIAMS, R., 1988. EDRF release 
on activation of NMDA receptors suggest role as intracellular messenger in the 
brain. Nature 336: 385-388, 1988.
GERZER, R., KARRENBROCK, B., SIESS, W. & HEIM, J-M., 1988. Direct
comparison of the effects of nitroprusside, SIN 1 and various nitrates on platelet 
aggregation and guanylate cyclase activity. Thromb. Res. 52: 11-21.
GERZER, R., BOHME, E., HOFMANN, F., SCHULTZ, G., 1981. Soluble guanylate 
cyclase purified from bovine lung contains haem and copper. FEBS lett 132: 71-74.
GERZER, R., HOFMANN, F., BOHME, E. KRASSIMIRA, I., SPIES, C. &
SCHULTZ, G., 1981. Purification of guanylate cyclase without loss of stimulation 
by sodium nitropmsside. Adv. Cyclic. Nucleotide Res. 14: 255-261.
138
GERZER, R., HOFMANN, F. & SCHULTZ, G., 1981. Purification of a soluble, sodium 
nitroprusside- stimulated guanylate cyclase from bovine lung. Eur. J. Biochem.
116: 479-486.
GERZER, R., RADNEY, E.W. & GARBERS, D.L., 1982. The separation of the haem 
and apohaem forms of guanylate cyclase. Biochem. Biophys. Res. Comm. 108: 
678-686.
GILL, G.N., HOLDY, K.E., WALTON, G.M. & KANSTEIN, C.B., 1976, Purification 
and characterisation of 3',5' cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. 
U.S.A. 73: 3918-3922.
GOESSL, C., KNISPEL, H.H. & BECKMANN, R., 1992. Nitric oxide mediates
relaxation in rabbit and human penile erectile tissue. Biology of nitric oxide (1) 
(Portland Press); 263-266.
GOLDBERG, N.D. & HADDOX, M.K., 1977. cGMP metabolism and involvement in 
biological regulation. Ann. Rev. Biochem. 46: 823-896.
GRANGER, D.L. & LEHNINGER, A.L., 1982. Sites of inhibition of mitochondrial
electron transport in macrophage injured neoplastic cells. J. Cell Biol. 95: 527-535.
GRANGER, D.L., TAINTOR, R.R., COOK, J.L. & HIBBS, J.B. Jr., 1980. Injury of 
neoplastic cells by murine macrophages leads to inhibition of mitochondrial 
respiration. J. Clin. Invest. 65: 357-370.
GRIFFITH, T.M., EDWARDS, D.H., LEWIS, M.J., NEWBY, A.C. & HENDERSON, 
A.H., 1984. the nature of EDRF. Nature 308: 645-647.
GRYGLEWSKI, R.J., MONCADA S., & PALMER, R.M.J., 1986. Bioassay of
prostacyclin and EDRF from porcine aortic endothelial cells. Br. J. Pharmacol. 87: 
685-694.
GRYGLEWSKI, R.J., MONCADA S. & PALMER, R.M.J., 1986b. Superoxide anion is 
involved in the breakdown of EDRF. Nature 320: 454-456.
GUERRA, R., BROTHERTON, A.F.A., GOODWIN, P.J., CLARK, C.R.,
ARMSTRONG, M.L. & HARRISON, D.J., 1989. Blood Vessels 26: 300-314.
139
HARRISON, D.G.. ARMSTRONG, M.L., FRIEMAN, P.O. & HEISTAD, D.D., 1987. 
Restoration of endothelium-dependent relaxation by dietary treatment of 
atherosclerosis. J. Clin, invest. 80: 1808-1811.
HARTZELL, H.C. & FISCHMEISTER, R , 1986. Opposite effects of cAMP & cGMP 
on calcium current in single heai t cells. Nature 323: 273-275.
HASLAM, R.J., SALAMA, S.E., FOX, J.E.B., LYNAM, J.A. & DAVIDSON, M.M.L. 
1980. Role of cyclic nucleotides and of protein phosphorylation in the regulation of 
platelet function. In Platelets: cellular response mechanisms and their biological 
significance (Eds. Rotman, Meyer, Gitler & Silberberg).
HASLAM, R.J., 1987. Signal tranduction in platelet activation. In Thrombosis and 
homeostasis (Eds. Verstraete,Vermylen, Lijnen and Sarnout).
HIBBS, J.B. Jr., TAINTOR, R.R., & VAVRIN, Z., 1987. Science 235: 473-476.
HIBBS J.B. Jr., TAINTOR, R.R., VAVRIN, Z. & RACHLIN, F.M., 1988. Nitric oxide: 
a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. 
Comm. 157: 87-94.
HIGGS, E.A., MONCADA, S., VANE, J.R., CAEN, J.P., MICHEL, H. & TOBELOM, 
G., 1978. Effects of prostacyclin (PGI2) on platelet adhesion to arterial 
subendothelium. Prostaglandins 16: 17-22.
HILL, A.V., 1942. On the time required for diffusion and its relation to processes in 
muscle. Proc. Roy. Soc. 135: 446-453.
HOFMANN, F. & SOLD, G., 1972. A protein kinase activity from rat cerebellum
stimulated by guanosine 3',5' monophosphate. Biochem. Biophys. Res. Commun. 
49: 1100-1107.
HOGAN, J.C., LEWIS, M.J. & HENDERSON, A.H., 1988. In vivo EDRF activity 
influences platelet function. Br. J. Pharmacol. 94: 1020-1022.
IGNARRO, L.J., (1988). Circ. Res. 66: 1561-1575.
140
IGNARRO, L.J., KADOWITZ, P.J. & BARICOS, W.H., 1981. Evidence that regulation 
of hepatic guanylate cyclase activity involves interactions between catalytic site -SH 
groups and both substrate and activator. Arch. Biochem. Biophys. 208: 75-86.
IGNARRO, L.J., LIPPTON, H., EDWARDS, J.C., BARICOS, W.H., HYMAN, A.L.,
KADOWITZ, P.J., & GREUTTER, C.A., 1981. Mechanism of vascular smooth muscle 
relaxation by organic nitrates, nitrites, nitropmsside and nitric oxide: evidence for the 
involvement of S-nitrosothiols as active intennediates. J. Pharmacol. Exp. Ther. 
218: 739-749.
IYENGAR, R., STUEHR, D.J. & MARLETTA, M.A., 1987. Macrophage synthesis of 
nitrite, nitrate and N-nitrosoamines: precursors and role of the respiratoiy burst.
Proc. Natl. Acad. Sci. U.S.A. 84: 6369-6373.
JACOBS, M., PLANE, F., BRUSKDORFER, R , 1990. Inhibition of endothelium-
derived NO and atherosclerosis, in Nitric Oxide from L-arginine, a bioregulatory 
system, eds Moncada and Higgs. Amsterdam. 107-114.
JONES, A.W., BYLAND, D.B. & FORTE, L.R., 1984. cAMP- dependent reduction in 
membrane fluxes duiing relaxation of arterial smooth muscle. Am. J. Physiol. 246: 
H306-H311.
KARLSSON, J.O.G., AXELSSON K.K. & ANDERSSON, R.G.G., 1984. effects of 
ultraviolet radiation on the tension and cGMP level of bovine mesenteric arteries.
Life Sci. 34: 1555-1563.
KARLSSON, J.O.G., AXELSSON, K.K. & ANDERSSON, R.G.G., 1985. Protein 
Phosphorylation Res. 10: 309-315.
KATSUKI, S., ARNOLD, W., MITTAL C.& MURAD, F., 1977. Stimulation of
guanylate cyclase by sodium nitropmsside, nitroglycerin and nitric oxide in various 
tissue preparations and comparison to the effects of sodium azide and 
hydroxy lamine. J. Cyclic Nucleotide Res. 3: 23-25.
KHAN, M.T. & FURCHGOTT , R.F., 1987. Additional evidence that EDRF is nitric 
oxide. In Pharmacolgy (Ed. Rand & Roper) 341-344.
141
KILBOURNE, R.G., KLOSTERGAARD, J. & LOPEZ-BERESTEIN, G., 1984.
Activated macrophages secrete a soluble factor that inhibits mitochondrial respiration 
of tumour cells. X Immunol. 133: 2577-2581.
KIMURA, H., MITTAL, C.K. & MURAD, F., 1975. Activation of guanylate cyclase 
from rat liver and other tissues by sodium azide. J. Biol. Chem. 250: 8016-8022.
KNOWLES, R.G., PALACIOS, M., PALMER, R.M.J. & MONCADA S., 1988. Kinetic 
characteristics of nitric oxide synthase from rat brain. Biochem J. 269: 207-210.
KOBAYASHI, S., KANAIDE, H. & NAKAMURA, M., 1985. Cytosolic free calcium 
transients in cultured smooth muscle cells: microfluorometric measurements.
Science 229: 553-556.
KOWALUK, POLISZCZUK & FUNG, 1987. Eur. J. Pharmacol. 144: 379-383.
KOWALUK, SETH & FUNG, 1992. Metabolic activation of sodium nitroprusside to
nitric oxide in vascular smooth muscle. J. Pharmacol. Exp. Ther. 262(3): 916-922.
KRAHENBUHL, J.E., 1980. Effects of activated macrophages on tumour target cells in 
discrete phases of the cell cycle. Cancer Res. 40: 4622-4627
KREYE, V.A.W., 1980. Sodium nitroprusside. in Pharmacology of Antihypertensive 
Drugs, (ed. Scriabine). Raven Press, New York p373-394.
KUO, J.F. & GREENGARD, P., 1970. Cyclic nucleotide - dependent protein kinase VI. 
Isolation and partial purification of a protein kinase activated by guanosine 3',5' 
monophosphate. J. Biol. Chem. 245: 2493-2498.
KWON, N.S., NATHAN, C.F., & STUEHR, D.J., 1989. Reduced biopterin as a cofactor 
in the generation of nitrogen oxides in murine macrophages. J. Biol. Chem. 264: 
20496-20501.
LA COMBE, M-L. & EBERENZ-L’HOMME, C., 1983. Protoporphyrin IX activates the 
Mg-dependent guanylate cyclase from rat liver plasma membranes. Biochem. 
Biophys. Res. Comm. 116: 47-53.
142
LEEUWENKAMP, O.R., VAN BENNEKOM, W.R, VAN DER MARK, E.J., &
BULT, A., 1984. In vitro degradation of nitroprusside in relation to in vivo 
decomposition and mechanism of action. Int. J. Pharmaceutics 33; 1-13.
LEONE, A.M., PALMER, R.M.J., KNOWLES, R.G., FRANCIS, P.L., ASHTON, D.S. 
& MONCADA, S., 1992. Molecular oxygen is incorporated into both nitric oxide 
and citrulline by constitutive and inducible nitric oxide synthases. Biology of nitric 
oxide (2) (Portland Press): 7-13.
LEWICKI, J.A., BRANDWEIN, H.J., MITTAL, C.K., ARNOLD W.P. & MURAD, F., 
1982. Properties of purified soluble guanylate cyclase activayed by nitric oxide and 
sodium nitroprusside. J. Cyclic Nucleotide Res. 8: 17-25.
LINCOLN, T.M., 1989. cGMP and the mechanism of vasodilation. Pharmacol. Ther. 41: 
479-502.
LIU, X., GILLESPIE, J.S., GIBSON, A. & MARTIN, W., 1991. Br. J. Pharmacol. 104: 
53-58.
LOHMANN, S.M. & WALTER, U., 1984. Regulation of the cellular and subcellular
concentrations and distribution of cyclic nucleotide-dependent protein kinases. Adv. 
Cyclic Nucleotide Protein Phosphorylation Res. 18: 63-117.
LONG, C.J., SHIKANO, K. & BERKOWITZ, B.A., 1987. Anion exchange resins
descriminate between nitric oxide and EDRF. Eur. J. Pharmacol., 142: 317-318.
LUSCHER, T.F. & VANHOUTTE, P.M., 1986. Hypertens. 8: 344-348.
MacPHEE, C.H., HARRISON, S.H. & BEAVO, J.A., 1986. Immunilogical identification 
of the major platelet low Km-phosphodiesterase: probable target for antithrombotic 
agents. Proc. Natl. Acad. Sci, U.S.A. 83: 6660-6663.
MARCZIN, N., RYAN, U.S. & CATRAVAS, 1992. Methylene blue inhibits
nitrovasodilator- and endothelium-induced cGMP accumulation in cultured 
pulmonai y arterial smooth muscle cells via generation of superoxide anion. J. 
Pharm. Exp. Ther. 263.1: 1-10.
143
MARLETTA, M.A., YOON, P.S., lYENGER, R., LEAF, C.D. & WISHNOK, J.S., 1 
988. macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an 
intermediate. Biochemistry 27: 8706-8711.
MARTIN. W„ GIBSON, A. & GILLESPIE. J.S., 1992, NO-monomethyl L-arginine
blocks the ability of NG-nitro-L-arginine to inhibit non-adrenergic. non-cholinergic 
relaxation of the bovine retractor penis. Biology of nitric oxide ( 1) (Portland Press): 
304.
MARTIN, W., VILLANI, G.M., JOTHIANANDAN, D. & FURCHGOTT, R.F., 1985. 
Selective blockade of endothelium-dependendent and glyceryl trinitrate-induced 
relaxation by haemoglobin, and by methylene blue in the rabbit aorta. J. Pharmacol. 
Exp. Ther. 232: 708-716.
MATSUNAGA, K. & FURCHGOTT, R.F., 1988. Potentiation of photorelaxation of
rabbit aorta by nitrite. Fed. Proc. 46: 385
McCORD, J.M. & FRIDOVICH, I., 1972. Production of 0%" in photolyzed water
demonstrated through the use of superoxide dismutase. Photochem. Photobiol. 17: 
115-121.
MELLION, B.T., IGNARRO, L.J., OHLESTEIN, E.H., PONTECORVO, E.G.,
HYMAN, A. & KADOWITZ, P.J., 1981. Evidence for the inhibitory role of guanosine 
3',5' monophosphate in ADP-induced human platelet aggregation in the presence of 
nitric oxide and related vasodilators. Blood 57: 946-955.
MIKI, N., KAWEBE, Y. & KURIYAMA, K., 1977. Activation of cerebral guanylate 
cyclase by nitric oxide. Biochem. Biophys. Res. Commun. 75: 851-856.
MITTAL, C.K. & MURAD, F., 1977. Activation of guanylate cyclase by superoxide 
dismutase and hydroxyl free radical: a physiological regulator of guanosine 3',5' 
monophosphate foiTnation. Proc. Natl. Acad. .Sci. U.S.A. 75: 4360-4364.
MONCADA, S., GRYGLEWSKI, R., BUNTING S. & VANE, J.R., 1976. An enzyme 
isolated from arteries transforms prostaglandin endoperoxides to an unstable 
substance that inhibits platelet aggregation. Nature 263: 663-665.
144
MONCADA, S. & PALMER R.M.J., 1990. The L-arginine:mtric oxide pathway in the 
vessel wall.In nitric oxide from L-arginine: a bioregulatory system (Ed. Moncada 
and Higgs) Amsterdam. 19-33.
MONCADA, S., PALMER, R.M.J. & HIGGS, E.A., 1986 . Generation of prostacyclin 
and EDRF from endothelial cells, in Biology and pathology of platelet-vessel wall 
interactions. G. Jolies, J-Y Legrand & A Nurden (Eds) p289-304.
MONCADA, S., PALMER, R.M.J.& GRYGLEWSKI, R.J., 1986. Mechanism of
action of some inhibitors of EDRF. Proc. Natl Acad. Sci. U.S.A. 83: 9164-9168.
MONCADA, S., REES, D.D., SCHULZ, R. & PALMER, R.M.J., 1991. Development 
and mechanism of a specific supersensitivity to nitrovasodilators following 
inhibition of nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 88: 2166- 
2170.
MORGAN, J. & MORGAN, K.G., 1984. Alteration of cytoplasmic ionised calcium levels 
in smooth muscle by vasodilators in the ferret. J. Physiol. 357: 539-551.
MURAD, F., ARNOLD, W.R, MITTAL, C.K. & BRAUGHLER, J.M., 1979. Properties 
and regulation of guanylate cyclase and some proposed functions for cGMR Adv. 
Cyclic Nucleotide Res. 175-204.
MURAD, R, MITTAL, C.K., ARNOLD, W.R, KATSUKI S., & KIMURA, H., 1978. 
Guanylate cyclase: activation by azide, nitrocompounds, nitric oxide, and hydroxyl 
radical and inhibition by haemoglobin and myoglobin. Adv. Cyclic Nucleotide 
Res. 9: 145-158.
NEEDLEMAN, P., JAKSCHIK, B. & JOHNSON, E.M., 1973. Sulphydryl requirement 
for the relaxation of smooth muscle. J. Pharmacol. Exp. Ther. 187: 324-331.
OHLSTEIN, E.H., WOOD K.S. & IGNARRO, L.J., 1982. Purification and properties of 
heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors 
on activation by NO, NO-heme and protoporphyrin IX. Arch. Biochem. Biophys. 
218: 187-198.
OMAR, H.A., CHERRY, P.D., MARTELLITI, M.R, BURKE-WOLIN, T. & WOLIN, 
M.S., 1991. Inhibition of coronary artery superoxide dismutase attenuates
145
endothelium-dependent & independent nitrovasodilator relaxation. Circ. Res. 69(3): 
601-608.
OTSUKA, U., DIPIERO, A., HIRT, E. BRENNAMEN, B. & LOCKETTE W., 1988. 
Vascular relaxation and cGMP in hypertension. At?i. J. Physiol. 254: H163-H169.
PAGE, I.H., CORCORAN, A., DUSTAN, H.P. & KOPPANYI, T., 1955.
Cardiovascular actions of sodium nitroprusside in animals and hypertensive patients. 
Circulation 11: 188-198.
PALMER, R.M.J., ASHTON, D.S. & MONCADA, S,.1988. Vascular endothelial cells 
synthesise nitric oxide from L-arginine. Nature 333: 664-666.
PALMER, R.M.J., FERRIGE A.G.& MONCADA, S., 1987. Nitric oxide release 
accounts for the biological activity of EDRF. Nature 327: 524-526.
PALMER, R.M.J. & MONCADA S., 1989. A novel citrulline forming enzyme implicated 
in the formation of nitric oxide in vascular endothelial cells. Biochem. Biophys. Res. 
Commun. 158: 348-352.
PALMER, R.M.J., REES, D.D., ASHTON, D.S.&MONCADA, S., 1988. L-arginine is 
the physiological precursor for the formation of nitric oxide in endothelium- 
dependent relaxation. Biochem. Biophys. Res. Commun. 153: 1251-1256.
POPESCU, L.M., PANOUI C., HINESCU, M. & NUTO, O., 1985. The mechanism of 
cGMP-induced relaxation of vascular smooth muscle. Eur. J. Pharmacol. 107: 
383-394.
RADOMSKI, M.W., PALMER, R.M.J, & MONCADA, S., 1987. Comparative
pharmacology of EDRF, NO and prostacyclin in platelets. Br. J. Pharmacol. 92: 
181-187.
RADOMSKI, M.W., PALMER, R.M.J. & MONCADA, S., 1990 a. An L-arginine:nitric 
oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. 
Sci. U.S.A. 87: 5193-5197.
RADOMSKI, M.W., PALMER, R.M.J. & MONCADA, S., 1990 b. Characterisation of 
the L-arginine nitric oxide pathway in human platelets . Br. J. Pharmacol. 101: 325- 
328.
146
RADOMSKI M.W., PALMER, R.M.J., MONCADA S., 1987b. The anti-aggregating 
properties of vascular endothelium: interactions between prostacyclin and nitric 
oxide. Br. J. Pharmacol. 92: 639-646.
RADOMSKI, M.W., PALMER, R.M.J., MONCADA, S., 1987c. The role of nitric oxide 
and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res. 
Commun. 148: 1482-1489.
RADOMSKI, M.W., PALMER, R.M.J. & MONCADA, S., 1987d. Endogewnous nitric 
oxide inhibits human platelet adhesion to vascular endothelium. Lancet 2: 1057- 
1058.
RAPOPORT, R.M. & MURAD, F., 1983. Agonist-induced endothelium-dependent
relaxation in rat thoracic aorta may be mediated through cGMP. Circ. Res. 52: 352- 
357.
RAPOPORT, R.M., 1986. Cyclic guanosine inhibition of contraction may be mediated 
through inhibition of phosphatidyl inositol hydrolysis in rat aorta. Circ. Res. 58: 
407-410.
RASMUSSEN, H., TAKUWA, Y & PARK, S., 1987. Protein kinase C in the regulation 
of smooth muscle contraction. FASEB J. 1:177-185.
REES, D.D., PALMER, R.M.J., SCHULTZ, R., HODSON H.F. & MONCADA, S.,
1990. Characterisation of three inhibitors of endothelial nitric oxide synthase in vitro 
and in vivo. Br. J. Pharmacol. 101: 746-752.
ROUSSIN, 1858. Recheres sur les nitrosulphures doubles de fer. Ann. Chim. Phys., 52: 
285-303.
RUB ANY I, G.M. & VANHOUTTE P.M., 1986. Superoxide anions and hyperoxia 
inactivate EDRF. Am. J. Physiol. 250: H822-H827,
RUBANYI G.M., HO, E.H., CANTOR E.H., LUMMA W.C. & BOTELHO L.H., 1991. 
Cytoprotective function of nitric oxide: Inactivation of superoxide radicals produced 
by human leukocytes. Biochem. Biophys. Res. Commun. 181(3): 1392-1397.
147
RUBANYI, G.M., GREENBERG, S.S. & WILCOX, D.E., 1990. EDRF cannot be
identified as nitric oxide by paramagnetic resonance spectroscopy. In Endothelium- 
derived relaxing factors. (Eds. Rubanyi & Vanhoutte). Basle 32-38.
RUBANYI, G.M., LORENZ, R.R. & VANHOUTTE, P.M., 1985. Bioassay of 
endothelium-derived relaxing factors: inactivation by catecholamines. Am. J.
Physiol. 250: H1145-H1149.
SAKUMA, I, HISAKAZU, Y., GROSS, S. & LEVI, R. L-arginine is the precursor of 
EDRF in various in various animal species and vascular beds.
SARAN, MICHEL & BORS, 1990. Reaction of nitric oxide with superoxide.
Implications for the action of EDRF. Free Rad. Res. Commun. 10(4-5): 221-226.
SCHMIDT, H.H.H.W., WILKE, P., EVERS, B., & BOHME, E., 1989. Enzymatic 
formation of nitrogen oxides from L-arginine in bovine brain cytosol. Biochem. 
Biophys. Res.Commun. 165: 284-291.
SHIBUKI, K. & OKADA, D., 1991. Nature 349: 326-328.
SMITH, R.P. & KRUZYNA, H., 1974. Nitroprusside produces cyanide poisoning via a 
reaction with haemoglobin. J. Pharmacol. Exp. Ther. 191: 557-563.
SOUTHAM, E,. & GARTHWAITE, J., 1991. Eur J. Neiirosci. 3: 379-382.
STAMLER, J.S., SIMON, D.L, OSBORNE, J.A., MULLINS, M.E., JARAKI, O., 
MICHEL, T., SINGEL, D.J. & LOSCALZO, J., 1992. S-nitrosylation of proteins with 
NO: synthesis and characterisation of biologically active compounds. Proc. Natl. 
Acad. Sci. U.S.A. 89. 444-448.
STEELE, J.A., STOCKBRIDGE, N., MALKJOVIC, G. & WEIR, B., 1991. Free
radicals mediate action of oxyhaemoglobin on cerebrovascular smooth muscle cells. 
Circ. Res. 68: 416-423.
STUEHR, D.J. & NATHAN, C.F., 1989. Nitric oxide, a macrophage product responsible 
for cytostasis and respiratory inhibition in tumor tai’get cells. J. Exp. Med. 169: 
1011- 1020.
148
STUEHR, D.J., O.A., FASEHUN, KWON, N.S., GROSS, S.S., GOZALEZ, J.A.,
LEVI, R. & NATHAN, C.F., 1991. Inhibition of macrophage and endothelial cell nitric 
oxide synthase by diphenyleneiodonium and its analogues. FASEB X, 5: 98-103,
STUEHR, D.J., KWON, N.S., NATHAN, C.F., GRIFFITH, O.W., FELDMAN, P.L. & 
WISEMAN, J., 1991. X BioLChem. 266: 6259-6263.
STUEHR, D.J., CHO, H.J., KWON, N.S. & NATHAN, C.F., 1991. Proc, Natl. Acad.
Sci. USA. 88: 7773-7777.
SUNG, S-S., GLIDEWELL, C., BUTLER, A.R., & HOFFMANN, R., 1985 . Bonding in 
nitrosylate iron-sulfer clusters. Inorganic Chemistry 24: 3856-3859.
TARE, M., PARKINGTON, H.C., COLEMAN, H.H., NEILD, T.O. & DUSTING, G.J.,
1991. NO hyperpolarises arterial smooth muscle. X Cardiovasc. Pharmacol. 17: 
5108-5112.
TESFAMARIAM, B. & HALPERN, W.,1988. Hypertens. 11: 440-444.
VALLANCE, P., COLLIER, J. & MONCADA, S., 1989. Effects of EDRF of peripheral 
arterial tone in man. Lancet 2: 997-1000.
VANIN, A., 1991. Hypothesis: EDRF is a nitrosylated iron complex with thiol ligands. 
FEBS Letts. 289: 1-3.
WALDMAN, S. & MURAD, F., 1987. cGMP synthesis & function. Pharmacol Rev. 
39.3: 163-196.
WALDMAN, S.A., LEWICKI, J.A., CHANG, L.Y. & MURAD, F., 1983. Highly
purified particulate guanylate cyclase from rat lung: characterisation and comparison 
with soluble guanylate cyclase. Mol. Cell Biochem. 57: 155-166.
WALDMAN, S.A., RAPOPORT R.M. & MURAD, F., 1987. Desensitisation to
nitroglycerin in vascular smooth muscle from rat and human. Biochem. Pharmacol. 
35: 3525-3531.
WALDMAN, S.A., SINACORE, M.S., LEWICKI, J.A., CHANG L.Y. & MURAD, F., 
1984. Selective activation of particulate guanylate cyclase by a specific class of 
porphyrins. X Biol. Chem. 259: 4038-4042.
149
WALDMANN, R. & WALTER, U,, 1989. cyclic nucleotide elevating vasodilators inhibit 
platelet aggregation at an early step of the activation cascade.
WALDMANN, R., BAUER, S., GOBEL, C,. HOFMANN, F., JACOBS, K.H. & 
WALTER, U., 1986. Demonstration of cGMP dependent protein kinase and cGMP-
dependent phosphorylation in cell-free extracts of platelets. Eur. J. Biochem. 158: 
203-210.
WALTER, U., 1981. Distribution of cGMP-dependent protein kinase in various rat tissues 
and cell lines determined by sensitive and specific radioimmunnoassay. Eur. J, 
Biochem. 118: 339-346.
WALTER, U., 1984. cGMP-regulated enzymes and their possible physiological functions. 
Adv. Cyclic Nucleotide Protein Phosphorylation Res. 17: 249-258.
WALTER, U., 1989. Physiological role of cGMP and cGMP-dependent protein kinase in 
the cardiovascular system. Rev. Physiol. Biochem. Pharmacol. 113: 41-87.
WALTER, U., NIEDERDING, M., WALDMANN, R., 1988. Intracellular mechanisms 
of actions of vasodilators. Eur. Heart J. 9 (suppl H) : 1-6.
WARE, J.A., JOHNSON, P.C., SMITH, M. & SALZMAN, E.W., 1986. The effects of 
common agonists on cytoplasmic ionised calcium concentration in platelets: 
measurement with quin2 and aequorin. J. Clin Invest. 77: 878-886.
WINQUIST, R.J., BUNTING, P.B., BASKIN, E.P., & WALLACE, A.A., 1984.
Decreased endothelium-dependent relaxation in New Zealand genetic hypertensive 
rats. J. Hypertens. 2: 541-545.
WOLIN, M.S., CHERRY, P.D., RODENBURG, J.M., MESSINA, E.J. & KALEY, G., 
1990. Methylene blue inhibits vasodilation of skeletal muscle arterioles to 
acetylcholine and NO via the generation of superoxide anion. J. Pharmacol. Exp. 
Ther. 254: 872-876.
150
APPENDICES
151
APPENDICES
Mean increase in pressure caused by \5piM Hb (n=15): 55.92 +A6.4 
Mean increase in pressure caused by SjM  Hb (n=8): 56.5 +Z-4.9
lOOpiM LNMMA (n=10): 57.1 +/-6.1
APPENDIX TO GRAPH 3.3
Below are the peak amplitude (% Active pressure) of responses 
to 10}4\ injections of SNAP and NP.
SNAP
Expt. N® 10-7 M 10-^M lO-^M 10-4m 10-3m
930112 98.1 95.4 56.2 43.7 25.6
930113/1 98.3 56.2 90.1 35.3 32.9
930114 97.1 92.4 35.4 20.3 10.5
930115 98.1 97.8 33.9 24.3 16.4
930113/2 90.1 87.7 44 35,3 33.9
MEAN 96.7 83.03 49.02 24.28 18.64
S.E. 1.68 7.62 10.35 4.17 5.9
SNAP In ISpM Hb
Expt. N2 lO-^M lO-^M lO-^M 10’3m
930112 100 94.8 45.7
930114 79.1 66.2 33.3
930115 99 65.8 37.1 10.2
930113/2 100 96.7 68.1 41
MEAN 99.5 85.4* 55.1* 32.6
S.E. 0.5 7.9 7.4 7.8
P = 0.335 0.044 0.019 0.349
NP RESULTS
Expt. N2 10-7 M 10-<>M 10-5m 2x10-5m 5x10-% 1 0 -% 1 0 -% 1 0 -W
901017/1 97 98 92 84 70 62 28 31
901017/2 96 97 85 75 63 55 32 31 i
901022/1 89 88 76 75 62 58 44 35 ?
901022/2 78 74 64 59 49 45 34 30 i
901023/1 99 98 90 83 71 67 47 38 1
901106 93 93 86 73 65 58 41 33 j
MEAN 92 91 82 75 63 57.5 38.5 33 '1
S.E. 3 4 4 4 3 3 3 1
NP in ISpM Hb
* = significantly different from the above at P = 0.05 confidence level.
** = significantly di Terent from the above at P = 0.0: confidence level
Expt. N2 10-7 M 10-% lO-^M 2x10-% 5 x 1 0 % 1 0 -% 1 0 -% 10-%
901022/1 98 99 92.5 88 73 60 37 23
901022/2 100 99 95 89 80 73 47 34
901023 100 100 94 91 82 70 50 39
901106 100 99 95 89 80 73 47 34
901016/2 100 100 97 91 89 89 68 46
901114 100 98 91 84 77 65 50 38
MEAN 100 99 94* 87** 79** 70* 50* 35
S.E. 0.3 0.3 1 2 2 4 4 3
P = 0.054 0.068 0.021 0.005 0.002 0.018 0.039 0.444
II
APPENDIX TO FIGURE 3.5
RBS RESULTS
E x p t  N 2 10-7 M 1 0 ' % lO '^ M 2 x 1 0 “^ 5x10-5 1 0 r % 2x10-4 5x10-4 1 0 - % 5x10-5
910121/1 95 95 89 81 7 4 65 58 51 46 23
910123/2 98 96 94 96 8 8 78 71 54 44 15
910123/1 1 0 0 1 0 0 97 91 84 67 45 41 26 15
910130/2 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 90 89 82 53 38
910201/1 1 0 0 1 0 0 1 0 0 1 0 0 96 91 8 8 83 73 35
M E A N 99 99 96 93 8 6 78 6 8 61 48 25
S .E . 1 1 2 4 4 5 8 8 8 5
RBS in 15/iM Hb
*♦ = statistically different from the above at the P = 0.01 confidence level.
E x p t  N 2 10-5m 5x 10-5m
910114/2 99 95
910115/1 1 0 0 92
910115/2 89
910117/1 93 52
910117/2 97 49
910118/2 97 59
M E A N 7 2 .6 **
S .E . 1 8
P  = 0 . 0 0 0 0 . 0 0 2
Ill
■ , s
CUB RESULTS
Expt N2 lOr^M 10-<*M 10‘% 3x10*5 5x10*5 10*% 2x10*4 5x10*4 10*% 5x10*5 1
901130/1 100 100 97 83 75 67 48 30 Î
901203/1 97 99 95 92 88 70 58 43 29
901203/2 99 100 9 4 91 81 74 56 42 32 24 :
901207/1 97 96 90 75 61 58 51 46 42 40 .
901210/2 95 97 96 93 85 61 41 35 33 30 .
901210/1 100 98 94 90 80 72 47 33 32 .  :
MEAN 98 98 94 88 80 68 55 43 38 30 :
S.E. 0.8 0,7 1 3 4 4 5 5 3 2
*** = statistically di
CUB in tSfiM Hb
Terent from the above at the P = 0.005 confidence level
E x p t  N 2 10*5m 5x 10*5m
901130 100 89
901210/1 100 96
901207 100 98
901203/1 100 98
901210/1 99 88
901203/2 100 96
m ean 100* * * 9 4 * * *
S .E . 2
P  = 0.000 0.000
IV
APPENDIX TO FIGURE 4.3 (a) & (b)
Below are the mean and standard error values for X/Y (% active pressure) and 7JY (% 
active pressure) for 10/<1 injections of SNAP and NP.
SNAP NP
log dose (M) X/Y SE ZIY SE
10-7 96.7 1.7 97.1 2
10-6 83.0 7.6 95.6 1.43
10-5 49.02 10.4 96.2 2.45
2x10-5
5x10-5
10-4 24.28 4.2 93.1 8.7
10-5 18.64 5.9 93.6 6.9
10-2
X/Y SE Z/Y SEÎ
92 3 100
91 4 101 i
82 4 100 Ï1 s
75 4 103 1.5 ^
63 3 103 2.5 Ï
58 3 103
39 3 101 2 ■?
33 1 107 4  ;
Figure 4.3 (c) & (d)
Below are the mean and standard error values for X/Y (% active pressure) and Z/Ÿ (% 
active pressure) for lOpl injections of RBS and CUB.
RBS
log dose (M) X/Y SE Z/Y SE
10-7 99 1 100
10-6 99 1 99 0.5
10-5 96 2 98 1
2x10-5 93 4 97 1
5x10-5 86 4 95 2
10-4 78 5 92 4
2x10-4 68 8 85 7
5x10-4 61 8 77 9
10-5 48 8 57 8
5x10-5 25 5 25 4
ClLJB
X/Y SE Z/Y SE i !
98 0.8 100 7 - ' i
98 0.7 100 I
94 1 100
88 3 100
80 4 99 0.5
68 4 98 2 '5
55 5 96 3 '
43 5 89 7
38 3 81 7
30 2 45 6
APPENDIX TO FIGURE 4.6
Below are the values for VI (transient vasodilator response) and V2 
(sustained vasodilator response) as projected by computer simulation.
RE(S CUB
dose (M) Vl(% ) V2 (%) Vl(% ) V2(%)
10-7 1 0 2 0
10-6 1 0 2 0
10-5 4 0 5 0
2x10-5 5 0 12 0
5x10-5 11 1 19 1
10-4 20 0 31 1
2x10-4 24 6 42 0
5x10-4 25 7 52 5
10-5 27 22 51 7
5x10-5 27 32 41 39
VI
APPENDIX TO FIGURE 6.5
The following tables summarise the maximum amplitude attained during laser- 
induced vasodilator responses (LIVR’s; %) under the conditions specified.
(a) 0.9/^m RBS, 457.9nm laser light
Expt. Nfi 0.2 mW 0.4 mW 0.8 mW 1.6 mW 3.2mW 6.0 mW
910820/1 13.8 22.2 38.1 42
910820/2 19.8 25.3 35.2 42.8 61.5 62.6
910820/3 4.6 10.8 17.7 33.1 45.1 51.4
910821/1 14.3 28.6 46.7 55.5 76.9 82.4
910821/2 7.3 12.2 54.3 66.8 81.2 84.1
910821/3 13.5 25.8 43.3 55.6 60.1 69.7
MEAN 12.3 20.9 39.2 49 65 70.1
S.E. 2.24 3.02 5.1 4.84 6.47 6.14
0.9 jiM  RBS, 514.5nm laser light
Expt. N2 0.5mW ImW 2mW 4mW 8mW
910729 48.1 55 76.5
910730/1 4.8 14.3 20.1 38.6 53.4
910730/2 17.5 32.2 48 58.8 61.5
910731 32.9 38.2 42.9 50 58.2
910805 10.2 19.8 29.9 35.6 48.8
910806 6.1 14.5 28.5 40.8 41.7
MEAN 14.3 23.8 36.1 48.1 56.9
S.E. 5.15 4.85 4.81 4.82 4.86
VII
(b) 0.3 fiM  RBS, 457.9nm laser light
Expt. N2 O.lOSmW 0.2 mW 0.4 mW 0.8 mW 1.6 mW 3.2mW 6.0 mW
920319 18.5 34.1 46.3 55.3 53.3 _
920320 12.8 27.8 33.3 42.6 47.4 _ _
920323 12.0 17.9 25.5 33.7 43.2 45.1 48.6
920324 10.4 22.4 27.5 37.5 39.5 41.1 50.7
920325 13.6 27.7 37.5 46.6 50.0 56.6 57.1
920326 18.9 22.4 36.1 54.2 51.2
MEAN 14.4 25.4 32.1 42.0 45.1 49.2 51.9
S.E. 1.4 2.3 3.8 3.3 2.6 3.7 1.8
0.3/fM RBS, 514.5nm laser light
Expt. N2 0.7mW 1.4 rtiW 2.8 mW 5.2 mW 10 mW
920302 9.5 17.9 27.5 37.4 52.2
920305 6.8 12.9 21.9 40.4 50.2
920309 11.4 20.1 33.3 46.7 54.3
MEAN 9.2 17.0 27.6 41.5 52.2
S.E. 1.3 2.1 3.3 2.7 1.2
VIII
(c) 1.6 JâM  c u b  457.9nm laser light
Expt. N2 2mW 4m W 8mW 16mW 32mW
910813 2.7 12.4 27.6
910814 6 14.7 29.3 33.7 33.7
910815 3.6 17.9 52.8 56.4 56.9
910820 9.6 39.4 64.9 68.1 71.3
910819 15.2 30.4 45.6 51.9 54.4
MEAN 6.89 20.5 39.1 44.5 48.8
S.E. 2.6 6.77 18.76 9.75 6
1.6/fM CUB 514.5nm laser light
Expt. N2 4mW 8mW 16mW 32mW 64mW
910813 9,6 18.1 38.3
910812 9.5 17 23.8 31.3 36.1
910814 0 4.6 19.8 41.7 61.5
910815 0 5.7 18.6 32.4 41.8
910818 6.1 15.6 30 35 37.2
910819 0 4.2 13 27.1 38
MEAN 3.2 8.5 17.7 28.6 40.3
S.E. 1.98 3.3 3.84 4.43 4.68
i
IX
APPENDIX TO FIGURE 6.7
457.9nm/
3.3mW 0.732 mins 1.047 mins
DELAY 
1.326 mins 1.689 mins 2.54 mins
■jÎ
i
?
i
•Î1
!
1
f
7
i
Expt. NSL
920127 53.0 39.0 26.0 23.0 12.0
920129 40.0 42.0 25.0 26.0 10.0
920130 50.0 29.0 19.0 13.0 7.0
920131 50.0 37.0 19.0 15.0 9.0
920211 43.0 21.0
920213 57.0 37.5 _
920214 33.0 17.0
920217 31.0
920218 41.0 12.0
MEAN 44.2 36.75 23.5 19.25 10.00
S.E. 3.0 2.8 2.6 3.1 0.9
514.5nm/
lOmW 0.732 mins 1.047 mins
DELAY 
1.326 mins 1.689 mins 2.54 mins 3.115 mins
Expt. N2
27.0 19.0911206
911209 46.0 34.0 22.0 20.0 14.0 SO %
911210 42.0 14.0 11.0
911212 51.0 47.0 32.0 31.0 13.0 13.0
911213 53.0 40.0 28.0 20.2 9.0 5.0 1
MEAN 48.0 37.0 25.25 23.67 12,5 8.5 g
S.E. 2.5 4.3 2.9 3.7 1.2 2.1
X
LIVR’s AT INCREASING DELAYS + SOD.
457.9nm/
3.3mW 0.732 mins 1.047 mins
DELAY 
1.326 mins 1.689 mins 2.54 mins
Expt. m
920127 55.0
920211 64.0 _
920213
920214 37.0
920217 37.0 44.0 47.0 57.0 48.0
920227 47.8 35.0 34.7 40.2 41.7
MEAN 40.6 39.5 50.18 48.6 44.85
S.E. 3.6 4.5 6.2 8.4 3.2
XI
APPENDIX TO 7.4
Mean responses (% active pressure) at times stated during photorelaxations elicited 
following set time intervals (TIs) following depletion exposure. S.E. values are shown in
brackets.
Time (secs) TI = 20 mins TI = 40 mins TI = 72 mins TI = 150 mins TI = 300 mins
12 95 (1.16) 92.5 (0.91) 85.6 (0.95) 81.1 (1.7) 71.2 (5.4)
24 94.17 (0.72) 89.8 (0.64) 82.9 (0.65) 75.5 (1.09) 67.4 (3.73)
48 94.6 (0.611) 91.2 (0.29) 85.3 (0.91) 77.5 (1.2) 72.4 (2.7)
72 95.33 (0.59) 92.4 (0.29) 88.7 (0.81) 82.0 (1.65) 77.1 (3.2)
96 95.87 (0.536) 93.7 (0.36) 91.6 (0.77) 85.6 (1.73) 82.5 (1.9)
120 96.6 (0.551) 94.8 (0.34) 93.4 (0.86) 88.3 (1.32) 85.6 (0.9)
144 97.6 (0.533) 95.7 (0.37) 94.4 (0.76) 90.1 (1.35) 88.2 (0.38)
168 97.7 (0.463) 96.4 (0.5) 95.2 (0.71) 91.8 (1.14) 89.4 (0.1)
192 97.8 (0.361) 96.9 (0.5) 95.9 (0.85) 92.8 (1.18) 90.8 (0.33)
216 97.97 (0.35) 97.34 (0.51) 96.4 (0.96) 93.7 (1.51) 91.6 (0.76)
240 97.93 (0.49) 97.42 (0.56) 96.4 (1.08) 93.9 (1.55) 91.8 (0.55)
264 98.37 (0.43) 97.58 (0.56) 96.6 (1.04) 94.3 (1.48) 92.6 (0.5)
288 98.7 (0.437) 97.66 (0.44) 96.95 (1.00) 94.9 (1.41) 92.8 (0.52)
312 98.93 (0.41) 97.88 (0.35) 97.62 (1.02) 95.2 (1.27) 93.3 (0.72)
336 98.63 (0.30) 97.82 (0.38) 97.6 (1.15) 95.7 (1.16) 93.3 (0.75)
360 98.53 (0.20) 97.72 (0.32) 97.5 (1.23) 95.9 (1.23) 93.3 (0.75)
384 98.87 (0.09) 98.34 (0.29) 98.4 (0.87) 96.7 (1.3) 95.4 (0.82)
408 99.53 (0.26) 98.84 (0.30) 98.8 (0.70) 97.4 (1.21) 96.7 (0.66)
432 99.37 (0.63) 99.16 (0.22) 99.1 (0.52) 98.4 (0.98) 97 (0.74)
456 99.5 (0.5) 99.38 (0.19) 99.3 (0.404) 99.0 (0.71) 97.3 (0.66)
480 99.7 (0.33) 99.56 (0.12) 99.5 (0.33) 99.1 (0.71) 97.7 (0.98)
XII
APPENDIX TO 7.5
EFFECT OF DELAYED LNMMA INFUSION FOLLOWING A DEPLETION 
EXPOSURE, ON THE FIRST TI = 40 RESPONSE IN ITS PRESENCE.
** = statistically different from control TI = 40 mins response at the P = 0.01 confidence
level.
*** statistically different from control TI = 40 mins response at the P = 0.001 confidence
level.
CONTROL 
TI = 40 mins (%)
+ LNMMA 
(immed after depl) 
TI = 40 mins (%)
+ LNMMA 
(20 min delay) 
TI = 40 mins (%)
MEAN 10.85 2.75*** 15.6**
S.E. 0.56 0.433 1.05
P = (unpaired T-test) 0.000 0.008
APPENDIX TO FIGURE 7.7 
EFFECT OF INCREASING INTERVALS BETWEEN EXPOSURES ON THE 
PEAK AMPLITUDE OF PHOTORELAXANT RESPONSES.
Expt. N2 10 mins 20 mins 40 mins 72 mins 150 mins 300 mins
930128 2.8 5.8 9.4 17.0
930129 5.2 9.5 11.6 27.8
930201 9.7 30.7
930202 2.6 6.3 10.3 17.1 26.7
930203 3 7.1 12.1 18.9 27.1
930504 37.8
930505 37.7
930506 30.0
MEAN 3.55 7.21 10.85 19.4 25.98 35.17
SE 0.4 0.71 0.56 2.15 1.51 3.62
XIII
PHOTORELAXATION IN 100/fM LNMMA (AND FOLLOWING WASHOUT
WITH ImM L-ARGININE).
A TI = 20 mills response was obtained before LNMMA infusion to evaluate the sensitivity 
of the preparation. This value was compared to the mean TI = 20 mins photorelaxant 
response (7.21 %) and all subsequent responses scaled accordingly.
IN lOOttM LNMMA /  IN ImM L-ARG
Expt. N2 10 mins 20 mins 40 mins 72 mins 150 mins 20 mins 40 mins 150 mins
930201 2.7 1.77 2.9 6.13 19.4
930211 3.42 3.34 4.22
930212 1.86 2.3 2.3
930216 2.2 3.1 4.8
930218 2.1 2.6 2.36 3.9 2.3
930302 4.4 4.8
930305 4.86 5.5
930303 2.3 8.6 12.8 27.5
MEAN 2.95 3.13 2.75 3.4 3.55 6.75 12.8 23.5
S.E. 0.338 0.351 0.433 0.5 1.25 0.95 » 4.0
PHOTORELAXATION IN SjiM Hb
Responses in each experiment have been scaled by the factor that the control TI = 20 mins 
response recorded before the introduction of Hb is scaled by to equal the mean TI =20 mins
Expt. N2 20 mins 40 mins 72 mins 150 mins 300 mins
930331 4.73 6.82 8.78
930401 3.56 3.02 3.57 2.51
930402 4.35 7.53 6.72 5.02
930507 6.1
930510 . 0
930512 . . _ 10.4
MEAN 4.21 5.79 S.U 5.44 5.5
SE 0,381 0.915 1.0 1.15 3.02
XIV
APPENDIX TO FIGURE 7.8
Below is a summary table for the effect of 100 piM ethacrynic acid (EA) (n =3 -5) on 
photorelaxations and responses to 10 pd bolus injections of NP and NO.
CONTROL S.E. + E.A, S.E.
TI = 20 mins 7.21 0.71 0
TI = 40 mins 10.85 0.56 0.8
TI = 72 mins 19.4 2.15 1
TI = 150 mins 26.0 1.5 2.1
ImM NP 45.4 6.2 15.9 1.8
NO 79 1.3 45.5 11.5
XV
APPENDIX TO FIGURE 7.10 and 7.11
Below are summary tables showing peak amplitudes of responses to increasing doses of 
NO, SNAP or NP and the enhanced photorelaxations following (i.e. after subtraction of the 
TI = 20 mins response before drug injection). All photorelaxations were elicited at a TI of
20 mins.
log [NO] (M) Response (%) S.E. TI = 20 PR (%) S.E.
-3 72.3 2.5 41.6 4.3
-4.3 61.2 7,4 24.2 15
-5.3 44.5 20.5 2.55 1.65
-6.3 28.2 14.7 3.15 0.45
-7.3 6.7 5.3 1.7 0
-8.3 8.9 7.5 1.1 1.1
mean of 5 SNAP experiments:
log [SNAP] (M) Response (%) S.E. TI = 20 PR (%) S.E.
-2 86.5 2.73 59.78 3.57
-3 84.6 1.87 47.35 5.6
-4 80.3 2.83 19.2 2.73
-5 69.3 1.67 3.43 0.347
-6 28 10.9 0.95 0.366
-7 1.95 0.52 0.075 0.075
mean of 5 NP experiments:
log [NP] (M) Response (%) S.E. TI = 20 PR (%) S.E.
-3 61.43 4.7 3.83 1.52
-4 45.44 6.22 0.66 0.41
-5 25.52 6.1 0 0
-6 6.83 1.68 0.02 0.02
-7 2.85 0.47 0 0
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N itrosylated  iron-su lphur clusters, a n ovel c lass o f nitrovasodilator : studies  
on the rat iso la ted  ta il artery
B y  F. W. F l i t n e y , I, L. M e g s o n , T. C l o u g h  and A. R. B u t l e r *. Departments o f 
Biology and Preclinical Medicine and ^Chemistry, University o f St Andrews, S t 
Andrews, Fife K Y I 6 9T S  Scotland
. Two iron-sulphur-nitrosyl complexes (A, heptanitrosyitri-zig-thioxotetrafer- 
rate( —1) and B, tetranitrosyl-tetra-z^g-sulphido-tctrahedro-tetrairon) have been 
investigated as potential antihypertensive agents. Compounds A and B contain seven 
and four nitrosyl groups respectively, linked to an iron-sulphur framework 
(Fig. iA ,  B \  see Butler et al, 1988). Rat isolated tail arteries (10-15 mm long) were 
internally perfused (2 ml min~^) with Krebs solution containing phenylephrine 
(1 -5 /^m). a  (0 5 mM) and B (OT mM) were injected (10/^1) into the perfusate and 
responses were monitored by a pressure transducer. Both compounds evoked 
vasodilator responses (Fig. 1C). Haemoglobin (15 fiu), haematoporphyrin (5 /tM) and 
methylene blue (75 yM) suppressed responses to A and B, but protoporphyrin IX  
(5 (m), the demetallated precursor of haematoporphyrin, and L-A^'-monomethyl- 
arginine (100 /a m ) ,  an inhibitor of endothelial nitric oxide (NO*) synthetase, did not 
do so.
/
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F ig . 1. A , B. T h re e -d im e n s io n a l s tru c tu res  o f  iro n -s u lp h u r-n itro s y l com plexes. C, vaso­
d ila to r  responses to  A  an d  B , co m p ared  to  those evoked b y  10 /i\ in jec tio n s o f  
carbacho l (C, 10~® m ) an d  n itro p ru ss id e  (N P , 250  jam) and b y  exposure to  laser lig h t (L ;  
p h o to re la x a n t response: w av e len g th  514-5 n m , in te n s ity  1 m W  fo r 2 m in , in d ica te d  by  
h o rizo n ta l b a r). A r te ry  p re -c o n tra c te d  (173  T o r r )  w ith  5 /^M -pheny lephrine. T e m p : 33 °C. 
V e rtic a l scale: 2 0 %  ag o n ist-in du ced  to n e ; h o rizo n ta l scale =  4  m in . E x p t :  900314 .
The results suggest that A and B cause vasodilatation by liberating NO’ and 
stimulating guanylatc cyclase, thereby mimicking the effect of endogenous 
(endothelial) NO* (Palmer et al, 1987).
W e  th a n k  th e  W e llc o m e  T ru s t  and  C ancer Research ('lam paign  fo r su p p o rt.
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Iron-sulphur cluster nitrosyls, a novel class of nitric oxide 
generator: mechanism of vasodilator action on rat isolated tail 
artery
'F.W, Flitney, I.L. Megson, tD .E . Flitney & *A.R. Butler
Cancer Biology Research G roup, School o f Biological & Medical Sciences and the * D epartm ent o f Chemistry, University o f  St 
Andrews, St Andrews, Fife, Scotland, KY16 9TS and f  University Laboratory o f Physiology, University o f Oxford, Parks Rd., 
Oxford 0X 1 3PT
1 Two iron-sulphur cluster nitrosyls have been investigated as potential nitric oxide (NO-) donor drugs 
(A: tetranitrosyltetra-g3-sulphidotetrahedro-tetrairon; and B: heptanitrosyltri-p3-thioxotetraferrate(l-)).
Both com pounds are shown to dilate precontracted, internally-perfused rat tail arteries.
2 Bolus injections (10 pi) o f  com pound A or B generate two kinds o f vasodilator response. Doses 
below a critical threshold concentration (Dr) evoke transient (or T-type) responses, which resemble those 
seen with conventional nitrovasodilators. Doses >  Dr produce sustained (or 5-type) responses, com pris­
ing an initial, rapid drop o f pressure, followed by incomplete recovery, resulting in a plateau o f  reduced 
tone which can persist for several hours.
3 T- and 5-type responses are attenuated  by ferrohaemoglobin (Hb) and by methylene blue (MB), bu t 
no t by inhibitors o f endothelial N O  synthase. A ddition o f either H b or MB to the internal perfusate 
can restore agonist-induced tone when administered during the plateau phase o f an 5-type response.
M oreover, subsequent removal o f H b causes the artery to re-dilate fully.
4 We conclude that T- and 5-type responses are both mediated by NO-. It is postulated tha t 5-type 
responses represent the sum o f two vasodilator components: a reversible component, superimposed upon 
a non-recoverable com ponent. The form er is attributed to free NO-, preformed in solution at the time o f  
injection; and the latter to NO- generated by gradual decomposition of a ‘store’ o f iron-sulphur-nitrosyl 
complexes within the tissue. This hypothesis is supported by histochemical studies which show that both 
clusters accum ulate in endothelial cells.
Keywords: N itric oxide donors; iron-sulphur-nitrosyls; vasodilator responses; nitrovasodilators; endothelium
Introduction
Endothelial cells release a labile factor which relaxes vascular 
sm ooth muscle (Furchgott & Zawadski, 1980). Endothelium - 
derived relaxing factor (or E D R F) has recently been 
identified as either nitric oxide (NO-; Palm er et al., 1987; 
Ignarro et a i,  1988); a labile nitrosothiol, possibly S-nitroso- 
cysteine (M yers et al., 1990); or a nitrosyl-iron complex with 
thiol ligands (Vanin, 1991). NO- is formed from the terminal 
guanidino nitrogen atom  o f L-arginine by a citrulline-forming 
enzyme, referred to as NO synthase (Palmer et a i, 1988a,b). 
Endothelial N O  synthase (NOS) is N A D PH - (Palmer & 
M oncada, 1989) and calm odulin-dependent (Bredt & Snyder,
1990). It can be inhibited by several L- (but not D-) analogues 
o f arginine (Rees et al., 1990).
Haem odynam ic studies using stereospecific NOS inhibitors 
have firmly established the im portance o f NO in controlling 
peripheral resistance in vivo (Vallance et al., 1989; A isaka et 
al., 1989; Rees et al., 1989; G ardiner et al., 1990; Chu et al.,
1991). Endothelium -dependent relaxations o f  vascular 
sm ooth muscle are attenuated in some diseased states, 
notably in hypertension (W inquist et a i, 1984; Luscher & 
V anhoutte, 1986; O tsuka et al., 1988; Tesfam ariam  & 
H alpern, 1988; Sunano et a i,  1989) and in atherosclerosis 
(H arrison et al., 1987; Chappell et al., 1987; H enry et al., 
1987; Forsterm ann et al., 1988, G uerra et a i,  1989), though 
it remains unclear whether these conditions are necessarily 
associated with impaired synthesis and /o r release o f NO 
(Van der Voorde & Leusen, 1986; Hoeffner & V anhoutte, 
1989; Chester et al., 1990; Jacobs et a i, 1990; Fozard & Part, 
1991).
Author for correspondence.
Clinical ‘nitrovasodilators’, including amyl nitrite, glyceryl 
trinitrate, nitroprusside (NP) and molsidomine, act 
independently o f the endothelium , augmenting its function 
temporarily by releasing NO- in vivo (W aldm an & M urad, 
1984; Feelisch & N oak, 1987). Their hypotensive actions are 
generally o f short duration and continuous drug infusions are 
necessary to effect sustained responses (Kreye, 1980). Here 
we show that two tetrairon-sulphur cluster nitrosyls (com­
pound A: tetranitrosyl-tetra-jx3-sulphidotetrahedro-tetrairon; 
and compound B: heptanitrosyl-tri-p.3-thioxotetraferrate(l-), 
also known as Roussin’s Black Salt; Roussin, 1858) are able 
to generate unusually protracted vasodilator responses when 
tested on rat isolated, internally-perfused tail artery prepara­
tions. The structures o f both clusters, based on X-ray 
diffraction studies (Chu & Dahl, 1977; Chu et al., 1982), are 
shown in f ig u re  la,b. The vasodilator actions o f A and B are 
blocked by haemoglobin and also by methylene blue, bu t not 
by agents which suppress NOS. Histochemical studies reveal 
that both clusters are able to penetrate cell m em branes with 
extraordii\ary ease and that they accum ulate inside the 
endothelium, forming a molecular ‘store’ o f NO-. O ur results 
suggest that their gradual decomposition from sites within 
the endothelium generates free NO- and that its slow release 
serves to sustain their vasodilator actions.
Preliminary accounts o f some aspects o f this work have 
appeared elsewhere (Flitney et al., 1990; 1992)
M ethods
Preparation
Experiments were performed on segments o f  tail artery taken 
from normotensive adult W istar rats (250-460 g). Animals
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were killed by cervical dislocation. A length o f artery 
(0 .8 -1 .5  cm) was dissected free, cannulated (Portex cannula) 
and transferred to a Perspex bath.
Apparatus
The apparatus is shown in Figure 1. The cannula (C) formed 
part of a constant flow perfusion circuit, driven by a peristal­
tic pum p (PI; Gilson Mini puls). The vessel (V) was perfused 
internally (flow rate; 2 ml min ') with solution pre-warmed by 
passage through a heat exchanger. Drugs were introduced 
into the lumen o f the artery by bolus injection through a side 
tube (I). The outer surface o f the vessel was superfused 
continuously with solution driven by a second peristaltic 
pum p (P2). The tem perature o f the cham ber was held at 
30-35°C  by adjustm ent o f the flow rate in the external circuit 
(ca. 8 ml m in ').
Light from an Argon ion laser (L; Spectra Physics Ltd., 
type 168-09) could be made to irradiate the artery directly, so 
as to induce photorelaxation o f vascular sm ooth muscle 
(Furchgott et a i, 1961). The beam (A =  514.5 nm; output 
intensity 1 mW) was reflected onto the preparation by means 
o f a front-silvered m irror (M; beam diam. at preparation: 
approx 2 cm).
A differential pressure transducer (T: Sensym type SCX 
150NC; Farnell Electronic Com ponents, Leeds) detected 
changes in back pressure due to changes in arterial tone. 
Responses were displayed on a chart recorder.
NO
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Figure 1 (a, b) Molecular structures of clusters A and B, as deter­
mined by X-ray diffraction studies. Compound A contains four and 
B seven ligated NO groups per molecule, (c) Apparatus used for 
perfusing isolated segments of rat tail artery and for irradiating 
preparations with laser light. See text for full description and exp­
lanation of lettering.
Experim ental protocol
Arteries were perfused internally with oxygenated Krebs 
solution (composition, mM: N aC l 118, KCl 4.7, N aH C O j 
25, NaHzPO^ 1.15, C aCb 2.5, M gCb 1.1, glucose 5.6, gassed 
with 95% O2/ 5 V0 CO2 to m aintain pH  7.4), initially at a low 
flow rate which was increased gradually over the next 10-20  
min to reach a final value o f 2 ml min *. The preparation was 
allowed to stabilize for 2 0 -3 0  min, after which it was pre­
contracted with Krebs plus phenylephrine HCl ( =  Krebs- 
-f PE: mean (± s .e .)  [PE] =  6.5 ±  0.5 r m . M ean ( ±  s.e.) 
agonist-induced perfusion pressure — 101 ±  3.5mmHg).
Experiments were made to establish the mode of action of 
iron-sulphur cluster nitrosyls. Responses to bolus injections 
(10 j:tl) o f A and B were com pared with those evoked by (i) 
carbachol (CCh), an endothelium -dependent vasodilator; and 
(ii) either nitroprusside (NP), S-nitroso-N-acetylpenicillamine 
(SNAP) or exposure to laser light (L) all o f which relax 
vascular sm ooth muscle independently o f the endothelium .
The effects of adding the following to the internal per­
fusate were examined: (i) ferro-haem oglobin (Hb) a nitric 
oxide ‘scavenger’; (ii) methylene blue (MB); and (iii) either 
N°-monomethyl-L-arginine (l-N M M A ) or N-nitro-L-arginine 
methyl ester (l-NAM E), both stereospecific inhibitors o f 
NOS. Comparisons were made with responses evoked by N P 
or SNAP.
Drugs: com m ercial sources and synthetic procedures
L-phenylephrine HCl (mol. wt. 203.7; Sigma Chemicals) was 
used at concentrations ranging from  2-12xlO®M. Stock solu­
tions (lO'^M) o f N P (mol. wt. 298; BDH Ltd., ‘A nalar’ grade) 
were m ade and the dose required adjusted by serial dilution 
immediately prior to use. SNAP (mol. wt. 220) was syn­
thesized by reacting N-acetylpenicillamine with sodium nitrite 
(Field et al., 1978). Com pound B was prepared by reacting 
iron(II) sulphate heptahydrate, sodium nitrite and sodium 
sulphide in hot aqeous solution under nitrogen gas (Brauer, 
1960). Com pound A was prepared by addition o f elemental 
sulphur to a solution o f B dissolved in re-distilled toluene 
and refluxed overnight (16 h) under dry nitrogen gas (Gall et 
al., 1974).
Purities o f iron sulphur nitrosyl com pounds were checked 
by (a) infra red spectroscopy (A had a single IR  absorption 
maximum at wave num ber 1790 cm'*; B had three maxima, a t 
1795 cm'*, 1747 cm * and at 1707 cm'*) and (b) "*N-nuclear 
magnetic resonance (N M R ) spectroscopy.
Solutions o f B (mol. wt. 553) were made up in Krebs 
solution, immediately before use. C om pound A (mol. wt. 
472) is not soluble in water and so working solutions were 
made by serial dilution o f 5 mg A dissolved in 1 ml dimethyl 
sulphoxide (ca. lO'^M).
An im portant note concerning experim ental procedures
All experiments were conducted in a darkened laboratory 
with a red safelight (60W) as the sole means o f illumination. 
There were two reasons for this. First, the am bient lighting 
under norm al laboratory conditions is sufficient to induce 
photorelaxation of precontracted vascular sm ooth muscle, 
causing a progressive loss o f vessel tone. Second, NP, A and 
B are photosensitive and decompose when exposed to light, 
releasing free NO (Wolfe & Swinehart, 1975; Flitney & 
Kennovin, 1988; Flitney et al., unpublished results). Drug 
solutions were therefore made up in the dark and stored in 
glass vials covered with alum inium foil prior to use.
Results
Bolus injections o f either N P or SNAP invariably produce 
fully-reversible (transient or T-type) vasodilator responses: an
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initial, rapid drop of pressure, followed by complete 
recovery, often with some positive ‘overshoot’. C om pounds 
A and B produced T-type responses only a t doses below a 
critical threshold concentration {Dt). Doses>T>T generate 
long-lasting (sustained or 5-type) responses, comprising an 
initial, rapid decrease o f pressure, followed either by partial 
recovery only, or no recovery at all. The hallm ark o f the 
5-type response is a rem arkably stable plateau o f reduced 
vessel tone which can persist for several hours.
Mediation o f T-type responses by NO-
Figure 2 compares vasodilator responses to carbachol (CCh), 
nitroprusside (NP) and laser light (L; =  514.5 nm; 1 mW 
intensity) with T-type responses produced by A and B. C ont­
rol responses are shown in Figure 2a. The responses to A and 
B were blocked by either methylene blue (b; 75 p.M) or by
CCh NP B
b
c
MB (76 iiM)
Hb (15 |j.m)
L
l-NMMA (100 h^m) 
Figure 2 (a) Vasodilator responses produced by microinjection 
(10 p i)  of test doses of carbachol (CCh: 10'^  m ) and nitroprusside 
(NP; 2.5.x 10"^  m) and by irradiation with laser light (L; A = 514.5 nm; 
1 mW; 2 min), compared with T-type responses produced by clusters 
A (10"^  m ) and B (5x10"'M). Artery pre-contracted with 5x10'  ^M 
phenylephrine (agonist-induced pressure = 135 mmHg). Female rat, 
274 g. Temp., 32°C. (b) Suppression of responses to A and B and to 
laser light by treatment with methylene blue (MB 7.5x10'  ^m).  Details 
as above, (c) Inhibition of responses to compound A and B by 
haemoglobin (Hb, 15x10'® m). Hb increased agonist-induced pressure 
to 1.8x control level (after ca. 6  min). Artery pre-contracted with 
4x10'® M phenylephrine (agonist-induced pressure =  114 mmHg). 
Female rat, 373 g. Temp. 32°C. (d) The NO synthase (NOS) 
inhibitor, N°-monomethyl-L-arginine (l-NMMA,IxlO"* m ) increased 
agonist-induced tone to around 1.28x the control level. Drugs tested 
20 min after beginning perfusion with l-NMMA. Responses to 
carbachol attenuated by l-NMMA, but not those produced by nit­
roprusside (NP), A, B or laser light. Details as for (c) above. 
Calibration bars (all recordings); vertical, 20% agonist-induced tone 
(0.2Y; see Figure 3a); horizontal, 4 min.
ferro-haem oglobin (c; 15 /XM), a NO- scavenger. However, 
neither L-NM M A (d; 100 Jlim) nor l-N A M E  (not illustrated), 
both o f which suppress endothelial N OS (Rees et al., 1990), 
inhibited responses to A o r B. Indeed, it was usual to  find 
that treatm ent with either L-NM M A or l-N A M E  increased 
the responsiveness o f arteries to A and B.
S-type responses produced by sequential injections o f 
increasing doses o f A or B
Pressure recordings made by injection o f  increasing doses of 
N P (Figure 3c) or SN AP (not illustrated) confirm that both 
com pounds produce T-type responses only. Similar 
experiments with A or B show th a t T-type responses give 
way to 5-type responses when the injected dose exceeds Df. 
both the rate and extent o f the recovery following successive 
injections become progressively reduced, resulting in a step­
wise and persistent loss o f vessel tone (Figure 3a,b).
Three param eters have been m easured (X, Y  and Z; see 
Figure 3a) to enable quantitative com parisons to be draw n 
between N P and SNAP and either A or B. Figure 4 shows 
perfusion pressure m inim a (filled circles) immediately follow­
ing injection o f each drug (X) and the steady-state pressures 
attained after recovery (Z; open circles), bo th  expressed as a 
fraction o f the initial agonist-induced pressure (Y) and plo t­
ted as a function o f  log,o injected dose. The concentrations o f 
SNAP, N P, A  and B ( pM) required to produce half-maximal
t o
Figure 3 Averaged pressure recordings obtained by successive 
injections of increasing doses of compound A, B or nitroprusside 
(NP) (graphs a, b and c, respectively). Mean values ( ±  s.e., vertical 
bars) are plotted (« =  6  preparations for a, and n =  5 for both b and 
c). Note that injection doses of A or B which exceed (see text) 
produce a sustained drop in vessel tone (5-type response), whereas 
responses to NP are fully reversible (T-type response). In (a), Y = 
agonist-induced pressure; X =  pressure minimum following each 
injection; and Z = steady-state (plateau) pressure attained after 
recovery (see also Figure 4). Calibration bars: vertical = 0.2Y; 
horizontal = 20 min (A and B) or 10 min (C).
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decreases o f X /Y  (EC50 values) are 36, 43, 126 and 399, 
respectively. The corresponding curves for Z/Y  reflect the 
tendency for A and B (but no t N P) to generate S-type 
responses. The effect is more pronounced for B than for A, 
as shown by the greater proximity o f the X /Y and Z/Y 
curves. D j is estimated to be around 1 - l O f X M  for B and 
2 0 -100  pM for A.
Abolition o f the 'plateau phase o f the S-type response by 
Hb or by M B
The ^-type response was rem arkable in tha t even prolonged 
perfusion (‘w ash-out’) with Krebs-t-PE solution alone (up to 
5 h) failed to induce any further vasoconstriction, once the 
plateau phase was established. However, the addition of 
either H b (15 pM) or MB (> 10 ftM ; no t illustrated) to the 
internal perfusate initiated a p rom pt and complete restora­
tion o f all agonist-induced tone; indeed, as Figure 5 clearly 
shows, the perfusion pressure rises well above the control
- H b
+  Hb
- H b
+  Hb
10 -7 - 6  - 5  - 4  -3  - 2  - 1
loQio [m], a , B or NP
Figure 5(a, b) Pressure recordings from two preparations showing 
responses to ferro-haemoglobin (Hb, 31.5x10'  ^m ) added to, and then 
later removed from, the internal perfusate during the plateau phase 
of an 5-type response. S-type responses were produced by a single 
bolus injection of 5x10'  ^m  A or B (upper and lower recordings 
respectively). The addition of Hb (upward arrows) elicits a prompt 
vasoconstriction which causes the perfusion pressure to rise above 
the control (pre-injection) value. Removal of Hb produces a 
vasodilatation which returns the pressure to the plateau value 
(curved dashed lines). Similar responses to these have been recorded 
when the time delay between the injection of A or B and treatment 
with Hb was increased to 6  h. Calibration bars: vertical = 0.2Y; 
horizontal = 4 min.
Figure 4 Mean ( + or -  s.e., vertical lines values for X/Y ( • )  and 
Z/Y (O; see Figure 3a) plotted as a function of logio injected dose 
for A (a), B (b) and nitroprusside (NP) (c). Responses to NP show 
complete recovery, with some pressure overshoot at the higher doses 
(Z/Y >1.0). S-nitroso-N-acetylpenicillamine (SNAP) (data not 
shown) gives results which are qualitatively similar to those seen with 
NP. The values of Z/Y for both clusters (measured 20 min after each 
injection) are < 1 . 0  at doses which exceed Dt (by definition; see 
text), reflecting the tendency for A and B to evoke 5-type responses. 
Data obtained from same pressure recordings used to construct 
Figure 3 (a-c).
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level (Y), here to around 1.6Y (A) and 1.8Y (B). Even more 
striking, the subsequent removal o f Hb (but not o f MB) 
causes arteries to re-dilate fully (Figure 5a.b). These observa­
tions lead us to conclude that extremely brief exposure of 
arteries to A or B (the ‘transit' time for a 10 pi bolus passing 
through the vessel is ca. 0.3 s) can suffice to establish a 
durable source o f NO within the tissue.
Histochemical studies showing that iron sulphur cluster 
nitrosyls penetrate endothelial cells and accumulate there
The existence o f a long-lasting source (store) o f NO in 
vessels exposed to either cluster is supported by microscopic 
studies of treated arteries. Solutions o f A and B are intensely 
black and visual inspection o f segments of artery subjected to 
repeated bolus injections (experiments o f the type used to 
construct Figure 3) revealed some discolouration of the vessel 
lining. Microscopic examination of freshly-frozen, unfixed 
sections of artery exposed to cluster B (5 x lO'^M, 5 min 
continuous perfusion, followed by 15 min washout with 
Krebs 4- PF to remove excess drug from the lumen o f the 
artery) showed that the discolouration was confined to the 
endothelium (Figure 6 a). Unfixed, frozen sections which had 
been stained with either bathophenanthroline (Figure 6 b) or 
ferrocyanide (not shown), to detect iron(II) derived from the 
clusters (Pearse, 1972), showed a similar distribution o f reac­
tion product, located predom inantly in endothelial cells, but 
sometimes with some faint staining of adjacent sm ooth mus­
cle cells also. C ontrol (untreated) arteries did not react 
positively for iron.
Discussion
This paper establishes iron-sulphur cluster nitrosyls as a 
novel class of NO donor drug with unusual vasodilator 
properties. The com pounds investigated here are able to 
generate two distinct kinds o f response, designated T-and 
5-type responses. In this respect they differ from either N P or 
SNAP, both o f which give fully-reversible responses only 
(Figures 3 and 4). The ability o f Hb and o f MB, but not 
NOS inhibitors, to block T- and 5-type responses (Figure 2) 
shows that they are mediated by NO derived from each 
cluster, and not by enhanced F D R F  production through 
stimulation o f the endothelial L-arginine:NO pathway.
Composite nature of the S-type response
O ur results lead us to postulate that the S-type response 
represents the sum o f two, distinct vasodilator components; a 
reversible component, attributable to free NO generated by 
the spontaneous decomposition o f clusters in solution and 
present at the time o f injection; superimposed on a ‘non- 
recoverable’ component, caused by the delayed release of 
NO from clusters which have become trapped within the 
endothelium. This hypothesis is supported by histochemical 
studies (Figure 6 ), which revealed the presence of Fe(II) 
within endothelial cells of treated (but not control) arteries, 
and by our observation that the plateau phase o f the 5-type 
response can be abolished in a reversible m anner by perfus­
ing preparations with Hb (Figure 5).
Vanin and co-workers (Vanin, 1991) have shown that iron- 
dinitrosyls (Fe(NO)]) complexed with low molecular weight 
thiols (e.g. cysteine or glutathione) can vasodilate isolated 
blood vessels and also inhibit platelet aggregation. Interest­
ingly. the vasodilator action exhibits two-phase kinetics when 
tested on intact animals, resembling the 5-type response des­
cribed in the present study: that is, an initial, rapid decrease 
of arterial pressure, followed by a persistent (several hours) 
hypotensive action. The rapid and sustained components of 
the response are attributed to NO released from (i) iron- 
dinitrosyl low-molecular thiol complexes ( = rapid phase) and
m
100 fim
Figure 6  Transverse sections (20 gm) o f a freshly-frozen artery per­
fused with B (5 m M , 2 ml min ') for 5 min, followed by 15 min per­
fusion (wash-out) with K reb s4-PE solution only, (a) U nstained, 
unfixed section showing discolouration o f the vessel lining, (b) 
Freshly-frozen, unfixed section after staining for 7 h with 
bathophenanthroline, followed by brief (4 min) counterstaining with 
methylene blue (scale as in (a)). Endothelial cells stain positively 
(red-brown colouration) for iron(ii) derived from the cluster, (c) 
Unfixed section stained for 4 min with methylene blue to show up 
sm ooth muscle cells. N ote that brown colouration  is confined to the 
endothelial lining of the vessel.
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(ii) from  iron-dinitrosyl protein-thiol complexes ( =  sustained 
phase) formed within the tissue. The latter are thought to 
result from the transfer o f Fe(N 0)2 groups from low 
molecular weight to protein-borne ligands, forming a long- 
lasting, m olecular ‘store’ o f NO- in the vascular bed.
Suppression o f endogenous EDRF production did not 
occur during the plateau phase o f S-type responses
The effects o f H b administered during established 5-type 
responses lead us to conclude that the form ation of 
endogenous NO- from L-arginine is not suppressed by either 
cluster and that its continued release from endothelial cells 
helps to sustain the plateau phase. Thus, perfusing vessels 
with H b does not merely re-establish the control (pre­
injection) perfusion pressure, but instead drives it to a level 
substantially greater than this (Figure 5). The inference to be 
drawn is that H b scavenges NO- from both exogenous 
(cluster-derived) and endothelial sources.
The nature of the intracellular mechanism(s) underlying 
the vasodilator actions o f iron-sulphur nitrosyls remains to 
be established before meaningful comparisons can be made 
with other nitrovasodilators. The fact that H b and MB can 
block responses to either cluster (and also to SNAP) but not 
those evoked by NP (Figure 2) clearly implies different cel­
lular mechanisms o f action. This has not been investigated in 
the present study. However, there is evidence to suggest that 
NP may relax vascular sm ooth muscle through both 
guanosine 3':5'-cyclic m onophosphate (cyclic G M P)- 
dependent and cyclic GM P-independent pathw ays (Otsuka et 
o/., 1988). A com ponent o f the relaxant effect o f glycerylt- 
rinitrate may also be mediated by a mechanism which does 
not involve elevated cyclic G M P levels (D iam ond & Chu, 
1983).
endothelium  can evidently generate physiologically significant 
am ounts o f NO- at this most relevant o f sites. The 
mechanism by which NO- is released from clusters trapped 
inside the endothelium (whether spontaneous or enzymatic) is 
not known. Extended Hiickel molecular orbital calculations 
show that A and B are electron precise (Sung et a!., 1985): 
this means that addition o f an electron to A, and either the 
addition or removal of an electron in the case o f B, will 
weaken the cage bonding and cause the iron sulphur 
framework to disintegrate, releasing free NO-. The oxidative 
status o f the endothelial cell may therefore prove to be an 
im portant factor in determining the rate o f NO- release in 
vivo.
The apparent ease with which both clusters are able to 
penetrate the endothelial cell mem brane is probably related 
to their high solubility in non-polar solvents (Butler et al.. 
1988). C om pound B is especially interesting in this regard 
because it is ionic (A is neutral) and therefore soluble in 
polar solvents too. Curiously, though, the marked contrast in 
the intensity o f staining as seen between endothelial cells and 
overlying smooth muscle cells (see Figure 6) shows that 
neither com pound can traverse the endothelial cell layer 
readily. The faint reaction product which is sometimes discer­
nible in sm ooth muscle cells immediately adjacent to the 
endothelium  is probably a diffusion artefact o f the staining 
procedure, because neither cluster survives conventional 
fixation methods (including vapour fixation) and so his­
tochemical observations were o f necessity made on freshly- 
frozen sections. This explanation is supported by preliminary 
X-ray m icroprobe studies o f rapidly-quenched arteries fol­
lowing treatm ent with A or B, which reveal elemental Fe and 
S within endothelial cells, but no evidence for either in 
nearby smooth muscle cells (unpublished observations: Elder, 
Pediani, Megson & Flitney).
Physicochemical properties o f iron-sulphur cluster 
nitrosyls
The physicochemical properties o f iron sulphur cluster nit­
rosyls (Butler et a i,  1988) provide some insight into their 
vasodilator actions. Both com pounds are potentially able to 
transport large quantities o f NO-, with 4 and 7 mol. o f 
ligated NO- per mol. o f A and B, respectively. Their selective 
retention and gradual decom position from within the
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synthesizing the clusters. Dr Richard Palmer (Wellcome Research 
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Iron-sulphur-ciuster nitrosyls: long-acting nitric oxide* donor drugs
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University of St Andrews, St Andrews, Fife KY16 9ST, Scotland, U.K.
A number o f  clinically useful vasodilator drugs (glyceryl trinitrate, amyl nitrite and 
sodium nitroprusside) appear to act by release o f  nitric oxide (N O ) />/ vivo. Other 
compounds containing N O  as a ligand have the same potential and we have 
examined the vasodilator properties o f  tw o such com pounds (Fig. 1): tetra- 
nitrosyltetra-/ig-sulphidotetrahedro-tetrairon (Cuba ne) and heptanitrosyb/tg- 
thioxotetraferrate (1 — ) (Roussin’s Black Salt). The latter is made by self-assembly 
from sulphide, iron (2-f-) and nitrite and converted into Cubane by reaction with  
elemental sulphur [1]. Both com pounds are known to release N O  readily [2].
Cubane Roussin’s Black Salt
Figure 1
The physiological action o f  these compounds was examined by measuring 
their effect on pressure generated in a small segment o f  pre-contracted rat tail artery 
perfused internally at constant flow rate. Relaxation o f  arterial muscle is registered 
on a pressure transducer and visualized on a chart recorder [3].
Bolus injection (10 //I) o f  Cubane solution or Roussin’s Black Salt 
solution into the internal perfusate generated tw o types o f  vasodilator response; {a) 
below a certain critical concentration the responses are transient and resemble those 
obtained with sodium nitroprusside (see Fig. 2, bottom trace), and {b) at higher 
concentrations there is an initial, rapid drop in pressure which is sustained and 
shows only partial recovery (see Fig. 2, top tw o traces). The vasodilator effects o f  
both Cubane and R oussin’s Black Salt are blocked by methylene blue, an inhibitor 
o f the soluble guanylatc cyclase and by ferrohaemoglobin, a N O  scavenger, but not 
by N°-m onom ethyl-L-arginine or by N°-nitro-L-arginine methyl ester, both o f  
which suppress N O  synthase.
Solutions o f  both com pounds are intensely black and visual inspection o f  
perfused preparations revealed discoloration o f  the artery lining. M icroscopic 
examination o f  freshly frozen arteries showed that the discoloration is confined to 
the endothelium. Unfixed, frozen solutions stained with bathophenanthraline 
showed a similar distribution o f  reaction product, located predominantly in 
endothelial cells but with some faint staining o f  adjacent sm ooth muscle cells.
Figure 2 J \
B
t o -
Vasodilator responses produced by (A ) Cubane, (B) Roussin’s Black Salt, 
(C) sodium  nitroprusside
The horizontal time scale is 20 min for A and B, and 10 min for C. The vertical scale 
is 20%  agonist-induced pressure.
Conclusions
The results described allow a number o f  conclusions to be made: (a) The 
vasodilatation brought about by Cubane and by R oussin’s Black Salt is caused by 
the release o f  N O . (b) Both com pounds are selectively taken up by endothelial cells 
and constitute a store from which N O  is slowly released, (r) The transient responses
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observed are caused by the N O  present in solution at the time o f  injection, (d) The 
slow  release o f  N O  from the store within the tissue is responsible for the sustained 
responses observed. (?) The ease with which the com pounds arc taken up by 
endothelial cells may be due to their substantial solubility in organic solvents; this 
is particularly surprising in the case o f  Roussin’s Black Salt which is ionic. ( / )  
Release o f  N O  from both com pounds occurs on oxidation and so the rate o f NO  
release in vivo may be controlled by the redox environment.
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Introduction
We have found that complexes between nitric oxide (N O ) and various nucleophiles 
[1] can be used for the controlled biological release o f  N O , and that this 
spontaneous, non-enzym ic generation o f  N O  provides an advantageous research 
tool, as well as a possible basis for drug design. Three specific applications o f these 
N O /nucleoph ile adducts illustrate what we believe to be their considerable utility 
in biomedical investigations.
Vasorelaxation
T o provide the groundwork for this first biological application, we measured the 
rates and extents o f  N O  release from five structurally diverse N O /nucleophile  
complexes in pH 7.4 buffer at 37 °C. The specific com pounds studied were those 
described by Maragos et al. [2]. All contained the anionic moiety, X -{N (0 )-N 0 }" , 
in which the nucleophile residue, X , was that o f  a secondary amine [EtgN, as in 
E tg N -(N (0 )-N 0 }N a , 1], a primary amine f  PrHN, as in ’P rH N -{N (0 )-N 0 }N a , 2], 
a polyamine, spermine [as in the zwitterion, HgN-(CHg)g-NH 2 ^-(CHg)^-N{N(0 )- 
NO}"-(CHg)g-NH 2 , 3], oxide [as in N a 0 -{ N (0 )-N 0 }N a , 4], and sulphite [as in 
N H ^ 0gS -{N (0)-N 0}N H ^ , 5]. Half-lives ranged from 2.1 min for 1 to 39 min for 3, 
with the amount o f N O  produced per molecule o f  N O /nucleoph ile adduct 
decomposed being as high as 1.9 (for 3) and as low  as 0 (for 5) [2].
Because N O  is widely considered to play a key role in vasodilatation [3], 
N O /nucleophile complexes that release the most N O  should be potent relaxants
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determined by lymphocyte [^HjTdR uptake. Again, at high concentrations o f  
RA\X' 264.7 (5 and 10 x  10“* per well), lymphocyte proliferation was inhibited and 
this inhibition was reversed in the presence o f l-NM M A  (data not shown).
An immune response is characterized by cellular interactions for both 
initiation and modulation o f  the response. Engagement o f  the T-cell receptor and 
provision o f an as yet incompletely defined co-stimulus by the macrophage results 
in T-cell signalling and production o f  cytokines necessary for T-lymphocyte 
proliferation. It is now clear that a previously undefined mechanism o f macrophage 
modulation o f the immune response exists via initiation o f the N O  pathway. This 
mechanism is operative at the post-cytokine production step, since detectable levels 
o f cytokines able to induce T-cell proliferation are present in the culture 
supernatants and yet lymphocyte proliferation is inhibited when NO  is produced.
T/jis work, was supported by National Cancer Institutes of Health grants A Î-16869 and 
C M -377S3 {R. L .S .). J. M. L . was supported by the German Research Council,
References
1. Hoffman. R. . Ljngrehr. J. M., Billiar, T. R., Curran, R. D. & Simmons, R. L. (199Ü) }. Immunol. 
145, 2220-2226
2. l.angrehr, J. M., 1 loffman. R. A.. Billiar, T. R,. Lee. K. K. VC’., Schraut, VC II & Simmons, R. L.
0991) Surgery 110, 3.35 342
3. Langrchr, j .  .M.. Dull, K. B... Ochoa. J. B., Billiar, T. R., lIJstad, S. T., Schraut. VC. IL. Simmons,
R. L. & Hoffman, R. .\. (1992) Transplantation 53, 632-640
The inhibition of lymphocyte proliferation by nitric oxide-producing m olecules and cells
I. J. Rowland’, S. D enham ’, A. R. Butler', F. W. Flitney' and 
I. L. M egson'
’ CRC Clinical Magnetic Resonance Research Group and Section of 
Medicine, Institute of Cancer Research and Royal Marsden Hospital, 
Sutton, Surrey, SM2 5PT and 'Department of Chemistry and ' Cell Biology 
and Neurosciences Research Division, School of Biology and Medical 
Sciences, University of St. Andrew’s, St, Andrew’s, Scotland,
KY16 9TS, U.K.
Introduction
Induction and amplification o f  a specific immunological response to antigen 
involves the proliferation o f  responding lymphocytes. As a consequence o f  such 
responses non-specific cellular effector mechanisms may be generated by the release 
from lymphocytes o f activating cytokines as, for example, in the activation o f  
macrophages by lymphocyte-released interfcron-y. .Activated macrophages syn­
thesize nitric oxide (NO ). Here we demonstrate the effects o f  NO  on lymphocyte 
proliferation and suggest a possible regulatory role for macrophage-derived NO . 
W e also demonstrate functional mimicry o f macrophage-synthesized N O  by the 
NO-releasing compounds, streptozocin, sodium nitroprusside and Roussin’s black 
salt.
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Methods
Thymic lymphocytes and activated macrophages were obtained from CBH/Cbi 
strain rats. Macrophages were activated by intraperitoneal injection o f 2 mg 
Corynebacterium parvum organisms 5 days before the cells were harvested by lavage. 
Monolayers o f  adherent macrophages in the wells o f  96-well plates were obtained 
by incubating the macrophage-containing cell suspensions in the wells for 
approximately 1 h, after which non-^adherent cells were washed off. Thymic 
lymphocytes were, after washing, suspended at 5 x 10® ml"' in D ulbecco’s modified 
Eagle’s medium (DM EM ) containing 10% foetal calf serum (v /v )  (PCS), 1 mM-L- 
arginine and 2 /tg ml"' concanavalin A. For cultures containing macrophages, 
100 /d  o f  lymphocyte suspension was added to 100 /d  o f  DM EM  (without 
concanavalin A) in the wells; to half o f  these cultures 500 /tM-iV°-monomethyl-L- 
arginine (l-N M M A ) was added. To test the effects o f  NO-releasing compounds, 
100 p \  o f  each concentration o f  compound (compounds were serially diluted in 
medium) was added to 100 p \  o f lymphocyte suspension. Six replicates o f each 
concentration o f macrophages or compound were made. The cultures were 
incubated for 48 h, after which 100 /d o f the supernatant medium was removed for 
determination o f  nitrite concentration. [®H]Thymidine was added (0.5 /tCi well"') 
and the cultures incubated for a further 12 h. Cells were harvested onto glass fibre 
discs. Incorporated [®H]thymidine, a measure o f lymphocyte proliferation, was 
then determined by scintillation counting. [^H]Thymidine incorporation by 
lymphocytes in the presence o f macrophages or NO-releasing compounds was 
expressed as a percentage o f  the incorporation by lymphocytes alone (control
1 2 0 i 0  With inhibitor (500 ^m-l-NMMA) □ Without inhibitor
Figure 1
Number of macrophages per well
Plot showing the inhibition of lymphocyte proliferation in the presence 
of increasing numbers of macrophages and the effect of the inhibitor 
N®-monomethyi-L-arginine (l-NMMA)
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value). Nitrite concentrations were assayed using a colorimetric method based on 
the Griess reaction [1],
Results
The effect o f  macrophages on lymphocyte proliferation is shown in Figure 1. 
Increasing numbers o f  macrophages in the cultures results in diminished thymidine 
uptake by lymphocytes and this effect is abrogated by the addition o f  500 
N M M A to the medium. l-NM M A  specifically inhibits the synthesis o f  L-arginine- 
derived N O  by macrophages. The effects o f co-incubation o f  lymphocytes with 
varying concentrations o f  NO-releasing compounds are shown in Figure 2.
Figure 2
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Inhibition o f lymphocyte proliferation by streptozocin, sodium nitroprusside and 
Roussin’s black salt is independent o f  the amounts o f  initial, chemically bound, NO  
per molecule. The approximate concentrations at which the compounds inhibited 
50% o f the control thymidine uptake values were found to be 1.2 mM-streptozocin, 
12 /(M-sodium nitroprusside and 4 /(v-R oussin ’s black salt. Figure 3 shows a 
correlation between nitrite levels in the culture supernatants and thymidine 
incorporation by the lymphocytes. Clearly, the effects on lymphocyte proliferation 
o f equivalent amounts o f N O  released from streptozocin, sodium nitroprusside and 
Roussin’s black salt are similar. Inhibition o f  lymphocyte proliferation by 50 % is 
achieved by the release o f  less than 4 /fM-NG during the 48 h o f culture.
Discussion
The inhibition o f  lymphocyte proliferation by activated macrophages has been 
shown to be dependent on L-arginine-derived N O  [2]. The results described here, 
however, show that NO-induced inhibition o f lymphocyte proliferation is 
independent o f  the source o f N O  ; inorganic and organic chemical sources as well 
as a biological source o f  N O  were all effective. The correlation o f inhibition o f  
lymphocyte proliferation with concentration o f nitrite ions in the culture 
supernatants is shown in Figure 3, with increasing nitrite concentrations reflecting 
decreased lymphocyte proliferation. Although these results do provide a substantial 
case for the direct effect o f  N O  on the target lymphocytes, the possibility remains 
that a common intermediate derived from N O  might be the effective agent. Our 
results suggest that the macrophage may be able to exert regulatory effects on local 
in m>o lymphocyte responses via the release o f  NO . In addition, as lymphocyte 
proliferation appears to be very sensitive to the release o f N O  from a variety o f  
sources, this could constitute a useful model system for the evaluation o f chemical 
and cellular agents, including anti-cancer agents which function via the release o f  
NO.
W'e thank the Cancer Kesearch Campaign for supporting this work.
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Evidence for the involvement of arginine-dependent nitric oxide formation In autodestructive processes
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Introduction
In type 1 diabetes the loss o f  insulin-producing /^-cells is associated with the 
infiltration o f  pancreatic islets by macrophages and lymphocytes. In animal models
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Photochemical release of nitric oxide from iron-sulphur cluster nitrosyls: laser 
potentiation of vasodilator actions on rat isolated tail artery
F.W. Flitney, I.L. Megson, Joanne L.M, Thomson and G.D. Kennovin
Cancer Research Group, School of Biological & Medical Sciences, University o f St 
Andrews, St Andrews, Fife K Y16 9TS
The ra t isolated tail a rtery  (RTA) preparation was used as a bioassay system  
to  show th a t the release of nitric oxide (NO-) from an iron-sulphur cluster 
nitrosyl (Roussin’s 1858 ‘black’ salt, or RBS; see Fig. 1 in F litney  et a l. 1990) is 
accelerated during exposure to laser light {X = 514.5 and 457.9 nm). The 
experiments were perform ed in a darkened laboratory. RTA segm ents were 
perfused with K rebs solution containing phenylephrine (5-20 juM; flow rate: 2  
m l.m in“*). The addition of RBS (0.3-1 pM ) to the internal perfusate caused the  
vessel to dilate. Exposure of RBS solutions to laser light en route to  the a rte r  
produced an additional vasodilator response during the period of irradiation 
(5 min). The am plitude of the light-induced vasodilator response (or L IV R ) 
increased with increasing intensities of illum ination and was greater a t the 
shorter wavelength. The photochemical efficiency of NO- production was 
measured by m onitoring the decrease in absorbance (360 nm: e — 14, 940 
cm*^) of RBS solutions following exposure to light under conditions which 
exactly sim ulated those used for recording LIVRs. The steady-sta te  [NO-]s 
formed during photolysis (means ± S.E.M.) were found to be 22.96 ± 1.43 nM. 
mW'^ (514.5 nm) and 88.62 ± 2.73 nM.mW ' (457.9 nm) for 1 /iM RBS; and 
8.16 ± 2.15 nM.mW^'^ (514.5 nm) and 43.2 ± 2.15 nM.mW'^ (457.9 nm) for 0.3 pM  
RBS. These values were used to construct log dose-response curves, relationg 
the am plitude of the L IV R  to [NO-] produced during irradiation. A correction 
was made for loss of NO- in transit from the site of photolysis to the detector 
a rte ry  (time delay = 45 s): the half-life for NO- in our apparatus was m easured 
and found to be 33 s. The [NO-] producing a half-maximal L IV R  (ED 5 0  value) 
was 15.6 nM.
This work is sup])orted by a grant from the Cancer Research Campaign.
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"RÊPRIMING" OF VASCULAR SMOOTH MUSCLE PHOTORELAXATION IS DEPENDENT 
ON ENDOGENOUS OR EXOGENOUS NITRIC OXIDE.
I.L. MEGSON, F.W. FLITNEY & R.N. WEBSTER.
Cancer Biology Research Group, School of Biological and Medical Sciences, University of St Andrews, 
St Andrews, Fife, Scotland.
Precontracted vascular smooth muscle relaxes on exposure to light (Furchgott et al., 1961 Journal of 
General Physiology 44, 499). The phenomenon is thought to involve activation of soluble guanylatc 
cyclase. Irradiation of precontracted, internally perfused segments of rat tail artery with laser light (514.5 
nm; 6min; photon flux = 2.7 x lO^  ^photons, sec'l.mm"^) causes a transient vasodilation which 
recovers fully during illumination (within ca. 4  mins). The amplitude of subsequent photorelaxations 
(PRs) is dependent on the time interval between consecutive exposures: the "repriming" process 
requires 2-3 hrs. The nitric oxide (NO) synthase inhibitor N^-monomethyl-L-arginine (LNMMA; 
lOOpM) prevents repriming. Bolus injections {lOpd) of S-nitroso-N-acetyl penicillamine (SNAP; ImM) 
or stimulation of endogenous NO production with a 5 min. perfusion of carbachol (O.lmM) both 
accelerate repriming, producing enhanced PRs within ca, 10 min. Ferrohaemoglobin, a scavenger of 
NO, suppresses PRs. These results suggest that PR is due to the photochemical release of NO from a 
molecular store within the tissue. The store can be depleted and then replenished, either by endothelium- 
derived NO (slow repriming) or from an NO donor drug, such as SNAP (fast repriming).
Supported by a grant from the Cancer Research Campaign.
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THE VASODILATOR ACTION OF S -NITROSOGLUTATHIONE: 
EVIDENCE FOR NO TRANSFER
A.R. Butler and S.C. Askew 
Department of Chemistry, St Andrews University, Scotland
F.W. Flitney and I. Megson 
School of Biological and Medicd Sciences,
St Andrews University, Scotland
Nitrosothiols are effective NO-donor drugs but, once in solution, are 
thermally unstable and therefore difficult to use. A survey has shown 
that amongst the most stable is 5'-nitrosoglutathione (SNOG). Its vaso-
COgH
SNOG
dilator action on precontracted isolated rat tail artery has been examined 
and compared with that of related compounds. In vitro studies have 
shown that, in the presence of an ionised thiol (RS ), there is transfer of 
the NO group from SNOG to form RSNO, which may decompose to 
NO and a disulphide far more readily than SNOG itself. Thus, RS‘ is a 
’catalyst' in the production of NO from SNOG. We have examined the 
in vitro chemistry of the production of NO from SNOG in the pres^ence 
of inter alia cystein, cystein methyl ester, V-acetylcystein, penicill­
amine, and A-acetylpenicillamine and the results are consistent with the 
slow step being the decomposition of the nitrosothiol formed by NO 
transfer from SNOG. Further, an examination of the vasodilator action 
of SNOG on precontracted isolated rat tail artery in the presence of a 
thiol in the perfusate is consistent with the vasodilator action of SNOG 
alone being due to NO transfer to endogenous cystein residues in the cells of the artery.
